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Abstract 
The aetiology and pathogenesis of type 2 diabetes (T20) are yet to be fully understood. 
However, there is a degree of agreement that the most important pathological factors of 
T20 are p-cell dysfunction and insulin resistance. Moreover T2D is characterised by 
varying degrees of impaired pancreatic p-cell responsiveness and/or insulin resistance. 
The ability to easily quantify insulin sensitivity is useful for investigating the role of 
impaired insulin secretion and action in the pathophysiology ofT2D. 
The current work provided novel knowledge in both clinical and methodological areas. 
On the clinical side, it provided new information about pathology of T2D. On the 
methodological side, it assessed validity, performance, and/or reproducibility of two 
powerful models to assess insulin responsiveness and sensitivity. 
The aim was to use modelling techniques employing data collected during tolerance 
tests to progress our understanding of pathology of type 2 diabetes. This research 
evaluated and/or validated two approaches namely, the insulin secretion model and the 
minimal model, respectively, to assess pancreatic p-cell responsiveness and insulin 
sensitivity. These methods were then applied to study the aetiology and pathology of 
T2D on its first clinical appearance (newly diagnosed SUbjects). 
The insulin secretion model was assessed with two reduced sampling schemes. The 
model was validated during the oral glucose tolerance test (OGTT). and its performance 
was compared during OGTT and the meal tolerance test (Mm. The reproducibility of 
the model indices was also assessed during MTT and OGTT. The one and two 
compartmental minimal model performance was evaluated and compared to the clamp 
in subjects with T20. The insulin secretion model and the one compartment minimal 
model were then applied to study newly presenting T2D in order to gain more 
understanding of the disease pathology. The output results showed the ability of these 
approaches to explain the inter-individual variability of important glucose clinical 
measures such as FPG and HbA1C• 
In conclusion the insulin secretion model and the one compartment minimal model 
demonstrated their validity and utility in assessing insulin sensitivity and p-cell 
responsiveness to provide better Wlderstanding of type 2 diabetes. 
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Diabetes mellitus is a group of metabolic diseases characterised by hypergJycaemia 
resulting from defects in insulin secretion, insulin action, or both. The persistent 
hyperglycaemia of diabetes is associated with long-term complications, and dysfunction 
of various organs, especially the eyes, kidneys, nerves, heart, and blood vessels. The 
estimated global prevalence of diabetes among adults was 7.4% in 1995 and is expected 
to rise to 9% by 2025 (1). However, specific popUlations and subgroups have a much 
higher prevalence of the disease. These subgroups have certain attributes or risk factors 
that either directly cause diabetes or are associated with it. 
In the United Kingdom the estimated number of diabetics in year 2000 was about 1.5 
million (2-3%) (2). In Manchester, the people with prevalence of known and new type 
2 diabetes, detected by oral glucose tolerance test, was 20% in Europeans, 22% in Afro-
Caribbeans, and 33% in Pakistanis (3). These findings provide an idea about the 
potential size of the diabetes epidemic facing the United Kingdom. The epidemic will 
have major implications for the NHS, which will have to provide diabetic services for 
these patients, as a substantial proportion of the total health care budget is spent on the 
care of diabetic patients as well as to deal with the clinical and psychosocial 
complications resulting from diabetes. 
Type 2 diabetes (T20) is the most common metabolic disease in the world and is one of 
the most common chronic diseases. It accounts for about 85--95 % among all diabetes 
(2). It is associated with a number of complications, such as nephropathy, retinopathy, 
arteriosclerotic heart disease, and peripheral neuropathy, which most often result from 
the prolonged exposure to hyperglycaemia. 
Type 2 diabetes mellitus is a heterogeneous syndrome resulting from a combination of 
insulin resistance and p-cell dysfunction. In addition, it is characterised by insulin 
resistance and impaired pancreatic responsiveness (4). Although insulin resistance may 
not be required for the development of T2D (2, 3), defects in insulin sensitivity and 
p-cell function have been demonstrated in most subjects with type 2 diabetes. In 
18 
addition, insulin resistance is associated with a number of other diseases, including 
obesity, hypertension, dyslipidaemias, and coronary artery disease (5; 6). 
The assessment of insulin sensitivity and p-cell function is essential to investigate the 
pathophysiology and epidemiology of T2D and to foJJow the clinical course of patients 
on various therapeutic regimens. In addition, the ability to easily quantify insulin 
sensitivity in large numbers of subjects will be useful for investigating the role of 
impaired insulin secretion and action in the pathophysiology of these major public 
health problems. 
1.2. Thesis hypothesis 
The aetiology and pathophysiology of T2D are yet to be fully understood and have not 
been fully characterised (7). It has been generally accepted that both insulin resistance 
and deficient p-ce]] function are the primary cause for the development of T2D mellitus 
(8). However a considerable uncertainty exists about the sequence and the nature of the 
earl iest biochemical changes and their relative contributions to the deterioration in 
glucose tolerance and development ofT2D. 
The genera]]y accepted but as yet not confirmed hypothesis is that the glucose tolerance 
tests in a large group of newly diagnosed patients provide a unique insight into the 
dynamic of the glucose/insulin interaction system after meal and iv glucose stimuli. 
This detailed information helps to further examine the natural history of Type 2 diabetes 
and provides a greater understanding of the processes involved in the development and 
progression of diabetes. Furthermore facilitates the estimation of essential indices of the 
whole-body carbohydrate metabolism with aid of model-based approaches. 
The approaches used in investigating glucose metabolism in the present thesis are 
assumed to be valid. However, this validity needs to be further assessed against 
experimental data. 
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1.3. Aims and objectives 
The primary aim of this thesis is to use modelling techniques employing data collected 
during MIT and IVGTT to progress our understanding of pathology of type 2 diabetes. 
The secondary aim is to evaluate the domain of validity ofISM and, in part the minimal 
model. Type 2 diabetic subjects are studied at presentation as they present the end-point 
of the natural development of the disease prior to therapeutic intervention. 
The aims of this thesis can be accomplished by achieving a subset of methodological 
and then clinical objectives. The methodological objectives are: 
- To evaluate indices of pancreatic p-cell responsiveness with two reduced 
sampling schemes and compare them against indices obtained during the full 
sampling scheme 
- To validate the insulin secretion model during OGTT and to compare the indices 
of pancreatic p-cell responsiveness during MTT and OGTT 
- To investigate reproducibility of the quantified measures of the pancreatic p-cell 
responsiveness (Ml and Mo) and glucose, insulin, and C-peptide responses 
during MTT and OGTT 
- To evaluate and compare the performance of I CMM and 2CMM for assessing 
insulin sensitivity in subjects with type 2 diabetes subjects during 
insulin-modified FSWGTT and compare its performance with 1 CMM 
The clinical objectives are: 
To quantify the association between insulin resistance and pancreatic 
responsiveness with (i) HbA1c, FPG, and FPI (ii) the responses of glucose and 
insulin to standardised meal 
- To investigate the ability of WGTT and MIT derived indices to explain the 
inter-individual variability of clinical measures of glucose control such as 
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fasting plasma glucose and insulin, glycated haemoglobin, and the glucose and 
insulin responses to a meal 
1.4. Thesis overview 
A review of the literature and associated approaches used are given in Chapter 2. The 
chapter starts with a background review to diabetes mellitus with more attention to type 
2 diabetes and its main pathological factors. This is followed by a review of the main 
approaches developed and used to assess insulin sensitivity and pancreatic p-cell 
responsiveness with more concentration on the approaches used in the research course 
throughout this thesis. 
In Chapter 3 the pancreatic p-cell responsiveness indices (M. and Mo) are evaluated with 
two reduced sampling schemes (9 samples and 5 samples) and compared against indices 
obtained during the full sampling scheme. 
Chapter 4 provides full details of the validation process of the insulin secretion model 
during OGIT in healthy subjects and subjects with T2D. It also includes the outcome of 
the comparisons between the p-cel1 responsiveness indices, and glucose, insulin. and 
C-peptide responses during MTT and OGTT. 
The reproducibility of the pancreatic p-cell responsiveness indices (MJ and Mo) are 
investigated in Chapter 5. In addition. the reproducibility of glucose, insulin, and 
C-peptide responses to MTT and OGTT are also evaluated by assessing the 
reproducibility of glucose, insulin, and C-peptide incremental area under curve. 
In Chapter 6, an evaluation of the performance of I CMM and 2CMM in type 2 diabetes 
subjects is performed during insulin-modified FSNGTT. The glucose clamp technique 
is used to assess the validity and performance of both I CMM and 2CMM 
measurements, as the glucose clamp is considered the gold standard reference method 
for measuring insulin sensitivity. 
Chapter 7 investigates the ability of the indices of insulin sensitivity and pancreatic 
p-cell responsiveness to explain inter-individual variability of clinical measures of 
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glucose control such as fasting plasma glucose and insulin, glycated haemoglobin, and 
the glucose and insulin responses to a meal. A quantification of the association between 
insulin sensitivity and pancreatic ~-cel1 responsiveness with (i) FPG, FPI, and glycated 
haemoglobin (ii) the responses of glucose and insulin to standardised mea) are also 
considered. 
An overall summary of the thesis and outlined achievements are given in Cllapter 8, in 
addition to recommendations for any possibility of future work and research interest. 
Appendices includes (l) tables relating to chapter 7, (In list of publications derived from 
the work included in this thesis. 
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2. Background 
2.1. Glucose Metabolism 
Glucose is the main energy source for the body cells to carry on with its biological 
activities and survive. The blood glucose level has a normal range which is important 
to maintain. If the blood glucose level exceeds the normal level then the diabetes 
symptoms will starts to appear and if not treated or controlled the diabetes 
complications start to appear with blindness and death are among them. 
2.1.1. Regulation of Blood Glucose 
Glucose is the main energy-supplying molecule of the body. It is used by the body to 
produce ATP (adenosine triphosphate), which is the body ultimate source of energy (9). 
Normally the glucose used by the body is in the blood stream; otherwise it is converted 
to glycogen and stored by the liver if it is not needed immediately (10). Two hormones 
produced and secreted by the pancreas mainly control the glucose level in the blood 
stream; glucagon which increases blood glucose level and insulin, which decreases and 
adjusts blood glucose level. Blood glucose level controls secretion of glucagon and 
insulin via negative feedback systems. 
Low blood glucose (hypoglycaemia) stimulates release of glucagon from alpha cells 
which acts on hepatocytes (liver cells) to accelerate the conversion of glycogen into 
glucose and to promote formation of glucose from lactic acids (11). As a result, the liver 
releases glucose into the blood more rapidly and blood glucose level rises. If the blood 
glucose continue to rise for any reason, or after food ingestion, high blood glucose 
(hyperglycaemia) stimulates release of insulin from beta cells (p-cells). Insulin acts on 
various body cells to accelerate facilitated diffusion of glucose into cells especially 
skeletal muscle fibres, and adipose tissues. and speeds up conversion of glucose into 
glycogen (glycogenesis) and slows and inhibits hepatic glucose production 
(glycogenolysis and gluconeogensis). As a result blood glucose levels falls to a normal 
level (10). 
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2.1.2. Pathology of Glucose Metabolism 
2.1.2.1. Insulin resistance 
Insulin resistance is a pathological condition and a metabolic feature of type 2 diabetes. 
It can be defined as a reduced response to a physiological amount of insulin (12-17). 
Scientists are still searching for the causes of insulin resistance, but they have identified 
two possible causes. The first could be a defect in insulin receptors in cells. There may 
not be enough receptors for insulin to bind to, or a defect in the receptors may prevent 
insulin from binding. Recognition of the insulin molecule by its receptor is a complex 
molecular event and is essential for signal transmission (18). 
A second possible cause involves the process that occurs after insulin plugs into the 
receptor. Insulin may bind to the receptor, but the cells do not read the signal to 
metabolise the glucose. Scientists are studying cells to see why this might happen. 
The cascade of insulin action in vivo involves many steps including transendothelial 
transport of hormone, binding to the insulin receptor, and activation of tyrosine kinase, 
followed by movement ofGLUT4 transporters from the cell interior to the membrane so 
that glucose may enter the cell to be stored or oxidised (19). The insulin action might be 
delayed, the delay may be due to diffusion of insulin throughout the interstitium, and a 
decrease in capillary density in obesity could potentially account for insulin resistance 
because the time necessary for diffusion would be increased (19). 
Current and previous researchers have showed some evidence for a relation between the 
insulin resistance and unhealthy life-style, endocrine abnormalities, and with several 
other abnormalities. Both the quantity and quality of food intake affect insulin binding 
and insulin action at a molecular level (20-23) 
Obesity is the most common cause of insulin resistance in humans and with or without 
the presence of hyperglycaemia, it is almost certainly the most common state of insulin 
resistance (24-27). An important new potential mechanism of insulin resistance in 
obesity has been the observation that fat tissue itself may produce and secrete hormones 
or cytokines that affect metabolism andlor insulin sensitivity (28). In addition, 
prolonged exposure of ~-cells to insulin leads to desensitisation and reduced 
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insulin-stimulated receptor autophosphorylation (29). On the other hand, exercIse 
enhances insulin sensitivity and glucose disposal in normal physiology. This is 
associated with increased insulin binding to muscles (30). Almost all obese subjects are 
showing an exaggerated insulin response to glucose. Being overweight is considered as 
one of the most important prediabetic conditions (9). 
2.1.2.2. ~cell dysfunction 
p-cell dysfunction is the disability of the pancreas to secrete the body needs of insulin. It. 
is defined as an inappropriate reduction in the rate of insulin secretion from the p-cells 
or the abnormality in the rate and pattern at which blood insulin concentration changes 
as a function of time (31). It might be due to the p cells themselves being not able to 
secrete insulin or the decrease in p-cell number because of an infection or an 
autoimmune disease. The pancreatic insulin secretion is regulated by many factors; with 
the plasma glucose level being the most important regulator. 
The alteration in the level and pattern of the p-cell dysfunction can present in different 
ways. It could be the reduction in insulin release to glucose (32). change in the 
pulsatilitiy pattern and oscillatory of insulin secretion (33), defect in first phase insulin 
response to glucose stimulus (34), abnormality in the proinsulin to insulin conversion 
(35), and reduced release of islet amyloid polypeptide (36). 
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2.2. Diabetes 
Diabetes mellitus is a group of metabolic disorders characterised by hyperglycaemia 
(elevation of glucose in the blood). These heterogeneous disorders usually result from 
defects in insulin secretion, and/or insulin action. The persistent hyperglycaemia of 
diabetes is associated with long-tenn complications, and dysfunction of various organs, 
especially the eyes, kidneys, nerves, heart, and blood vessels. The aetiology and 
pathogenesis of diabetes are not fulJy understood and is believed to be a genetic 
inheritance with environmental factors. Several pathogenic processes ranging from 
autoimmune destruction of the p-cells of the pancreas with subsequent insulin 
deficiency to abnonnalities that result in resistance to insulin action are involved in the 
development of diabetes. 
The previous classification of diabetes was based on the extent to which a patient was 
dependent on insulin • Few years ago, both the reports of the American Diabetes 
Association (37) and the World Health Organisation (WHO) (I) recommended changing 
the classification to define four main SUbtypes of diabetes (Table 2-1) reflecting the 
heterogeneity of processes that lead to diabetes which hopefully will lead to more 
precise targeting of speci fie treatments and eventually to better outcomes ... 
Table 2-1. Etiologic classification of diabetes mellitus, adopted from Alberti et al (1). 
I. Type 1 diabetes (~-cell destruction, usually leading to absolute insulin deficiency) 
A. Immune mediated 
B. Idiopathic 
II. Type 2 diabetes (may range from predominantly insulin resistance with relative insulin 
deficiency to a predominantly secretory defect with insulin resistance) 
III. Other specifiC types 
A. Genetic defects of ~-cell function 
B. Genetic defects in insulin action 
C. Diseases of the exocrine pancreas 
D. Endocrinopathies 
E. Drug- or chemical-induced 
F. Infections 
G. Uncommon forms of immune-mediated diabetes 
H. Other genetic syndromes sometimes associated with diabetes 
IV. Gestational diabetes mellitus (GDM) 
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Type 1 includes immune mediated and idiopathic forms of ~-cell dysfunction which 
lead to absolute insulin deficiency. Type 2 diabetes is a disease of adult onset, which 
may range from predominantly insulin resistance with relative insulin deficiency to a 
predominantly secretory defect with insulin resistance. Type 3 disease covers a wide 
range of specific types of diabetes including the various genetic defects of ~-cell 
function, genetic defects in insulin action, and diseases of the exocrine pancreas. Type 
4 disease is gestational diabetes (GDM) which is only found during pregnancy. It 
normally vanishes after the delivery, but those women will have a higher chance to get 
Type 2 (37). The revised criteria for the diagnosis of diabetes are shown in Table 2-2. 
Type 2 will be discussed in more details as it is the scope of research in this thesis. 
Table 2-2. Diabetes mellitus diagnostic criteria, adopted from the report of the Expert 
Committee on the Diagnosis and Classification of Diabetes Mellitus (37). 
J""~'~"";;;~::~":;~~:~'~~~'~';~:"~'~::~';~::~";~':~~~~"~:'~'~~~;~~'~~"~;~~":;~~'('~"~'~'~"'" 
:1 mmolll). Casual is defined as any time of day without regard to time since last meal. . 




i or i 




:I 3. 2-h plasma glucose ~ 200 mg/dl (Il.I nunoVI) during an OGTT. The test should 
be performed as described by the World Health Organization using a glucose load 
containing the equivalent of75 g anhydrous glucose dissolved in water. 
In the absence of unequivocal hyperglycaemia with acute metabolic decompensation, 
these criteria should be confirmed by repeat testing on a different day. The third 
it,=.:::::;.~,~,~:~,.~,~.::~.~,~:::~,~,~:~;;~:~;;~::~~,~,~"~,:~:~::~"::~"".,.,."";"'.""""";;.''';;''' .. ;" .. ,,.'''' .. ,,;; .. 
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2.2.1. Type' Diabetes Mellitus 
Previously called "insulin dependent diabetes mellitus" (IDOM), because there is an 
absolute chronic deficiency of insulin secretion, and regular injections of insulin are 
required to prevent death. Normally it affects children or adolescents only, although it 
can appear at any age. It is commonly developed in young people (under 20 years old) 
and persists throughout life. Type I appears to be an autoimmune disorder, one in which 
a person's immune system destroys the pancreatic beta cells. It is believed that both 
genetic factors and virus infections are responsible. Individuals at increased risk of 
developing type 1 of diabetes could be identified by using immunologic markers to islet 
antigens and serological evidence of an autoimmune pathologic process occurring in the 
pancreatic islets. Up to ten per cent of all diabetes diseases are of Type I. Some of its 
first symptoms are increased needs of sleep, constant hunger and thirst, a bleary vision, 
and a loss of weight (1; 18; 37). 
2.2.2. Type 2 diabetes Mellitus 
Previously known as non-insulin dependent diabetes mellitus (NIDDM). Type 2 
diabetes is a heterogeneous disorder characterised by insulin deficiency due to ~-cell 
failure associated with insulin resistance, which represents more than 90% of all cases 
of diabetes, and most often occurs in people over 40 years and overweight. About 150 
million are estimated to have type 2 diabetes worldwide (38) and the numbers of type 2 
diabetic patients are increasing each year as a result of several factors including 
increased obesity, civilised life style, and other enviromnental factors related to diet and 
nutrition (12; 38). 
2.2.2.1. Pathophysoilogy of type 2 diabetes 
The aetiology and pathogenesis of type 2 diabetes mellitus are not fully understood. It 
can be considered as being a complex interaction of genetic predisposition and 
environmental factors (7). The strong genetic component of type 2 diabetes is clearly 
found in certain families and ethnic groups such as Hispanic, and Pima Indians (39-42). 
There is a degree of agreement that the most important pathological factors of type 2 
diabetes are ~-cell dysfunction and insulin resistance (37). However a considerable 
28 
uncertainty exists about the sequence and the nature of the earliest biochemical changes 
and their relative contributions to the deterioration in glucose tolerance and 
development of type 2 diabetes. At the same time it is well founded that an intermediate 
stage of impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) predicts 
and precedes the progression ofT2D (37). 
It is well accepted that a substantial loss of p-cell function should be present for a 
hyperglycaemia to appear in type 2 diabetes, and it is implicated that insulin deficiency 
is the proximate cause of the progressive increase in plasma glucose levels (17; 31). The 
p-cell dysfunction could be reduction in insulin release to glucose (32), change in the 
pulsatile and oscillatory of insulin secretion (33), defect first phase insulin response to 
glucose stimulus (34), abnormality in the proinsulin to insulin conversion (35), and 
reduced release of islet amyloid polypeptide (36). However it is still a matter of 
controversy as to whether insulin resistance or p-cel1 dysfunction is the primary 
pathogenic defect in type 2 diabetes. 
Many studies have focused on and reported the insulin resistance as the primary defect, 
where insulin resistance precedes and causes the hyperinsulinaemia and provides a 
stronger signal for p-cell stimulation (31; 43-45). The increase in plasma insulin is 
generally regarded as a compensation mechanism aiming to reverse the effect of insulin 
resistance (46). While the pancreatic p-cell decomposition is caused by the long 
exposure to high concentration of glucose (glucose toxicity) (47), and reflecting ~-cell 
'exhaustion' (48). Overt diabetes appears when the pancreas is not able to meet the 
body's demand for insulin in the face of increasing insulin resistance (49). The above 
aetiology hypothesis was supported by other studies which reported that the majority of 
patients with type 2 diabetes and subjects at risk for diabetes are insulin resistant (41; 
50; 51). and are hyperinsulinaemic even before hyperglycaemia appears (52). 
Others suggested the conception of a defect in insulin secretion to be the major early 
abnormality (53-55). In accordance with this concept, low early insulin response 
predicted diabetes in other studies (56). and the progression from normal glucose 
tolerance to impaired glucose tolerance (57), while insulin resistance predicted the 
transition from impaired glucose tolerance to type 2 diabetes (58; 59). Type 2 diabetes 
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can develop in individuals with nonnal insulin sensitivity with defective p-cel1 function 
(60), and individuals at high risk of diabetes demonstrated a diminished p-cell function 
while maintaining normal glucose tolerance (61-63). 
Part of the United Kingdom Population Diabetes Study (UKPDS) findings and 
suggestions in individuals with established type 2 diabetes is that the onset of p-cell 
dysfunction is present early before the escalation of hyper glycaemia and could exist for 
years before diagnosis (64). This concept was supported by another longitudinal study 
on a group of high risk population with nonnal glucose tolerance, the study reported a 
progressive decrease in insulin secretion in subjects who developed hyperglycaemia, 
whereas insulin sensitivity was similar to those who retained normal glycemia (65). 
Many other studies supported the idea that p-cell dysfunction together with insulin 
resistance predicts the development of type 2 diabetes (8; 65; 66), and the difficulty for 
these defects to be assessed in isolation. Thus, it is generally agreed that type 2 diabetes 
is a broad metabolic heterogeneous disorder and its development and progression is 
associated with and predicted by defects in both insulin secretion and insulin resistance, 
in addition to the genetic factor (56; 67). Other factors such as obesity (68). diet (69). 
physical activity (70), and many other known and unknown factors may interact and 
contribute to the development of type 2 diabetes. 
2.2.2.2. Symptoms and risk factors 
The main symptoms of the type 2 diabetes include polyuria, polydipsia, weight loss, 
sometimes with polyphagia, thirst, frequent urination, weakness and great tiredness, 
lack of ability to contrast, loss of co-ordination, and blurred vision. Impainnent of 
growth and susceptibility to certain infections may also accompany chronic 
hyperglycaemia. Acute, life-threatening consequences of diabetes are hyperglycaemia 
with ketoacidosis or the nonketotic hyperosmolar syndrome (18; 37). 
Although the major cause for diabetes is insufficient insulin produced by the pancreas 
or insulin resistance. There are some factors which increase the risk of diabetes 
incidences, the most important known risk factors are; obesity, stress, pregnancy, use of 
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certain drugs, including oral contraceptives, thiazide diuretics, cortisone or phenytoin, 
and family history of diabetes mellitus (18)(37). 
2.2.2.3. Complications 
Nonnally the diabetes complications are more dangerous than the disease itself. The 
most common and dangerous complications are cardiovascular disease, vision 
impainnent, peripheral vascular disease, with gangrene in legs and feet, and sexual 
impotence in men (18). Long-tenn complications of diabetes include retinopathy with 
potential loss of vision; nephropathy leading to renal failure; peripheral neuropathy and 
foot ulcers. Glycation of tissue proteins and other macromolecules are among the 
mechanisms believed to produce tissue damage from chronic hyperglycaemia. 
Hypertension, abnonnalities of lipoprotein metabolism, and periodontal disease are 
often found in people with diabetes. In addition, the emotional and social impact of 
diabetes and the demands of therapy may cause significant psychosocial dysfunction in 
patients and their families (37). 
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2.3. Assessment of Insulin sensitivity 
Glucose tolerance is an expression of the efficiency with which homeostatic 
mechanisms restore glycaemia to basal levels after a perturbation. Insulin is a key 
regulator of glucose homeostasis.. Insulin resistance (decreased sensitivity or 
responsiveness to the metabolic actions of insulin) is detennined by both genetic and 
environmental factors and plays an important pathophysiological role in diabetes (5). 
The term "insulin resistance" refers to an impaired biological response to either 
exogenous or endogenous insulin. In addition, insulin resistance is associated with a 
number of other diseases, including obesity, hypertension, dyslipidemias, and coronary 
artery disease (5; 6). Therefore, it is of great interest to quantify insulin sensitivity and 
resistance in humans to investigate the pathophysiology and epidemiology of major 
public health problems and to follow the clinical course of patients on various 
therapeutic regimens. In addition, the ability to easily quantify insulin sensitivity in 
large numbers of subjects may be useful for investigating the role of insulin resistance 
in the pathophysiology of these major public health problems. 
The glucose-insulin system is composed of a complex set of metabolic interactions and 
regulatory components. Even if all these were included in the description of a proposed 
system model, it would be still a kind of oversimplification because the system is 
embedded within the entire complex system, which is made up of energy metabolism 
and its honnonal and neural regulation. Many mathematical formulations for the 
glucose system have been made, from the comprehensive to the relatively simple. 
Clinically, the most desired assessment of insulin sensitivity is following an oral 
glucose load, a surrogate for a more physiological meal (71). The homeostatic response 
includes an increase in the insulin levels and, therefore, also the insulin-dependent 
processes that lower glycaemia. ll1eoretically, the oral glucose tolerance test should 
yield an estimate of insulin sensitivity. Many mathematical formulations have been 
developed to estimate insulin sensitivity following an oral glucose load (72-74). 
After oral glucose or meals, the increments in insulin do not depend entirely on glucose, 
but also on other factors such as gut hormones and neural stimulation. Thus the insulin 
response deviates from the purely glucose-dependent pattern. In addition, glucose 
concentrations also change in a manner that is partly dependent on insulin, but also 
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partly on gastric emptying and absorption (75; 76). Therefore, many attempts have been 
made to isolate the glucose-insulin relationship. as much as possible, from other factors. 
A host of methods have been developed to assess insulin sensitivity (or insulin 
resistance) in vivo. These include the hyperinsulinaemic euglycaemic glucose clamp 
(77). minimal model analysis of a frequently sampled intravenous glucose tolerance test 
(FSIVGIT) (78), continuous infusion of glucose with model assessment (CIGMA) (79), 
and various indices derived from an oral glucose and meal tolerance tests (72; 80-83), 
and simple indices based on fasting glucose and insulin levels (84) including 
homeostasis model assessment (HOMA) (85), and QUICKI (86). A number of 
variations on each of these approaches are available. For example, the glucose clamp 
technique can be performed under other conditions such as hyperglycaemic with or 
without infusion of tracer-labelled glucose (87; 88). Similarly, minimal model analysis 
has been extended to analyse tolbutamide or insulin modified FSIVGTT (19; 89) with 
or without infusion of tracer-labelled glucose (90). 
The hyperinsulinaemic eugJycaemic glucose clamp is generally regarded as the "gold 
standard" reference method for assessing insulin sensitivity in humans because it 
directly measures metabolic actions of insulin under steady state conditions. However, 
the glucose clamp is not easily applied in large-scale investigations because intravenous 
(IV) infusion of insulin, frequent blood samples over a 3 to 6h period, and continuous 
adjustment of a glucose infusion are required for each subject studied (77). 
Simple indices of insulin sensitivity based on fasting values such as fasting insulin 
value, IIfasting insulin. and insulin-to-glucose ratio have been used as a surrogate 
measure for insulin resistance (84). In addition, the Bennett index (91), homeostasis 
model assessment (HOMA) (85) and QUICKI (86) are easily obtained during fasting 
(basal) states, and may be useful tools for large epidemiological studies. In the context 
of the current review, some of these methods will be explored with varying degree of 
depth. 
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2.3.1. Hyperinsulinaemic euglycaemic glucose clamp 
The euglycaemic insulin clamp and the frequently sampled IV glucose tolerance test 
with the minimal model analysis are the standard methods of assessing insulin 
sensitivity (SI). The former is considered to be the gold standard in the assessment of 
insulin resistance because it directly measures the effects of insulin to promote glucose 
utilisation under steady state conditions (77). It is a conceptually simple test. although 
technically. somewhat more complex. 
The hyperinsulinaemic euglycaemic glucose clamp is performed by infusing insulin as a 
priming dose followed by a constant infusion rate to achieve and maintain a preset 
hyperinsulinaemic plateau. Simultaneously. glucose is monitored frequently and infused 
at variable rates to maintain near-constant glycaemia. which is equivalent to normal 
fasting glucose levels (or in the isoglycaemic case. the subject's own fasting glycaemia). 
When the glucose infusion rate has stabilised (2-3 h). this rate. divided by the 
incremental insulin level (subtracting basal insulin) and corrected for the ambient 
glucose concentration. is defined as clamp insulin sensitivity index (SI). When a steady 
state is achieved, the exogenous glucose infusion rate equals the glucose disposal rate 
(M) (sum of suppression of endogenous glucose production and the stimulation of 
glucose disposal). If endogenous hepatic glucose production is completely inhibited by 
an intravenous infusion of insulin then the quantity of exogenous glucose required to 
maintain euglycaemia (the M value) is a reflection of the net sensitivity of target tissues 
(mainly skeletal muscle) to insulin (77). 
Sit during the clamp. was derived from the steady-state glucose infusion rate (M value) 






where M is the increment in insulin concentration from basal. and G is the clamped 
glucose concentration. 
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However, the clamp is a complicated method to implement because it requires 
simultaneous infusions of insulin, and glucose, multiple blood draws. and an 
experienced operator to adjust the glucose infusion appropriately over a 3- to 6-h time 
period. In addition, the clamp generates insulin levels above those usually experienced 
by subjects and may therefore fail to reveal potential abnormalities of processes 
regulated by lower insulin concentrations. The manner in which insulin sensitivity is 
determined during the hyperinsulinaemic euglycaemic clamp is based upon the 
assumption (unless appropriate tracer techniques are used) that endogenous glucose 
production is completely shut off by the insulin infusion. Moreover, during a clamp, 
insulin is administered as a constant infusion and, therefore, does not reflect the 
variations inherent in endogenous secretion (92). 
2.3.2. Insulin tolerance test 
TIle insulin tolerance test (ITT) was one among the first methods to assess the insulin 
sensitivity in vivo (93). The test consists of an intravenous insulin bolus injection and 
the slope of the decreased blood glucose concentration over the following 60 min is 
used as an index of insulin sensitivity. However the test does not provide a good 
quantitative measure as the hyperinsulinaemic euglycaemic glucose clamp. TIle rate and 
degree of plasma glucose fall in response to ITT are dependent not only on insulin 
sensiti~ty, but also on the presence and magnitude of the counterregulatory hormone 
response (including adrendin, glucagon, and cortisol), thus decreasing the value of ITT 
in assessing insulin sensitivity per se (92). 
2.3.3. HOMA 
The homeostatic model assessment (HOMA) focuses on and estimates insulin resistance 
function from basal fasting glucose and insulin levels. The HOMA method was first put 
forward ill 1985 by Matthews e/ al. (85). This mathematical model is based on the 
theory of a negative feedback loop between the liver and ~-cells that regulates both 
fasting glucose and insulin concentrations which can be used to estimate pancreatic 
~-cen function and degree of insulin resistance. Therefore, considering its simplicity, it 
may be a useful non-invasive tool for population studies. 
35 
The insulin resistance (RHOM,J is calculated as: 
RHOMA = g • il22.S (2-2) 
where g and i is the fasting plasma glucose (mmol/l) and insulin (J.1U/ml), respectively. 
It is critical to note, however, that HOMA is an index of insulin resistance. Whereas 
insulin sensitivity (SlHOMA) is calculated as exactly the inverse of the formula for 
resistance shown in equation (2-1): 
SIHOMA = 22.5/(g • i) (2-3) 
The basic rationale for the model is stated as: "The basal hyperglycaemia of diabetes 
may be considered as a compensatory response with a major role in maintaining 
sufficient insulin secretion, from a reduced p-cell capacity, to control hepatic glucose 
effiux"(85). 
However it has sometimes been concluded that the HOMA index does not correlate well 
with other measures of insulin sensitivity (80). 
2.3.4. Minimal Model of Glucose Kinetics 
TIle minimal model (or thereafter one compartment minimal model, 1 CMM) was 
developed to analyse data from frequently sampled intravenous glucose tolerance test 
(FSIVGTT) and to produce measures of peripheral insulin sensitivity (Sl) (94). It was 
termed the "minimal model," because it was the mathematical model with the fewest 
parameters that was found to provide a good fit to the data and the fits to data are 
remarkably good (94). It should be noted that the fits are obtained using, for example, 
non-linear least squares techniques: parameters are varied according to a defined 
strategy and are assigned a final value that minimizes the sum of squares of differences 
between the data and the glucose and insulin values predicted by the model (which is 
non-linear) for any parameter set. The goodness of fit and, therefore, the reliability of 
the parameters can then be evaluated statistically. 
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The FSIVGTI is constructed with a glucose bolus (300 mglkg body weight as a 50% 
solution in water) injected at zero minute and about thirty samples withdrawn over more 
than three hours (95). The 1 CMM works well in subjects with normal insulin secretion, 
because the model assumes that insulin action is zero at the start of the test and it reset 
to zero at each iteration loop for solving the equations for glucose disposal. In the case 
of impaired or poor insulin secretion in the presence of insulin resistance, the value of 
insulin action will be close to zero, which makes the estimation of SI very sensitive to 
any small change in the plasma insulin leading to the test variability and poor 
quantification of insulin sensitivity (96). Thus, Beard et ai, have injected tolbutamide 
intravenously 20 min after glucose injection to produce a large insulin secretory 
response (89). 
This modification was not suitable for diabetic patients because most of the patients 
suffer from pancreatic dysfunction and do not have significant insulin secretion in type 
I diabetes or the combination of reduced insulin response and pancreatic dysfunction. 
To overcome this problem, in the modified FSIVGTT the tolbutamide injection was 
replaced by an insulin injection (O.OSmU/kg) instead at time 20 min (16). This 
exogenous insulin simulates the function of the endogenous insulin by the pancreas and 
enables the model to make calculations with improved accuracy of the parameters 
estimation (19). Also different sampling techniques were used which reduced the 
numbers of samples to 13 samples and 12 samples (16; 95-97). 
The modified intravenous glucose tolerance test (WGTT) with insulin injection 
interpreted with the 1 CMM of glucose kinetics is a powerful non-invasive tool to 
investigate glucose metabolism in physiological studies (98). The model analyses 
IVGTT data and provides two metabolic indices measuring glucose effectiveness (SG) 
and insulin sensitivity (SI) in a single individual. SI and SG are composite parameters, 
which measure the net effect of glucose and insulin respectively to promote glucose 
disappearance and inhibit endogenous glucose production (98). The I CMM method has 
gained increasing popularity and is used by investigation around the world (99) because 
it is simple and non-invasive. The 1 CMM is represented in Figure 2-1. 
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Figure 2-1. Minimal model of glucose kinetics (100). k.a and ~ relate to the efficiency of 
coupling of remote insulin with target biochemical processes. While kl and ~ represent the 
effect of glucose to accelerate its utilisation. 
The glucose space is represented as a single extracellular compartment (Q), the glucose 
in this space is determined by a balance between the net production of glucose by the 
liver and the utilisation of glucose by the peripheral tissues. The effects of glucose to 
accelerate its own uptake by the periphery and inhibit production are represented by rate 
coefficients kl and k2 respectively. Insulin in the model (I) is envisaged to act on 
glucose metabolism not directly, but via a component remote from plasma (1'). This 
component represents the effect of insulin and account for the delayed insulin actions on 
glucose. The rate of metabolism of the remote insulin effect is envisioned as being 
independent of plasma insulin and determined by kJ. Independent metabolism of the 
insulin effect is consistent with insulin action continuing long after plasma insulin is 
normalised (100). G is the plasma glucose concentration, V is the distribution volume 
per unit body weight (ml/kg). The equations of the minimal model are: 
Q{I) = - [Sa + X (I)] Q (I) + Sa Qb 
Q(O) = Qb 





X(O) = 0 
G(I) = Q(I)IV 
(2-7) 
(2-8) 
In equation (2-4) the rate of change in plasma glucose Q(t) is depending on So and the 
effect of glucose that is enhanced by remote insulin X(t). Qb is baseline value for 
glucose compartment. Equation (2-5) describes the rate of change of insulin action 
(dX(t)/dt), P3 describes how the increase in insulin action is dependent on the 
incremental insulin response while P2 describes how the disappearance of insulin action 
is dependent on how much insulin action (X) was present at the time. So is taken 
directly from the first equation (Pl= kl +k5) (98). While SI is calculated as the ratio 




The I CMM approach uses the computer to analyse the plasma glucose and insulin 
dynamics observed following glucose injection (101-103). It yields in vivo 
measurement of the relative contributions of the pancreas and tissues to glucose 
disposal. The insulin time course is part of the input to the computer program input, 
which then used to compare the prediction of the model with measured glucose level. 
This enables the program to estimate the equations parameters and by analysing 
frequently sampled intravenous glucose tolerance test (FSIVGTT) data the program 
provides values for the parameters of insulin sensitivity (SI) and glucose effectiveness 
(So)(101). 
The model assumes that the injected glucose is distributed rapidly in a single 
compartment. After injection of glucose, plasma glucose falls by two mechanisms: (1) a 
component of glucose disposal that is dependent only on plasma glucose concentration 
and independent of any increment in insulin level, (2) disposal which is dependent on 
the incremental insulin response. Glucose inhibits its own production and increases its 
own utilisation in proportion to its concentration in plasma. Insulin synergies these 
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effects of glucose and insulin. The insulin effect is proportional to its concentration in a 
remote compartment. 
Finally, the assessment of an index of insulin sensitivity (S1), by employing the minimal 
model kinetic analysis to data obtained from the FSNGTT, appears to represent a more 
accurate means of quantifying insulin sensitivity (78). The S1 correlates well with the 
insulin-mediated glucose disposal rate (M). and S1 as determined by the euglycaemic 
hyperinsulinaemic clamp (16; 104-106). The dynamic and physiological nature of this 
test and the relative simplicity of its performance count among its attractive features. 
Differences and potential problems arise from the same source: the rapid dynamics may 
confound transients based on the distribution of glucose throughout the system and 
those due to glucose removal. Two-pool or higher order descriptions of glucose 
dynamics and the use of tracers were suggested (107; 108) as possible solutions to such 
difficulties. 
2.3.5. Two compartment minimal model of glucose kinetics 
Recent published reports and studies indicate that So is overestimated (109-113) and S1 
is underestimated (l09-112) during ICMM attributing the main reason to the under 
modelling effect of using one compartment to represent the glucose pool (110; 113). 
The new two compartment minimal model (2CMM) was first introduced in 1993 to 
measure hepatic glucose production during an isotopically labelled IVGTT by 
appending a second non-accessible compartment to the classic 1 CMM. The new model 
was needed because, at that time, the available single compartmental minimal model 
specifically developed to interpret labelled IVGTT data. provided a non-physiological 
pattern of hepatic glucose production (114). In 1997 Vicini et al (109) validated the 
2CMM to estimate Sit Sen and plasma clearance rate during an isotopically labelled 
FSIVGTT. Recently Cobelli et al (115) incorporated a priori knowledge on glucose 
exchange kinetics using Bayesian estimation to derive insulin sensitivity and glucose 




Figure 2-2. Two compartment minimal model (2CMM), (110). 
The 2CMM appends a second non-accessible compartment to the 1 CMM. The 2CMM 
was validated in normal subjects during standard IVGTT by applying a Bayesian 
approach to incorporate prior knowledge on k12 and k21 parameters (II5). TIle model 
equations are as follows: 
(2-12) 
X{O)=O (2-13) 
G(t) = QI (t)IVI (2-14) 
where Ql and Q2 (mglkg) denote the glucose masses m the accessible and 
non-accessible compartments, respectively, with subscript b denoting their basal 
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(end-test) steady-state values; VIis the volume of the accessible compartment (mglkg); 
k12 and k21 are rate parameters describing glucose exchange kinetics (l/min); D, G, I, X, 
Pit P2. and P3 are variables and parameters already defined for the 1 CMM. The 2CMM 
parameters S? and So2 are calculated as follows: 




The 2CMM differs from 1 CMM only in allowing an exchange of glucose between the 
accessible and the non-accessible compartment, see Figure 2-2. This added complexity 
brings a priori identifiably problems. The theoretical or a priori identifiably address the 
ability of getting unique solutions for the unknown parameters on the basis of the 
experiment-generated data. A Bayesian analysis using a priori information on the 
glucose exchange kinetics parameters k12 and k21 was applied to solve these problems 
and reach unique identifiability (115). 
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2.4. Assessment of pancreatic p-cell responsiveness 
Type 2 diabetes results from varying fonns and degrees of abnormality in p-cell 
function and insulin sensitivity. p-cell dysfunction predicted diabetes in many studies 
(56), and the progression from normal glucose tolerance to impaired glucose tolerance 
(57). In addition, the progression from IGT to T2D is characterised by progressive loss 
ofp-cell function (116) and T2D is characterised by impaired pancreatic p-cell response 
to glucose. It is weJl founded that a substantial loss of p-cell function should be present 
for a hyperglycaemia to appear in type 2 diabetes, and it is implicated that insulin 
deficiency is the proximate cause of the progressive increase in plasma glucose levels 
(31). 
Several methods with varying approaches and complexity were introduced to assess in 
vivo pancreatic p-cell responsiveness to glucose (117-119). The methods range from 
simple time series plots, and simple calculations such as the methods and indexes 
relating fasting insulin to fasting glucose (85; 119), the increase in plasma insulin or 
C-peptide in plasma insulin after oral glucose and meal tolerance test (119; 120), after 
IV glucose tolerance test (121) including the calculation of the acute insulin response to 
glucose (AIRglucose) (122), and the increase in insulin or C-peptide after stimulation by 
glucagon (123), to moderate and sophisticated techniques and model-based approaches 
(77; 79; 124; 125). These approaches and methods have great value in the 
understanding and predicting the progression of the disease. 
The hyperglycaemic glucose clamp is the gold standard method for assessing p-cell 
responsiveness in vivo (77). In spite of this, the clamp methods are not suitable for 
routine use and not feasible for investigating insulin secretion in large groups and 
population studies because it is costly and labour intensive. Other models and 
approaches were proposed and used after oral glucose tolerance test (126), after IV 
glucose tolerance test (127) and under other conditions (79; 85; 128). The insulin 
secretion model (ISM) was validated to assess pancreatic p-cell responsiveness during 
more physiological conditions (32). Among these method and approaches, some will be 
discussed and summarised in the following text. 
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2.4.1. The hyperglycaemic clamp 
The hyperglycaemic clamp (77) is considered the gold standard which provides the 
most reliable and direct method for assessing pancreatic responsiveness. During the 
hyperglycaemic glucose clamp. plasma glucose is rapidly elevated by an exogenous 
bolus and maintained by a variable infusion of glucose to produce a desired circulating 
glucose level, thus stimulating the endogenous insulin secretion. The extent of the 
stimulation is employed as an index of pancreatic ~-cell responsiveness, and the 
response is usually evaluated in terms of plasma insulin concentrations. The exogenous 
glucose injection is followed by a frequent sampling schedule to enable the evolution of 
the early pancreatic response. Samples are withdrawn also at basal states before the 
glucose administration. The sampling schedule is usually every 1-5 minutes for the first 
15-30 minutes then reduced and made every 1 0-30 minutes thereafter. 
The time-secretion profile of insulin can be estimated by combining the hyperglycaemic 
clamp with the combined model which employs both insulin and C-peptide to calculate 
insulin secretion (129). The incremental area under the curve (O-lOmin) can be used to 
calculate and evaluate the first phase insulin secretion. However the use of the 
hyperglycaemic glucose clamp is limited due to the great investment of resources 
required and the complexity of the experimental interventions which make considerable 
demands on both labour and subjects. 
2.4.2. Minimal model of C-peptide secretion during IVGTT 
The minimal model of C-peptide secretion and kinetics builds upon the insulin minimal 
model (130; 131). However the C-peptide has the ability to reflect the pre-hepatic 
insulin secretion. In addition the C-peptide has been shown to exhibit a linear kinetics 
over a wide range of physiological plasma concentrations, and under fasting and 
postprandial conditions. The model provides two indices of first phase and second phase 
~-cell responsiveness (127). It yields a true pre-hepatic picture of the ~-cell secretion 
and response to glucose stimuli. 
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2.4.3. HOMA 
As described previously. the homeostasis model assessment (HOMA) is a simple 
computer-solved model. which takes advantages of the analysis of the fasting 
homeostatic state and provides reasonable measures of p-cell function as well as insulin 
sensitivity (85). The % p-cell function index is derived as: 
p-cell function (%) = 20 x insulinl(glucose-3.5) (2-17) 
The accuracy and precision of estimates were assessed by comparison with independent 
measures of p-cell function (132) including the hyperglycaemic glucose clamp, and 
intravenous glucose tolerance test (85; 133). It is critical to take into account the degree 
of insulin resistance when assessing p-cell function with the HOMA model (134). 
However, because of its simplicity it fonns a useful method to assess both insulin 
resistance and p-cell function in epidemiological studies (134; 135). 
2.4.4. CIGMA 
Continuous infusion of glucose with model assessment (CIGMA) is a model-based 
approach for assessing glucose tolerance and p-cell function (79). It consists of a 
continuous glucose infusion (5 mg glucose/kg ideal body weight per min) for 60 min, 
with measurement of plasma glucose and insulin concentrations. These are similar to 
the postprandial levels. These levels change slowly depending on the dynamic 
interaction between the insulin produced and its effect on glucose clearance. The 
glucose and insulin concentrations after 30 min can be compared with reference values 
and interpreted using a mathematical model of glucose and insulin homeostasis to 
assess insulin resistance and p-cell function. 
The model is based on the available physiological data describing quantitatively the 
relationships between glucose and insulin (136; 137). The functions used in describing 
the model are drawn from experimental physiological data, which do not have simple 
mathematical fonnulations. p-cell responsiveness is defined as the ability of the 
pancreas to respond to glucose and is expressed as % of nonnal p-cell function. 
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CIGMA provides a near-physiological glucose load and the slowly changing glucose 
and insulin homeostasis can be easily assessed. It can be considered as a test of glucose 
tolerance and is analogous to the oral glucose tolerance test. The p-cell function 
measured by CIGMA correlated in a linear fashion with the steady state plasma insulin 
levels during hyperglycaemic clamp in diabetic but not normal (79). In addition 
CIGMA could be used with C-peptide instead of insulin measurements. It therefore 
assesses pancreatic secretion rather than the post-hepatic delivery rate which is more 
likely to cross-react with insulin assay than with C-peptide. 
Theoretically the p-cell function values from CIGMA are independent of the glucose 
levels achieved because the model includes responses for different levels of glycaemia. 
However the model assumes that the assessment parameters are relevant to studied 
subjects, which apply more to diabetic than normal subjects. These assumptions include 
equality of liver and peripheral insulin resistance, and that the reduction in p-cell 
function in diabetes is a quantitative decrease. Therefore the model may not be suitable 
in special situations, such as in the case of a change in the shape of the p-cell dose 
response curve. 
2.4.5. Intravenous glucose tolerance test 
Insulin response to an intravenous glucose stimulus has been observed to have a 
biphasic pattern. In healthy humans, an intravenous glucose bolus results in an 
immediate and sharp and rapid insulin secretion (first phase insulin secretion with 
response to glucose injection; AIRG). This peak in insulin secretion normally lasts for 
about 10 min and is followed by a second slow phase of insulin secretion which lasts for 
a longer duration. First phase insulin secretion has been observed during other 
techniques such as the hyperglycaemic glucose clamp (77; 138), glucagon injection 
(124), and stepped glucose injection (139). 
There is no standard consensus as to how the first and second phase should be 
calculated. The first phase insulin secretion generally is defined as that secretion 
occurring 2-10 min after glucose injection. The second phase is usually defined as the 
overall secretion occuring during the rest of the experiment (130). The first and second 
phase insulin secretion during IVGTT can be measured by the minimal model of C-
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peptide kinetics (140). The incremental area under the curve of insulin (or C-peptide) 
curve 2-10 min is usually used to calculate the first phase insulin secretion and assess 
the acute insulin response (123). 
2.4.6. Insulin Secretion Model 
The insulin secretion model (ISM) is a simple relatively non-invasive model-based 
approach developed several years ago to quantify pancreatic p-cell responsiveness 
during a meal tolerance test (MIT) (32). The model measures the prehepatic insulin 
secretion and assesses pancreatic p-cell responsiveness providing two indices of 
pancreatic responsiveness. Fasting (basal) pancreatic p-cell responsiveness (Mo; ability 
of fasting glucose to stimulate C-peptide secretion) and postprandial responsiveness 
(M}; ability of postprandial glucose to stimulate C-peptide secretion). The model is able 
to quantify pancreatic responsiveness in healthy and disease states, and confirms 
significant differences between healthy subjects and subjects with newly diagnosed type 
2 diabetes (141). The insulin secretion model is shown in Figure 2-3. 
kOl 
Figure 2-3. Insulin secretion model (ISM) (32). 
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Insulin and C-peptide are co-secreted in an equimolar ratio by j}-cells, and this 
phenomenon has been exploited to assess prehepatic insulin secretion (130). The liver 
does not clear C-peptide to any significant extent. C-peptide kinetics have been shown 
to be linear over a physiological to supraphysiological range of plasma C-peptide 
concentration (32). Under steady state conditions a single measurement of plasma 
C-peptide is expected to provide a more reproducible index of insulin secretion than a 
single measurement of plasma insulin (130). 
In the ISM a linear relationship between C-peptide secretion and plasma glucose was 
postulated and combined with the population model of C-peptide kinetics (32). This 
linear relationship was imposed from the time of meal ingestion until plasma glucose 
returned to its fasting concentration. 
The population model of C-peptide kinetics was reported by Van Cauter et al in 1992 
(142). It has been developed from the analysis ofC-peptide decay curves obtained from 
experiments carried out in 200 adult subjects. It enables the parameters of the C-peptide 
kinetic to be approximated from a subject's height, weight, age, sex, and the 
classification of being normal, obese, and type 2 diabetic. 
The model is described by a set of differential equations: 
{ 
MI(g(t) - St» + Most, ifM.(g(t) - St> + MoSt> > 0, 
u(t) = 




where CI(t) is C-peptide concentration in the central (plasma) compartment, C2(t) is 
equivalent concentration in the peripheral compartment, kij are transfer rate constant per 
min, get) is plasma glucose concentration, ~ is fasting plasma glucose concentration, 
u(t) is secretion rate of C-peptide per unit volume of the central compartment and is 
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constrained to non-negative values and tnWl is either 240 min or the time when plasma 
glucose returns to its fasting value. 
Ml (postprandial sensitivity index) is the ability of postprandial glucose to stimulate 
p-cells. A change in plasma glucose by 1 mmoVL results in a change in the C-peptide 
secretion rate by MJ pmollL min. Mo (basal sensitivity index) is the ability of fasting 
glucose to stimulate p-cells. Mo is numerically equal to the fasting C-peptide divided by 
the fasting plasma glucose concentration. The population model of C-peptide kinetics 
provides parameters ~j of C-peptide kinetics from a subject's demographic data using a 
regression model and avoiding the need to assess C-peptide kinetics on an individual 
basis (142). The model uses the computer to analyse the plasma glucose and C-peptide 
during MIT. A sample of the graphs produced by the model is shown in Figure 2-4. 
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Figure 2-4. A sample of the graphs produced by the insulin secretion model. 
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2.5. Parameter estimation 
The process of parameter estimation is carried out in order to get a set of numerical 
estimates of the parameters which best fit the data and a measure of their precision. The 
standard least square method is the most commonly used one. The following is a brief 
explanation of the parameter estimation methods used in this thesis. 
2.5.1. Standard two-stage method 
In the standard two-stage method (STS), the model parameters are identified and 
estimated in each subject separately (each subject is analysed individually) and the 
mean and covariance of the population are determined as the sample mean and the 
covariance. The technique used to resolve the true value of the model parameters, which 
best fit the model, is the non-linear regression (weighted non-linear least squares). The 
values of sample mean (IJ) and covariance (r,2) of the estimated parameters represent 
the mean and the variance of the population distribution. To determine each subject's 
parameters, the weighted residuals sum of squares is minimised with respect to the 
vector of model parameters Pj for a subject j 
NI [GOBS _ G( I )]2 
WRSS(Pj) = L i.j 2Pj ' i.j 
i=l O"i.j 
(2-21) 
where Nj is the number of data points available for the jth subject; tij and GitBS are the 
ith time point and the observed data point, respectively, of the jth subject; a\ is the 
variance of the measurement error of the ith data point; and G(Pj,tij) is the model 
prediction of glucose concentration for a given Pj. 
The population mean for each parameter is calculated as the sample mean of all the 
individual parameter estimates ( P j ) 
(2-22) 
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where N is the number of subjects, and the population variance is calculated as the 
corresponding sample variance 
(2-23) 
The STS method simply calculates the population statistics based on the best fit of each 
subject parameters independently. However, large between-subjects variability can lead 
to errors in the statistics for the population (143; 144). 
2.5.2. Iterative two-stage population analysis 
The iterative two-stage population analysis (ITS) is a methodology used to quantify 
between-subject variability relative to a given population model. It helps solving crucial 
problems in clinical studies such as parameter estimations with few sampling points, 
similarly in physiological and metabolic studies like the IVGTT moving out of the 
investigative stage into clinical and population studies (145). 
The method calculates the population mean and the standard deviation at each iteration 
and then uses the information from the sample mean and the covariance as prior 
information for the individual analysis. The use of a prior in the popUlation analysis 
should improve the precision of the individual estimates and provides a more reliable 
measure of the popUlation parameters (J 44). Such estimates can be performed, despite 
the fact that the number of data points obtained from each individual may be less than 
the number of model parameters. 
The ITS is based on the concepts of population prior knowledge and maximum a 
posteriori (MAP) probability empirical Bayesian estimation. The process starts with an 
initialisation step where the mean and the covariance are estimated as in the standard 
two-stage. The next step is to perform the parameter estimation on each subject j again, 
but this time minimising the following extended MAP Bayesian objective function with 
respect to Pj 
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(2-24) 
where pj,i is the ith element of the parameter vector for subject j and Np is the number of 
elements in the vector Pj' The estimate P J obtained by minimising this objective 
function is often caIled post hoc, or empirical Bayesian estimate. J.li(k) is the value of the 
population mean at the kth iteration of the method, and rdk) is the ith diagonal element 
of the population covariance matrix at the kth iteration. The updated population mean of 
the parameter vector can then be calculated as: 
(2-25) 
and the covariance is calculated as: 
(2-26) 
where Vj is the variance (precision) of the resulting estimate P J ofpj. 
This approach can mtnlmlse the sampling requirements from each individual 
dramatically. The iterative two-stage method assumes that the distribution of the 
population parameters is multivariate normal. However it is expected to perform well 
even if the assumptions of normality is not fully met (146; 147). 
2.5.3. Bayesian estimation 
Bayesian analysis is based on the idea that unknown quantities such as population mean 
and distribution have a probability distribution. This probability distribution for a 
population is based on the available prior knowledge about the popUlation, then adding 
the knowledge which comes from the data set. The prior knowledge could be 
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summarised as the mean and the standard deviation or variance, which is constructing 
on a priori distribution. The data set is then used to refine and modify the prior 
probability distribution, which then results in the posterior distribution. The modified 
probability n(p) is obtained according to the Bayes theorem: 
&(p) = p(pIY) = p(J1p)p(p) 
p(y) (2-27) 
where y = yl .... yN is the vector of measurements, p(P) is the prior probability of 
parameters, p(y) is the prior probability of measurements, and p(ylp) is the conditional 
probability of measurements given data (148). 
The great influence of the prior distribution on the results could be a major limitation of 
the Bayesian approach (149; 150). 
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3. Reduced sampling schemes for estimating pancreatic 
responsiveness during meal tolerance test 
3.1. Introduction 
Population studies for the assessment of p-cell function in subjects at risk of and with 
type 2 diabetes (T2D) are of primary importance to understand the disease aetiology and 
design preventative strategies. Most of the tools and models available for assessing the 
p-cell function are costly and labour and time consuming such as the hyperglycaemic 
clamp (79). and minimal model of C-peptide secretion during intravenous glucose 
tolerance test (123). Thus the in-depth examinations of p-cell function are limited to 
research studies. 
The availability of a simple and easy model-based approach to quantify ~-cell function 
will extend its use to population and clinical utilization which should help in predicting 
and understanding the progression of the disease. 
The insulin secretion model (ISM) with the meal tolerance test (MTT) is a simple 
relatively non-invasive tool to investigate pancreatic responsiveness (32). It measures 
the prehepatic insulin secretion and assesses pancreatic p-cell responsiveness giving 
postprandial pancreatic p-cell responsiveness (M1) and basal pancreatic p-cell 
responsiveness (Mo). 
Different sampling schemes were used in the process of estimating pancreatic p-cell 
responsiveness with the insulin secretion model. The full sampling scheme employed in 
model development consisted of 14 samples over four hours at 0, 10,20,30,40,50,60, 
75, 90, 120, ISO, 180, 210 and 240 min as determined by clinical personnel when 
designing the experimental protocol. 
A sampling scheme consisting of nine samples has also been used and will be used in 
the course of studies in this thesis (51) but its performance with the model is currently 
unknown. A reduced five sample scheme over two hours at 0, 30, 60, 90, and 120 min 
(151) will further reduce the time, labour and cost, facilitating a wide use of the model. 
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In the present study, the pancreatic p-cell responsiveness indices (MJ and Mo) were 
evaluated with two reduced sampling schemes (nine samples and five samples) and 
compared against indices obtained during the full sampling scheme. 
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3.2. Methods 
3.2.1. Subjects and experimental design 
A total of twenty one subjects with newly presenting Type 2 diabetes participated in the 
study, see Table 3-1. Ethical approval for the studies was obtained from the South 
Glamorgan Local Research Ethics Committee, Cardiff, UK. 
The subjects were admitted on the study day to the Diabetes Research Unit, Llandough 
Hospital (Penarth, UK). Each subject underwent the meal tolerance test to assess 
parameters of carbohydrate metabolism and to measure glucose, insulin, and C-peptide. 
The subjects were studied after an overnight fast for 12 hours. 
Table 3-1. Demographic data for subjects participating in the study (N = 21 ). 
Sex Age Height Weight 8MI 
(M/F) (year) (m) (kg) (kg/m2) 
Mean 16/5 52 1.71 87.9 30.4 
SE 2 0.02 4.2 1.2 
3.2.2. Meal tolerance test 
The standard meal tolerance test (MIT) consisted of digesting 15g Weetabix, 109 
skimmed milk, 250mL pineapple juice, 50g white meat chicken, 60g wholemeal 
bread, 109 polyunsaturated margarine (75g carbohydrates; total 500 Cal; calorie 
contribution: 58% carbohydrate, 23% fat and 19% protein) (49). The subjects were 
required to consume the whole meal within 10 minutes. In total 15 blood samples 
were taken over 240 minutes to measure plasma glucose, insulin and C-peptide, 
samples were taken at -30, 0, 10,20, 30, 40, 50, 60, 75. 90, 120, 150, 180, 210 and 
240 minutes relative to meal ingestion. At each sanlple time the infusion is stopped 
and the first 2-ml blood withdrawn and discarded, prior to obtaining the sample for 
assay. 
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Blood was taken via an indwelling intravenous (IV) cannula which was inserted into the 
antecubital fossa vein and connected via a three-way tap to a slow running saline 
(0.IS4nmoVl) infusion to maintain the patency of vein. 
3.2.3. Sample Analysis 
Glucose was assayed using the glucose oxidase method (intra-assay CV < 2%). Insulin 
and C-peptide were assayed using a monoclonal antibodies method (intra-assay CV < 
5% and < 6%, respectively). Insulin in plasma is measured by an enzyme immunoassay 
which does not cross- react with other insulin-like components, and C-peptide in plasma 
is also measured by an enzyme immunoassay which does not cross-react with insulin. 
Following blood sampling the samples were separated as soon as possible. Blood 
was centrifuged (2000g, Smin) in a refrigerated (4°C) centrifuge and the plasma 
put into aliquots and frozen at _20° C immediately. Samples remained frozen until 
assay. 
3.2.4. Insulin secretion model 
The insulin secretion model was used to quantify pancreatic p-cell responsiveness from 
MIT data, providing fasting p-cell responsiveness (Mo; ability of fasting glucose to 
stimulate C-peptide secretion) and postprandial p-cell responsiveness (M1; ability of 
postprandial glucose to stimulate C-peptide secretion) (32). 
The package used to calculate Mo and MI was version 1.0 of CPR (Calculating 
Pancreatic Responsiveness; written by R. Hovorka and H.C. Subasinghe, MIM Centre, 
City University, London, UK, 1997). 
The model parameters Mo and Ml were estimated employing weighted non-linear 
regression analysis. The measured errors wereassumed to be uncorrelated, with zero 
mean and a constant coefficient of variance (CV = 6%). The precision of the parameters 
was obtained from the inverse of the Fisher information matrix and expressed as CV of 
the parameter estimates. The model is fully described in section (2.4.6). 
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3.2.5. Sampling schemes 
3.2.5.1. Full sampling scheme 
The full sampling scheme consisted of 14 samples at 0, 10, 20, 30, 40, 50, 60, 75, 90, 
120, 150, 180,210 and 240 min relative to meal ingestion. The full sampling scheme 
was employed by the insulin secretion model to estimate M1-ful1 and MQ-fuU. Parameter 
estimation results (estimates and precision) obtained with the full sampling scheme 
were used as the reference measurements. 
3.2.5.2. Nine-sample scheme 
The nine-sample is a reduced sampling scheme consisted of 9 samples at 0, 30, 60, 90, 
120, 150, 180,210 and 240 min relative to the meal ingestion. The nine-sample scheme 
was used to estimate the fasting (Mo.9) and postprandial (Ml-9) pancreatic ~-cel1 
responsiveness indices. 
3.2.5.3. Five-sample scheme 
A further reduced sampling scheme consisted of 5 samples at 0, 30, 60, 90, and 120 min 
relative to the meal ingestion. This sampling scheme was used to estimate the indices; 
Ml-S and Mo.s. 
3.2.6. Statistical analysis 
The Pearson correlation coefficient was used to assess the relationship between indices. 
A paired sample t-test was applied to assess the difference between indices. 
Significance was declared at P < 0.05. The precision of estimation with respect to the 
reference measurement, and the agreement between variables was assessed by the 
Bland-Altman plots (plotting the difference between methods [Y-axis] against the 
reference method [X-axis]) (152). A 20% region of agreement was defined reflecting 
the day-to-day variability of fasting plasma glucose (FPG), insulin (FPI). and 
postprandial plasma glucose and insulin responses to a mixed meal. In subjects with 
type 2 diabetes, a 15% FPG within subjects variation was reported (153) and 20% for 
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FPI (154). The posbneal glucose and insulin variation were 15% and 20%, respectively 
(155). A 20% variation should not affect the discrepancy between healthy and type 2 
diabetic subjects (32; 141). 
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3.3. Results 
3.3.1. Plasma glucose, insulin, and C-peptide 
Plasma glucose, insulin, and C-peptide profiles during MIT are shown in Figure 3-1. 
TIle data are presented as mean ± SEe 
3.3.2. Parameter estimates with nine-sample, five-sample and full 
sampling schemes 
Individual estimates of the pancreatic responsiveness indices with the full sampling 
(Ml-full and MO-fuU), and the reduced sampling schemes (MI-9, M0-9, Ml-S and Mo..s) are 
given in Table 3-2. The parameters were estimated with good precision with the reduced 
sampling schemes (mean CV :s 9%, and < 6% for Ml and Mo, respectively), and with 
the full sampling scheme. The precision of the Ml estimates with the full sampling was 
slightly better than with the reduced schemes, see Table 3-2. Postparandial and fasting 
p-cell responsiveness with full sampling, nine-sample, and five-sample schemes are 
summarised in Figure 3-2. 
3.3.3. Evaluation of nine-sample Indices 
Ml-9 was significantly correlated with Ml-full (rs = 0.99, P < 0.001). However it was 
significantly higher than Ml-fuIl (P < 0.05), see Table 3-3. The observed statistical 
significant does not imply the clinical significance as demonstrated in Figure 3-3, as 
most of the cases (19 out of 21) are lying within the predefined 20% clinical region of 
agreement. No systemic deviation or error trend was observed during the examination 
of the difference between Ml-9 and M1-full_ The scatter plot in Figure 3-5 shows the 
estimates' distribution around the equality line. 
M0-9 was significantly correlated with MO-full (rs = 0.98, P < 0.001), and the individual 
estimates of Mo..9 were similar to Mo..full (P = NS). All MO-9 estimates lied within the 
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Figure 3-1. Plasma glucose, insulin, and C-peptide profiles during MIT in subjects with T2D 
(mean ± SE, N = 20). 
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Table 3-2. Parameter estimates with nine-sample, five-sample, and full sampling schemes in 
subjects with T2D (N = 21). 
Full-Sample Nine-Sample Five-Sample 
Sub. 
No. 
606 21.2 8* 7.7 3 21.7 9 7.6 4 22.9 10 7.0 5 
607 8.5 7 3.7 3 9.6 8 3.6 5 8.5 11 3.6 5 
608 8.6 8 2.9 3 9.1 10 2.9 5 7.5 13 2.7 5 
610 17.5 7 8.1 3 17.0 9 8.2 5 16.9 11 7.7 5 
612 15.4 7 6.4 3 18.2 7 5.6 5 16.4 9 5.4 6 
616 11.5 5 5.4 3 11.5 6 5.5 5 13.2 7 5.3 5 
618 26.4 6 7.8 3 26.4 8 8.3 5 26.7 8 7.7 6 
624 28.5 4 3.5 3 32.5 5 3.4 5 30.1 5 3.2 6 
626 22.4 4 5.0 3 22.9 5 5.1 5 21.1 7 4.8 6 
638 17.5 6 6.0 3 18.1 7 6.0 5 16.6 9 5.8 5 
639 37.4 5 10.4 3 37.9 6 10.9 5 36.0 7 10.5 5 
647 26.2 6 8.2 3 28.4 6 8.2 5 24.0 8 7.7 5 
649 21.8 6 4.2 3 21.7 8 4.3 5 22.0 8 3.9 6 
651 16.1 6 3.6 3 20.4 7 3.2 5 18.2 8 2.9 5 
655 16.5 7 7.4 3 17.5 8 7.2 5 16.9 10 7.0 5 
660 4.5 6 2.4 3 4.9 7 2.3 5 4.3 11 2.3 5 
672 15.2 4 3.0 3 16.5 5 3.3 4 15.0 6 3.0 5 
673 18.9 7 7.4 3 18.7 10 7.1 5 21.3 10 7.4 5 
674 12.2 5 4.7 3 14.8 5 4.2 5 12.9 7 3.9 5 
678 7.4 15 3.2 4 7.5 21 3.3 6 8.2 20 3.4 5 
680 21.1 6 9.4 3 21.2 7 9.3 5 20.3 9 9.2 5 
Mean 17.9 6 5.7 3 18.9 8 5.7 5 18.0 9 5.5 5 
SE 1.7 1 0.5 0 1.8 1 0.5 0 1.7 1 0.5 0 
.Precision ofparnmeters estimates expressed as coefficient of variation (CV) 
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3.3.4. Evaluation five-sample indices 
MI-S was significantly correlated with M1-Cull (rs = 0.99, P < 0.001), and was not 
statistically different (P = NS). The individual estimates of M1-S and M1-full were quite 
similar as the differences between individual estimates were quite well within tlle 
agreed level of variation, see Figure 3-4. 
MOoS was significantly correlated with Mo-fuU (rs = 0.99, P < 0.001), but it was 
significantly lower than Mo-Cull (P < 0.05). However MOoS were not clinically different 
from the full sampling estimates. The Bland-Altman plot in Figure 3-4 shows no 
systematic deviation in the parameter estimates with the five-sample scheme. All 
individual estimates of Mo-s were within the clinically predefined 20% region of 
agreement. TIle tight association and agreement between the five-sample indices with 
the full sampling indices are shown in Figure 3-6. 
Table 3-3. Paired sample t-test and Pearson correlation with Bonferroni adjustment between 
pancreatic responsiveness indices (M( and Mo) with nine-sample, five-sample and full sampling 
schemes in subjects with T2D (N = 21)_ 
Pearson correlation T-test 
Correlation P-value t P-value 
Mi-full - M I-9 0.99 0.000 -3.46 0.012 
M(}'f~l- M(}'9 0.98 0.000 0.83 0.416 
Mi-full - MI-5 0.99 0.000 -0.69 0.501 
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Figure 3-2. Postparandial (M'.full, M'_9, and M,.s) and fasting (MOofulh M009, and MOos) p-cell 
responsiveness with full sampling, nine-sample, and five-sample schemes in subjects with T2D 
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Figure 3-3. Comparison of postprandial (top) and fasting (bottom) ~-cel1 responsiveness with 
full sampling and nine-sample indices in subjects with T2D. Differences between methods 
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Figure 3-4. Comparison of postprandial (top), and fasting (bottom) ~-cell responsiveness with 
full sampling and five-sample indices in subjects with T2D. Differences between methods 
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Figure 3-5. Relationship between individual estimates of postprandial pancreatic p-cell 
responsiveness indices with full sampling (MI-fuU), and nine-sample (MI_9) schemes (top panel), 
and between fasting pam,Teatic ~-cell responsiveness indices with full sampling (Mo.fuI1), and 
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Figure 3-6, Relationship between individual estimates of postprandial pancreatic p-cell 
responsiveness indices with full sampling (M/_fuU), and five-sample (M/_s) schemes (top panel), 
and between fasting pancreatic p-cell responsiveness indices with full sampling (Mo-fuu), and 
five-sample (M(}.s) schemes (bottom panel), (N = 21), A unity line is shown, 
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3.4. Discussion 
In the present study, ISM indices of pancreatic ~-cell responsiveness were successfully 
estimated and evaluated during MTT with nine-sample and five-sample schemes. 
Reduction in sample number from 14 to 9 and 5 did not have any significant effect on 
the clinical utility and the calculation and precision of the ~-cell responsiveness indices 
Ml and Mo. The reduced sample schedules did not produce any observed clinical bias on 
the calculated value of Ml and Mo. 
To derive reliable estimates of ~-cell responsiveness during MTT, a rich data set was 
initially used with 14 samples taken over four hours. However a sampling scheme with 
nine samples is in use (49), and a standard five sample scheme (lSI) is widely adopted, 
reducing the cost, time and labour. 
A 20% clinical region of agreement was defined depending on reported variation in 
FPG, FPI, and postprandial glucose and insulin responses. Ollerton et al (153) reported 
a ±15% FPG day-to-day variability. They suggested that 14% of the variability is due to 
the biological variability in 193 subjects with newly diagnosed type 2 diabetes (153). In 
eight subjects with mild diabetes Wolever et al (154) reported about 20% fasting and 
postmeal plasma insulin within-subject variability. They reported 11 % as an overall 
mean plasma glucose within-subject variation after meal (154). 
Nine-sample scheme 
ISM pancreatic J3-cell responsiveness parameters (MI-9 and MO-9) during MTT were 
estimated with good precision with the nine-sample scheme. MI-9 was significantly 
correlated with M1-full, but was statistically higher than Ml-full (P < 0.05). However Ml-9 
was not clinically different from the M1-full and the difference between the index 
measurements with the two schemes was within the predefined clinical accepted range. 
No systematic bias was observed in calculating MI from nine-sample scheme as 
demonstrated by the Bland-Altman plot. M0-9 was well correlated with and identical to 
MO-full. 
Five-sample scheme 
The five-sample scheme was sufficient and rich enough to get reliable estimates of both 
Ml-S and MO-s. The model was able to fit the data and to provide pancreatic J3-cell 
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responsiveness parameters during MIT with good precision (mean CV:5 9%). M1-S was 
significantly correlated with and identical to Ml-fuu and the differences between the 
individual estimates of indices were within the predefined variation level. 
MO-s was significantly correlated with MO-full. but was statistically lower (P < 0.05). 
However it was not clinically different. the differences between the individual estimates 
were all within the clinically accepted range. The MO-s individual estimates are in 
agreement with the reported range in subjects with newly diagnosed T2D (32; 141). The 
MO-s estimates were not biased. or different from MO-full as documented by the 
Bland-Altman plot. No systemic trend or deviation was observed (see Figure 3-4). 
3.5. Summary 
Nine-sample and five-sample reduced sampling schemes were proposed and 
successfully evaluated against the full sampling scheme. Reduction in sample number 
did not have any significant effect on the calculation and precision of the p-cell 
responsiveness indices providing accurate estimates of both Ml and Mo. 
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4. Validation of the insulin secretion model during OGTT in healthy 
subjects and subjects with type 2 diabetes 
4.1. Introduction 
Type 2 diabetes (T2D) is characterised by various degree of p-cell defect (64), and it is 
well accepted that a substantial loss of p-cel1 function should be present for a 
hyperglycaemia to appear in type 2 diabetes (60). In addition, individuals at high risk of 
diabetes demonstrated a diminished p-cell function while maintaining normal glucose 
tolerance (62; 63; 155). 
The availability of p-cell function indices is important for understanding and identifying 
with other factors, such as insulin sensitivity the aetiology of type 2 diabetes. A reliable 
quantification of p-cell functions and insulin resistance could make it possible to predict 
the disease progression. Various methods and approaches have been developed to assess 
pancreatic p-cell function including the hyperglycaemic clamp (77), minimal model of 
C-peptide secretion during intravenous glucose tolerance test (J 23), combined model of 
insulin and C-peptide secretion (156), Low-dose insulin and glucose-infusion test (157), 
Homeostasis Model Assessment (HOMA) (85), and Continuous Infusion of Glucose 
with Model Assessment (CIGMA) (79), in addition to several other simple one 
measurement and simple mathematical calculations. 
The insulin secretion model (ISM) is a non-invasive model-based method developed to 
quantify pancreatic p-cell responsiveness during a meal tolerance test (MTT) (32). The 
model calculates two indices of pancreatic responsiveness. It measures the prehepatic 
insulin secretion and assesses pancreatic p-cell responsiveness giving fasting pancreatic 
p-cell responsiveness (Mo; ability of fasting glucose to stimulate C-peptide secretion) 
and postprandial responsiveness (M1; ability of postprandial glucose to stimulate 
C-peptide secretion). The model is able to quantify pancreatic responsiveness in healthy 
and disease states, and confirms significant differences between healthy subjects and 
subj ects with newly diagnosed type 2 diabetes (141). 
MTT is used because it results in a typical postprandial exposure of the pancreas to 
glucose and gut and vagal honnones.( 158). However the oral glucose tolerance test 
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(OGTT) is the most widely used test because of its simplicity, its ease of 
implementation and the fact that it is easy to standardised. In addition OGTT is the 
standard diagnostic test of type 2 diabetes and impaired glucose tolerance (IGT) 
approved by the World Health Organisation (WHO) (1). 
The insulin secretion model was developed and validated during MTT (32). In the 
present study we validated the insulin secretion model during OGTT in healthy subjects 
and subjects with T2D. Comparisons between the ISM estimates, and glucose, insulin, 
and C-peptide responses during MTT and OGTT were carried out. 
MTT has the advantage of increased the stimulatory effect of incretin as a result of the 
meal composition (see Methodology). However, both MIT and OGTT represent a 
physiological stimulation and represent a typical postprandial exposure of pancreas to 
glucose and gut and vagal hormones, and OGTT is expected to perform in a comparable 
manner to MIT. 
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4.2. Methods 
4.2.1. Subjects and experimental design 
Two groups of subjects were studied, namely a healthy group and a T2D group having 
subjects with newly presenting type 2 diabetes (Table 4-1, and 4-2, respectively). Each 
group underwent a meal tolerance test and an oral glucose tolerance test on two 
occasions one week apart. The subjects were admitted on the study day to the Diabetes 
Research Unit, Llandough Hospital, Penarth, UK. The subjects were studied after an 
overnight 12 hour fast. The ethics approval for the studies was obtained from the South 
Glamorgan Local Research Ethics Committee, Cardiff, UK. 
Table 4-1. Demographic data for healthy subjects (N = 9). 
Sex Age Height Weight BMI 
(M/F) (year) (m) (kg) (kg/m2) 
Mean 9/0 28 1.80 78.1 24.2 
SE 2 0.02 1.5 0.5 
Table 4-2. Demographic data for subjects with newly presenting T2D (N = 20). 
Sex Age Height Weight BMI 
(M/F) (year) (m) (kg) (kg/m2) 
Mean 1713 55 1.71 83.1 28.6 
SE 2 0.02 2.3 0.8 
4.2.1.1. Meal tolerance test 
The meal tolerance test consisted of digestion of ISg Weetabix, 109 skimmed milk, 
250mL pineapple juice, 50g white meat chicken, 60g wholemeal bread, 109 
polyunsaturated margarine (75g carbohydrates; total 500 Cal; calorie contribution: 58% 
carbohydrate, 23% fat and 19% protein) (49). The subjects were required to consume 
the whole meal within 10 min. 
Samples were taken over 240 minutes in addition to another two samples withdrawn at 
fasting states to measure glucose, IRI and C-peptide. The samples were taken at -30, 0, 
30,60,90, 120, 150, 180,210, and 240 min in T2D group. The sampling in the healthy 
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group had an additional five samples at 10, 15, 20, 25, and 45 min, relative to meal 
ingestion. At each sample time the infusion is stopped and the first 2-ml blood 
withdrawn and discarded, prior to obtaining the sample for assay. 
4.2.1.2. Oral glucose tolerance test 
The oral glucose tolerance test consisted of 75g glucose syrup taken by mouth. 
Samples were taken over 240 min in addition to another two samples withdrawn at 
fasting states to measure glucose, IRI and C-peptide. The samples were taken at 
-30,0,30,60,90, 120, 150, 180,210, and 240 min in T2D group. The sampling in 
the healthy group had an additional five samples at 10, 15, 20, 25 and 45 min, 
relative to glucose intake. At each sample time the infusion is stopped and the first 
2-ml blood withdrawn and discarded, prior to obtaining the sample for assay. 
4.2.1.3. Assay methods 
Following blood sampling, the samples were separated as soon as possible. Blood was 
centrifuged (2000g, 5min) in a refrigerated (4°C) centrifuge and the plasma put into 
aliquots and frozen at _200 C immediately. 
Glucose was assayed using the glucose oxidase method (intra-assay CV < 2%). Insulin 
and C-peptide were assayed using a conventional radioimmunoassay (intra-assay CV < 
6%). 
4.2.2. Insulin secretion model 
The model provides two indices, MJ (postprandial responsiveness index) represents the 
ability of postprandial glucose to stimulate the ~-ce]]. Mo (fasting responsiveness index) 
represents the ability of fasting glucose to stimulate p-cells. The model is 
comprehensively described in Chapter 2. 
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4.3. Data analysis 
4.3.1. Model validation and parameter estimation during OGTT 
To assess the adequacy of the ISM with OaTT in healthy subjects and subjects with 
T2D. we evaluated practical (a posteriori) identifiability. and goodness of fit (143). The 
following criteria were used to assess model validity: 
• coefficient of variation (CV) measured as the fractional standard deviation 
(FSD) for the assessment of precision of parameter estimates 
• distribution of normalised residual for the assessment of model ability to fit data 
(goodness of fit) considering the measurement errors. and to detect any 
systematic deviation between the data and the model prediction 
• runs test to assess the distribution of the residuals and check for presence of 
model misfit. 
The package used to calculate Mo and Ml was version 1.0 of CPR (Calculating 
Pancreatic Responsiveness; written by R. Hovorka and H.C. Subasinghe. MIM Centre. 
City University, London. UK 1997). The model parameters Mo and Ml were estimated 
employing weighted non-linear regression analysis. The measured errors were assumed 
to be uncorrelated, with zero mean and a constant coefficient of variance (CV = 6%). 
The precision of parameters was obtained from the inverse of the Fisher information 
matrix and expressed as CV of parameter estimates (32). 
4.3.2. Incremental area under curve 
In addition to the parameters obtai?ed from the insulin secretion model. we evaluated an 
incremental area under the curve (AUC) from 0-90 minutes for glucose (AUCG). insulin 
(AUCl). and C-peptide (AUCc) during both MTT and OOTT. The incremental response 
was used to eliminate the effect of the basal values on the analysis. The calculation was 
done over 0-90 min because glucose concentrations reach the basal level by 90 min in 
the majority of subjects. Fasting plasma glucose (FPO). insulin (FP!). and C-peptide 
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(FPC) were calculated as the mean of fasting values (at -30 and 0 min) during both 
MTT and OGTT 
4.3.3. Statistical analysis 
A Spearman correlation analysis with Boniferroni correction was carried out to assess 
relationships between indices. Wilcoxon signed ranks test was applied to assess the 
difference between the model indices and glucose, insulin, and C-peptide responses 
during MTT and OGTT. 
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4.4. Results 
4.4.1. Healthy subjects 
4.4.1.1. Plasma glucose, insulin, and C-peptide 
Table 4-3 shows the individuals, fasting values of glucose, insulin, and C-peptide 
(HbAIC is not available). No significant difference in fasting values (FPa, FPI, and 
FPC) was observed between the two test days (P = NS). Plasma glucose, insulin, and 
C-peptide profiles during oaTT and MIT are shown in Figure 4-1. During MTT and 
OaTT, the glucose and insulin levels reached their peak values at 30-60 minutes. 
However the glucose returned to the fasting level more quickly during MTT at 90 min. 
The glucose levels during oaTT remained elevated for longer and returned to fasting 
levels at 120-150 minutes. 
Table 4-3. Fasting plasma glucose (FPG), insulin (FPI), and C-peptide (FPC) in healthy 
subjects. 
FPG FPI FPC 
Subject No. (mmol/I) (pmol/I) (nmolll) 
1 5.4* 73* 0.407* 
2 5.5 20 0.232 
3 5.2 35 0.360 
4 5.5 44 0.338 
5 4.9 34 0.258 
6 5.2 24 0.465 
7 5.6 40 0.288 
8 5.9 59 0.257 
9 5.2 39 0.283 
Mean 5.4 41 0.321 
SE 0.1 6 0.026 
• Mean of fasting values on two study days 
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Figure 4-1. Plasma glucose, insulin, and C-peptide profiles in healthy subjects during COIT 
and MIT (mean ± SE, N=9). 
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4.4.1.2. Model validation during OGTT in healthy subjects 
Parameter estimates were obtained with excellent precision (mean CV for M, and 
Mo ~ 4%). see Table 4-4. During OGTT the model had a tendency to underestimate 
plasma C-peptide at 5 min and overestimate at 10-20 min. However the non-significant 
Runs test indicates a random distribution of the residuals. The value and distribution of 
normalised residuals around the zero line after 20 minutes indicate a good model fit 
(Figure 4-2). 
4.4.1.3. Parameter estimation 
The results of parameter estimation during MTT and OGTT are given in Table 4-4. The 
parameters were computed with excellent precision during both MTT and oaTT (mean 
CV for M, and Mo $ 4%), see Table 4-4. Healthy subjects exhibited a wide range of 
postprandial pancreatic responsiveness, whereas fasting pancreatic responsiveness was 
low and comparable to those observed in subjects with type 2 diabetes (32). 





M. CV Mo CV M. CV Mo CV 
(10.9 x 1/min) (%) (10.9 x 1/min) (%) (10.11 x 1/min) (%) (10.11 x 1/min) (%) 
1 54.55 5* 6.36 3 34.29 3. 3.22 4 
2 21.64 4 2.04 4 16.12 3 3.55 4 
3 43.85 5 3.72 5 54.63 4 4.88 5 
4 102.45 5 6.43 2 33.64 3 2.23 5 
5 52.08 4 4.04 4 8.34 6 2.28 5 
6 17.74 5 2.97 3 23.61 4 3.21 4 
7 57.68 4 3.59 4 35.51 4 3.95 4 
8 53.78 4 2.75 4 40.43 3 2.61 6 
9 47.40 4 3.46 4 30.70 3 4.16 3 
Mean 50.13 4 3.93 4 30.81 4 3.34 4 
SE 8.11 0 0.51 0 4.53 0 0.30 0 
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Figure 4-2. Normalised residual (difference between calculated and measured C-peptide 
concentration divided by measurement error) vs. time in healthy subjects during OGTT (top 
panel) and during MIT (bottom panel), (mean ± SE). 
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4.4.1.4. Comparability of pancreatic responsiveness during MIT and OGIT 
Pancreatic responsiveness indices (M, and Mo), and glucose, insulin, and e-peptide 
responses during MIT and oaTT are given in Table 4-5. M, was about 35% higher 
during MIT than OGrT (p = NS), while Mo was comparable. ooIT resulted in a two 
fold higher glucose incremental Ave than MIT (P = 0.055), while e-peptide 
incremental AVe was only 1.2 fold higher (P = NS). Insulin incremental AVe was 
comparable and strongly correlated between tests (rs = 0.90, P < 0.01). Wilcoxon signed 
ranks test and Spearman correlation are summarised in Table 4-6. Figures 4-3 to 4-6 
summarise the pancreatic responsiveness indices (M, and Mo) results and the 
relationship between indices. 
Table 4-5. Pancreatic responsiveness indices (M. and Mo), and glucose, insulin, and C-peptide 




M Mo AUCG AUCc AUC, M, Mo AUCo AUCc AUC, 
{10·9 X {10·9 x (mmollli (nmollli (mmollli (10·' x (10·' x (mmollli (nmol/ll (mmollli 
1/mln) 1Imln) 90mln) 9amln) 9amln) 1/mln) 1/mln) 90mln) 90mln) 9amln) 
1 54.55 6.36 116.0 76.48 19.1 34.29 3.22 200.5 72.83 23.3 
2 21.64 2.04 182.0 42.13 11.7 16.12 3.55 356.5 64.10 12.3 
3 43.85 3.72 43.5 52.53 13.7 54.63 4.88 103.8 96.50 19.7 
4 102.45 6.43 35.5 75.23 26.6 33.64 2.23 154.3 81.88 20.2 
5 52.0B 4.04 98.3 74.13 12.9 B.34 2.28 232.0 25.65 11.8 
6 17.74 2.97 133.0 9.38 5.9 23.61 3.21 198.5 53.73 8.4 
7 57.68 3.59 121.3 79.95 15.8 35.51 3.95 114.8 88.50 17.2 
8 53.78 2.75 95.0 79.08 18.3 40.43 2.61 194.0 99.15 22.0 
9 47.4 3.46 59.8 31.20 8.0 30.7 4.16 176.8 48.00 2.9 
Mean 50.13 3.93 98.3 57.79 14.7 30.81 3.34 192.3 70.04 15.3 
SE 8.11 0.51 15.6 8.49 1.9. 4.53 0.30 24.8 8.16 2.3 
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Table 4-6. Wilcoxon signed ranks test and Speannan correlation with Bonferroni adjustment 
between pancreatic responsiveness indices (M, and Mo) and AUCG, AUCc, and AVC, during 
MTT and OGTT. 
Speannan correlation Wilcoxon signed ranks test 
Correlation P-value test P-value 
M, 0.35 0.356 -2.037 0.190 
Mo -0.28 0.460 -0.296 0.767 
AUCG 0.62 0.385 
-2.547 0.055 
AUCc 0.62 0.385 -1.481 0.139 
AUC, 0.90 0.005 -0.533 0.594 
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Figure 4-3. Pancreatic responsiveness indices (M! and Mo) during MTT and OGTT in healthy 
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Figure 4-4. Relationship between individual estimates of postprandial pancreatic p-cel1 
responsiveness indices during MTT and oarr (top panel), and between fasting pancreatic 
p-cell responsiveness indices during Mrr and oarr (bottom panel) in healthy subjects, (N = 
9). A unity line is shown. 
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Figure 4-5. Postprandial pancreatic p-cell responsiveness during OGTT and MIT in healthy 
subjects (N =9). 
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Figure 4-6. Fasting pancreatic p-cel1 responsiveness during OGTT and MIT in healthy subjects 
(N =9). 
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4.4.2. Subjects with type 2 diabetes 
4.4.2.1. Plasma glucose, insulin, and C-peptide 
Newly presenting type 2 diabetes demonstrated elevated fasting plasma glucose and 
HbAlc as indicate for the lack of control. At the same time, fasting plasma insulin was 
elevated which might indicate a high degree of insulin resistance (159). Individuals 
fasting values of glucose, insulin, and C-peptide together with HbAlc are given in Table 
4-7. No significant difference in fasting values (FPG, FPI. and FPC) was observed 
between the two test days (P = NS). Plasma glucose, insulin, and C-peptide profiles 
during OGrr and MTT are shown in Figure 4-7. The glucose and insulin levels 
remained elevated for longer than in non-diabetic subjects with peak values reached at 
60-120 minutes. 
Table 4-7. Fasting plasma glucose (FPG). insulin (FPI). C-peptide (FPC), and glycated 
haemoglobin (HbAIC) in subjects with type 2 diabetes. 
Subject No. FPG FPI FPC HbA10 (mmolll) (pmolll) (nmol/l) (%) 
1 14.6* 36* 0.368- 13.8 
2 9.1 21 0.653 9.2 
3 14.6 12 0.563 13.9 
4 9.9 32 0.768 8.0 
6 10.7 129 1.095 8.4 
6 7.7 78 1.133 9.5 
7 10.7 50 0.613 8.7 
8 12.6 6 0.363 11.2 
9 15.8 113 0.990 11.1 
10 15.5 95 0.710 13.2 
11 11.6 128 0.258 11.6 
12 9.9 164 0.880 11.5 
13 6.9 138 0.700 12.5 
14 10.0 155 0.583 9.3 
15 5.9 170 1.280 10.7 
16 10.3 138 1.023 12.5 
17 9.9 122 0.723 12.0 
18 11.9 53 0.705 12.6 
19 10.8 135 0.483 11.1 
20 7.6 156 0.773 9.8 
Mean 10.8 97 0.733 11.0 
SE 0.6 13 0.061 0.4 







-(I) 14 en 
0 
0 






















E. 1000 (I) 
c.. o 800 
600 
I : OGnl 
--.- MTT 
-30 0 30 60 90 120 150 180 210 240 
-30 0 30 60 90 120 150 180 210 240 
-30 0 30 60 90 120 150 180 210 240 
Time (min) 
Figure 4-7. Plasma glucose, insulin, and C-peptide proflles during MTI and OaTI in subjects 
with T2D (mean ± SE, N=20). 
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4.4.2.2. Model validation during OGTT in subjects with type 2 diabetes 
Parameter estimates were obtained with good precision (mean CV of parameter 
estimates for Ml and Mo ~ 10% and 5%, respectively), see Table 4-8. The magnitude 
and distribution of normalised residuals around the zero line indicate a good model fit 
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Figure 4-8. Nonnalised residual (difference between calculated and measured C-peptide 
concentration divided by measurement error) in subjects with T2D during OGrr (top panel) 
and MTT (bottom panel), (mean ± SE). 
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4.4.2.3. Parameter estimation 
Parameters were estimated with good precision during both MlT and OGlT (mean CV 
of parameter estimates for MJ and Mo ~ 10% and 5%, respectively). Individual estimates 
of pancreatic responsiveness indices during MIT and OGTI together with their 
precision are presented in Table 4-8. 





MI CV Mo CV MI CV Mo CV 
(10.9 x 1/min) (%) (10.9 x 1/min) (%) (10.9 x 1/min) (%) (10.9 x 1/mln) (%) 
1 7.12 6* 1.42 5 3.83 5 1.23 4 
2 14.92 6 3.80 6 8.61 7 4.74 5 
3 6.31 10 2.73 4 2.15 15 2.63 4 
4 43.39 7 4.19 6 12.83 6 4.69 5 
5 35.75 8 6.99 4 14.09 10 7.13 5 
6 23.18 10 9.14 5 19.46 7 9.80 5 
7 12.84 8 4.07 5 6.71 7 3.29 5 
8 9.53 7 1.84 5 4.63 6 1.81 5 
9 8.18 9 4.68 4 3.29 15 3.72 4 
10 7.09 12 2.67 5 2.22 20 2.63 5 
11 1.69 15 0.97 4 3.17 7 1.50 5 
12 26.86 7 7.05 5 3.74 9 1.84 6 
13 6.08 11 3.81 6 7.52 8 7.93 4 
14 12.19 7 4.67 5 1.88 15 3.27 5 
15 29.08 7 14.33 5 12.75 7 13.67 4 
16 16.31 7 5.40 5 5.47 13 5.63 5 
17 8.53 9 4.44 5 5.78 12 5.13 4 
18 7.04 6 2.53 6 3.94 13 3.97 5 
19 15.93 7 2.81 4 8.83 a 3.01 4 
20 11.88 10 6.25 5 12.88 7 7.16 5 
Mean 15.19 9 4.69 5 7.19 10 4.74 5 
SE 2.46 1 0.68 0 1.09 1 0.70 0 















4.4.2.4. Comparability of pancreatic responsiveness during MIT and OGIT 
M. was two fold higher during MIT than OGrr (p = 0.001), see Table 4-9 and Fig 4-9. 
The two indices were correlated (rs = 0.62; P < 0.05). Mo was identical and highly 
correlated during MIT and OGTT (rs = 0.70; P < O.Ol). Glucose response during 
OGrr was higher than during MTT (P = 0.001), however the insulin and C-peptide 
responses were slightly higber during MTT (P = NS). Pancreatic responsiveness indices 
(M) and Mo), and glucose, insulin, and C-peptide response during MTT and OGTT are 
presented in Table 4·11. 
Table 4·9. Wilcoxon signed ranks test and Speannan correlation with Bonferroni adjustment 
between pancreatic responsiveness indices (M) and Mo) and AUCo, AVCc, and AVC. during 
MTT and OGTT. 
Spearman correlation Wilcoxon signed ranks test 
Correlation P-value test P-value 
M. 0.62 0.020 -3.696 0.001 
Mo 0.70 0.005 -0.672 0.502 
AUCG 0.48 0.155 -3.696 0.001 
AVec 0.44 0.275 ·0.859 0.390 
AUC. 0.49 0.135 -1.549 0.121 
P = 0.001 P=NS 
5 
o 2 ~ 
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Figure 4-9. Pancreatic responsiveness indices (M) and Mo) during MIT and OGIT in 
subjects with T2D, (mean ± SE, N = 20). 
90 
4.4.2.5. Correlation between ~-ce" responsiveness and glucose control 
The p-cell response during OGTT represents the effect of postprandial glucose on 
insulin secretion, while it represents the effect of postprandial glucose and the effect due 
to the fat and protein contents of the meal during MTT. The difference between MI 
during MIT and OGTT (~MI) theoretically could represent the p-cell response to the 
non-carbohydrate meal contents during MTT and could account for the effect of fat and 
protein on insulin secretion (incretin effect). 
Postprandial p-cell responsiveness (Mv during MTT and OGTT was strongly correlated 
with HbA1C and FPG. However ~MI was correlated with HbA1C (rs = 0.51, P was not 
significant after conservative adjustment) but not with FPG. Fasting p-cell 
responsiveness during MTT and OGTT was strongly correlated with FPG. Table 4-10 
shows the results of the Spearman correlation analysis between glucose control (HbA)c 
and FPG) and fasting and postprandial p-cell responsiveness during MTT and OGIT. 
The correlations between glucose control and the difference between MI during MIT 
and OGTT are also given. 
Table 4-10. Spearman correlation with Bonferroni adjustment between pancreatic 
responsiveness indices (M, and Mo) during MTI and CaTI and ~Ml (difference between M, 




* P< 0.05 









MIT OGIT (MIT-OGTI) 
-0.71** -0.59 -0.51 
-0.48 -0.63* -0.15 
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Table 4-11. Pancreatic responsiveness indices (MI and Mo), and glucose, insulin, and C-peptide 
























Mo AUCG AUCc AUC, Mo AUCo AUCc AUC, 
(10-9 X (10-9 x (mmallll (nmallll 
1/min) 1/min) 90min) 90min) 
(mmollll (10-11 x (10-11 x (mmollll (nmollll (mmollll 













12.84 4.07 330 
9.53 1.84 242 
8.18 4.68 579 
7.09 2.67 272 
1.69 0.97 230 
26.86 7.05 305 
6.08 3.81 216 
12.19 4_67 344 
29.08 14.33 279 
16.31 5.40 422 
8_53 4.44 293 
7.04 2_53 437 
15.93 2.81 198 
11.88 6.25 278 
23.55 
44.25 
3.1 3.83 1.23 444 21.90 1.9 
12.6 8.61 4.74 552 34.50 4.5 
19_20 4.0 2.15 2.63 465 18.30 1.7 
64.05 22.7 12.83 4.69 327 62.25 19.5 
57.30 18.5 14.09 7.13 434 66.45 8.6 
44.40 12.7 19.46 9.80 387 53.40 25.4 
60.90 16.2 6.71 3.29 279 25_80 2.7 
22.65 3.2 4.63 1.81 428 38.70 7.6 
51.30 9.3 3.29 3.72 560 20.85 3.4 
10_95 4-1 2_22 2_63 360 8_25 1.4 
9.00 6_6 3.17 1.50 582 17.85 7.9 
71.10 27.0 3.74 1_84 468 6.00 22.1 
3.75 11.8 7.52 7.93 372 22.50 2.9 







29.1 12.75 13.67 509 92.55 31.3 
10.2 5.47 5.63 536 43.80 14.9 
5.0 5.78 5.13 398 29.85 3.2 
4.2 3.94 3.97 414 16.35 18.0 
6.8 8.83 3.01 281 33.30 6.2 
14.9 12.88 7.16 372 39.30 7.6 




12.2 7.19 4.74 430 33.38 9.7 
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Figure 4-10. Relationship between individual estimates of postprandial pancreatic ~-cell 
responsiveness indices during MIT and OGIT (top panel), and between fasting pancreatic 
p-cell responsiveness indices during MTT and oorr (bottom panel), (N = 20). A unity line is 
shown. 
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Figure 4-11. Postprandial pancreatic ~-cell responsiveness during OOTI and MIT in subjects 



















The insulin secretion model was validated successfully during the oral glucose tolerance 
test. The validity was assessed and supported by the precision of parameter estimates, 
the distribution and statistics ofnonnalised residuals, and the non-significant Runs test. 
Parameter estimates were calculated with high precision (CV of parameter estimates 
< 10%) in both normal subjects and subjects with T2D. The behaviour of the normalised 
residuals was satisfactory in terms of both distribution and magnitude. These results 
suggest that a standard OGIT results in data that allow the insulin secretion model 
assessment over a wide range of p-cell responsiveness. The model fit in healthy group 
was not as good as in T2D group, which could be due to the subject characteristics 
(young and lean subjects). The healthy subjects have a high glucose and C-peptide 
variation in response to glucose load. 
p-cell responsiveness indices were proposed during NGTT (121) and clamp (77), 
however the oral load (OGIT and MIT) has some advantages with respect to NGIT or 
clamp approaches. It allows an accurate assessment of the p-cell function under 
physiological conditions, and represents a typical postprandial exposure of the pancreas 
to glucose and gut and vagal hormones. It is easy to perfoml, reducing the labour and 
financial costs, making it an appealing tool for population studies. 
Other methods exist to measure pancreatic ~-cell responsiveness, e.g. hyperglycaemic 
clamp (77), homeostasis model assessment (HOMA) (85), and continuous infusion of 
glucose with model assessment (CIGMA) (79). p-cell responsiveness indices were also 
derived from the fasting measures of plasma glucose and insulin (85) and during MIT 
(119) and OGTT (118; 126; 160). The postprandial secretion index Ml is basically the 
ratio (.1C-peptide secretion)/(Aplasma glucose concentration) and thus is very similar to 
that obtained by the CIGMA method, but evaluated during dynamic conditions after 
meal ingestion. Simple methods have been used in the past to assess postprandial 
insulin secretion during MIT, such as insulin incremental concentration at 30 min, or 
insulin incremental concentration at 30 min over glucose incremental concentration at 
30 min. However, methodological considerations (the effect of the measurement error 
and the inter-subject variability in insulin and C-peptide kinetics) suggest the superiority 
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of the model-based method over a simple one or two concentration-point assessment. 
Furthermore, the model-based method has been shown to be reproducible in subjects 
with Type 2 diabetes as reported in Chapter 5. 
Comparability o/pancreatic responsiveness in healthy subjects 
In healthy subjects, OGIT resulted in a two fold higher glucose incremental AUC than 
MIT, while C-peptide incremental AUC were only 1.2 fold higher (P = NS). Marena et 
al (161) observed higher glucose response to OGTT than MTT, and similar insulin and 
C-peptide responses in healthy sUbjects. This could be explained by the fat content of 
MIT stimulating the secretion of incretin hormones, which in tum stimulate insulin 
secretion (75; 76; 162). As a result of high C-peptide secretion during MTT with respect 
to the glucose concentration, MTT resulted in 1.5 fold higher postprandial pancreatic 
J3-cell responsiveness than OGTI. In healthy subjects, no correlation was observed 
between glucose and C-peptide responses across MTT and OGIT. Explaining the lack 
of correlation between Ml'S. Robert et al (163) also reported poor correlation (rs = 0.15) 
between 2hour glucose values after OGIT and standard meal in health pregnant 
women. 
Comparability o/pancreatic responsiveness in subjects with T2D 
hl subjects with T2D, glucose response during OGIT was higher than during MTT (P = 
0.001). whereas the insulin response was slightly higher during MTT (P = NS). Marena 
et al (161) also observed a higher glucose response to OGTT than MTT, and similar 
insulin and C-peptide responses in subjects with T2D. Ml was two fold higher during 
MIT than OGIT (P = 0.001). TIle two indices were correlated. The higher insulin 
response during MIT is explained by the stimulatory effect of incretin hormones on 
insulin secretion (162). as a result of the meal composition which contain carbohydrate, 
fat, and protein. Glucagon-like peptide and gastric inhibitory polypeptide are glucose 
and fat dependent gut hormones (164). Mo was identical and highly correlated. 
The J3-cell response during OGTT represents the effect of the postprandial glucose on 
insulin secretion, while it represents the effect of postprandial glucose and the effect due 
to the fat and protein contents of the meal during MIT. It is suggested that the 
difference between Ml during MIT and OGIT (~Ml) represents the effect of fat and 
protein on insulin secretion (incretin effect). The effect of incretin on insulin secretion 
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and postprandial glucose control could be a good explanation for the correlation 
between ~Ml and HbAlc and the lack of correlation with FPG. HbAIC was more 
strongly correlated with the postprandial than with fasting p-cen responses during MTT 
and OGTT. On the other hand FPG was strongly correlated with the fasting p-cell 
responsiveness during MIT and OGTT. This suggests that ~Ml is a clinically relevant 
index of the incretin effect and that it could be used in clinical studies to characterise the 
phannacodynamics of the incretin effect as compared to the measurement of incretin 
hormones, which characterise the pharmacokinetics properties. 
4.6. Summary 
The insulin secretion model was validated during OGIT in healthy subjects, and 
subjects with T2D. The model is able to assess pancreatic p-cell responsiveness from 
MTT as well as OGTT data. However the postprandial p-cen responsiveness during 
MIT is higher than that measured during OGTT, most likely due to the stimulatory 
effect of incretin hormones on insulin secretion during MIT. The meal tolerance test 
provides more physiological challenge to the p-cell than OGTT, enhances p-cell 
responsiveness compared to OGTT, and facilitates more comprehensive assessment of 
p-cell function. 
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5. Reproducibility of pancreatic l3-cell responsiveness in healthy 
subjects and subjects with type 2 diabetes 
5.1. Introduction 
Pancreatic p-cell responsiveness can be quantified by a model-based method during 
meal tolerance test (MIT) (32). In the previous chapter this model (insulin secretion 
model; ISM) was validated also to quantify pancreatic p-sell responsiveness during oral 
glucose tolerance test (OGTT). 
ISM measures the prehepatic insulin secretion and assesses pancreatic p-cell 
responsiveness giving postprandial pancreatic p-cell responsiveness (M l ; ability of 
postprandial glucose to stimulate C-peptide secretion) and basal pancreatic p-cell 
responsiveness (Mo; ability of basal glucose to stimulate C-peptide secretion). However 
these quantified measures were not studied for reproducibility. 
In the present study we investigated the reproducibility of the quantified measures of the 
pancreatic p-cell responsiveness (Ml and Mo) and glucose, insulin, and C-peptide 
responses during both MIT and OGTT. In part one, we assessed the reproducibility 
during MTT and OGIT in healthy subjects. In the second part and due to the limitation 
of data availability, we investigated the reproducibility during MTT but not OGTT in 
subjects with type 2 diabetes (T2D). 
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5.2. Methods 
5.2.1. Subjects and experimental design 
Two groups of subjects participated in the current study namely: healthy group. and 
T20 group. 
Healthy group. Healthy male subjects (N=9. age 27.6 ± 2.3 year. BMI 24.2 ± O.S 
kg/m2; mean ± SE) participated in the study see Table (5-1). Each subject in this group 
underwent MTT and OGTT twice on four separate occasions. one week apart. Part of 
the data obtained from healthy subjects was used in the previous chapter. 
Table 5-1. Demographic data for healthy subjects participating in the study (N - 9). 
Sex Age Height Weight 8MI 
(M/F) (year) (m) (kg) (kg/m2) 
Mean 9/0 28 1.80 78.1 24.2 
SE 2 0.02 1.5 0.5 
T2D group. Twelve male subjects with T20 (N = 12. age 46.3 ± 3.0 year. BMI 
29.2 ± 1.6 kg/m2; mean ± SE) participated in the study. see Table 5-2. Each subject 
underwent MTT twice in two separate occasions one day apart. 
Table 5-2 Demographic data for subjects with T2D (N = 9). 
Sex Age Height Weight 8MI 
(M/F) (year) (m) (kg) (kg/m2) 
Mean 1210 46 1.70 85.0 29.2 
SE 3 0.04 7.2 1.6 
5.2.1.1. Meal tolerance test 
The meal tolerance test consisted of digestion of 15g Weetabix. 109 skimmed milk. 
250mL pineapple juice. SOg white meat chicken. 60g wholemeal bread. 109 
polyunsaturated margarine (7Sg carbohydrates; total 500 Cal; calorie contribution: 58% 
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carbohydrate, 23% fat and 19% protein) (49). The subjects were required to consume 
the whole meal within 10 min. 
Samples were taken over 240 minutes in addition to one sample withdrawn in the 
fasting states to measure plasma glucose, insulin, and C-peptide. The samples were 
taken at -30,0,30,60,90,120,150, 180,210, and 240 min in T2D group. The sampling 
in the healthy group had an additional six samples at -15, 10, 15, 20, 25 and 45 min, 
relative to meal ingestion. At each sample time the infusion was stopped and the first 
2-ml blood withdrawn and discarded, prior to obtaining the sample for assay. 
5.2.1.2. Oral glucose tolerance test 
The oral glucose tolerance test consisted of 75g glucose syrup taken by mouth. 
Samples were taken over 240 min in addition to another two samples withdrawn in 
the fasting state to measure glucose, insulin, and C-peptide. The samples were 
taken at -30, -15, 0, 10, 15,20,25,30,45,60,90, 120, ISO, 180,210 and 240 min 
relative to glucose intake. At each sample time the infusion was stopped and the 
first 2-ml blood withdrawn and discarded, prior to obtaining the sample for assay. 
5.2.1.3. Assay methods 
Glucose was assayed using the glucose oxidase method (intra-assay CV < 2%). Insulin 
and C-peptide were assayed using conventional radioimmunoassay (intra-assay CV < 
6%). 
5.2.1.4. Insulin secretion model 
The insulin secretion model was used to quantify pancreatic responsiveness using MTT 
or OGTT data, providing basal sensitivity (Mo; ability of basal glucose to stimulate 
C-peptide secretion) and postprandial sensitivity (Ml ; ability of postprandial glucose to 
stimulate C-peptide secretion) (32). The package used to calculate Mo and Ml was 
version 1.0 of CPR (Calculating Pancreatic Responsiveness; written by R. Hovorka and 
H.C. Subasinghe, MIM Centre, City University, London, UK 1997). The model 
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parameters Mo and MI were estimated employing weighted non-linear regression 
analysis. The measured errors were assumed to be uncorrelated, with zero mean and a 
constant coefficient of variance (CV = 6%). The precision of the parameters was 
obtained from the inverse of the Fisher information matrix and expressed as CV of 
parameter estimates. For more detailed description see Chapter 2. 
5.2.2. Data analysis 
5.2.2.1. Incremental area under curve 
In addition to the parameters obtained from the insulin secretion model, we evaluated an 
incremental area under the curve from 0-90 minutes for glucose (AUCG), insulin 
(AUCI), and C-peptide (AUec) during both MTT and OGTT. 
5.2.2.2. Statistical analysis 
Reproducibility was assessed by ANOVA allowing for effects due to sUbjects. giving 
estimates of within subject CV, within subject variation as % of total variation and 
95% range for difference between duplicate measurements. Comparison was made by 
Spearman correlation analysis and Wilcoxon signed ranks test. The results are 
expressed as mean ± SE unless stated otherwise. 
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5.3. Results 
5.3.1. Healthy group 
5.3.1.1. Plasma glucose, insulin, and C-peptide 
Plasma glucose, insulin and C-peptide profiles during the repeated OaTT and MTT are 
shown in Figure 5-1 and 5-2 respectively. 
5.3.1.2. Parameter estimation during OGTT and MIT 
Parameter estimates were obtained with high precision during OaTT and MTT (CV of 
parameters estimates for Ml and Mo :s 6%). The individual estimates of the pancreatic 
responsiveness indices during oaTT and MTT together with their precision are 
summarised in Tables 5-3 and 5-4, respectively. 
Table 5-3. Pancreatic responsiveness indices (MI and Mo) during OGTT at occasions 1 and 2 in 
healthy subjects. 
Subject M' CV MI2 CV Mo' CV Mo2 CV 
No. (10.9 x 1/min) % (10.9 x 1/min) % (10.9 x 1/min) % (10.9 x 1/min) % 
1 34.29 3- 33.62 4 3.22 4 6.72 3 
2 16.12 3 27.42 4 3.55 4 3.81 4 
3 54.63 4 30.65 5 4.88 5 4.76 4 
4 33.64 3 25.98 3 2.23 5 2.93 4 
5 8.34 6 55.64 4 2.28 5 5.52 5 
6 23.61 4 22.92 4 3.21 4 3.69 3 
7 35.51 4 42.95 3 3.95 4 2.38 4 
8 40.43 3 28.07 4 2.61 6 1.86 4 
9 30.70 3 39.5 4 4.16 3 4.38 4 
Mean 30.81 4 34.08 4 3.34 4 4.01 4 
SE 4.53 0 3.45 0 0.30 0 0.51 0 
.Precision of parameter estimate expressed as coefficient of variation 
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Table 5-4. Pancreatic responsiveness indices (M, and Mo) during MIT at occasions 1 and 2 in 
healthy subjects. 
Subject MI1 CV MI2 CV M01 CV Mo2 CV 
No. (10.9 x 1/min) % (10.9 x 1/min) % (10.9 x 1/min) % (10.9 x 1/min) % 
1 54.6 5- 56.6 5 6.36 3 7.16 3 
2 21.6 4 38.5 4 2.04 4 3.65 4 
3 43.9 5 59.1 3 3.72 5 2.63 5 
4 102.5 5 53.7 3 6.43 2 2.01 5 
5 52.1 4 18.0 6 4.04 4 2.4 4 
6 17.7 5 44.1 5 2.97 3 3.96 3 
7 57.7 4 34.2 4 3.59 4 2.63 5 
8 53.8 4 72.4 4 2.75 4 2.79 3 
9 47.4 4 60.4 4 3.46 4 4.55 3 
Mean 50.1 4 48.6 4 3.9 4 3.5 4 
SE 8.1 0 5.5 0 0.51 0 0.53 0 
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Figure 5-1. Plasma glucose, insulin, and C-peptide profiles (mean ± SE, N = 9) in healthy 
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Figure 5-2. Plasma glucose, insulin, and C-peptide profiles (mean ± SE, N = 9) in healthy 
subjects during MIT on two separate occasions. 
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5.3.1.3. Reproducibility 
Reproducibility of glucose, insulin, C-peptide, and pancreatic responsiveness indices 
(Ml and Mo) during MTT and OGTT are reported in Table 5-7. Within subjects 
variation (CV) was high for all variables during both MTT and OGTT (CY :::= 26%). 
The within subjects variation as a % of total variation was also quite high (CV:::= 31 %) 
except for insulin (CY ~ 19%). In general the reproducibility of parameters during 
MIT was slightly better than OGTT, while it was markedly better for Ml and AUCc 
during MTT. No significant difference was found between repeated measures during 
MIT and OGTT. However, no significant correlation was found between repeated 
measures during MTT and OGTT except for AUCl (Table 5-5 and 5-6). Figures 5-3 
and 5-4 show the relationship between individual estimates of repeated measures of 
pancreatic p-cell responsiveness (Ml and Mo) during OGTT and MTT. 
Table 5-5. Spearman correlation and Wilcoxon signed ranks test with Bonferroni corrections 
between repeated measures during OGIT in healthy subjects. 
Spearman correlation Wilcoxon signed ranks test 
Variables 
correlation P-value Test P-value 
MI 0.00 1.000 -0.059 0.953 
Mo 0.22 0.576 -1.007 0.314 
AUCG 0.75 0.100 -0.059 0.953 
AUCc 0.48 0.187 -0.178 0.859 
AUC1 0.80 0.048 -0.889 0.374 
Table 5-6. Spearman correlation and Wilcoxon signed ranks test with Bonferroni corrections 
between repeated measures during MIT in healthy subjects. 
Spearman correlation Wilcoxon Signed ranks test 
Variables 
correlation P-value Test P-value 
MI 0.00 1.000 -0.059 0.953 
Mo -0.38 0.318 -0.356 0.722 
AUCG 0.53 0.145 -1.599 0.110 
AUCc 0.20 0.606 -0.296 0.767 
AUC. 0.85 0.019 -0.889 0.374 
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Table 5-7. Reproducibility of pancreatic responsiveness indices (M, and Mo) and glucose, insulin, and C-peptide responses during MTT and OGTT in 
healthy subjects. Mean ± SE values are reported. 
MIT OGIT 
MI Mo AUCG AUCc AUC1 MI Mo AUCG AUCc AUC, 
(10" x 1/min) (10" x 1/min) (mmoIN9Omin) (nmoUII90min) (mmoUl/901min) (10" x 1/min) (10" x 1/min) (mmolll/9Omin) (nmoUl/90min) (mmoW90/min) 
Day 1 50.13±B.11 3.62±0,45 9B.25±15.59 57.79±B.49 14.7±2.1 32.81±4.53 3.34±O.30 192.33±24.77 70.04±B.16 15.3±2.3 
Day 2 4B.57±5.49 3.53±O.53 76.69±9.66 59.02±6.04 16.5±2.7 34.0B±3.45 4.00±O.51 185.11±20.72 72.72±2.09 1B.1±2.9 
Mean 49.35±5.2B 3.4B±0,45 87.47±11.05 58.40±5.41 15.6±2.2 32.45±2.78 3.67±O.31 188.72±18.12 71.38±3.86 16.7±2.4 
Within subjects CV 36% 34% 36% 34% 26% 42% 33% 30% 37% 29% 
Within subjects variation 
as % of total variation 39% 35% 31% 43% 16% 66% 45% 35% 72% 19% 
95% range for difference 
between duplicate 
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Figure 5-3. Relationship between individual estimates of repeated measures of pancreatic p-cell 
responsiveness indices (M1) top panel, and (110) bottom panel during aarr in healthy subjects 
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Figure 5-4, Relationship between individual estimates of repeated measures of pancreatic ~-cell 
responsiveness indices (Ml) top panel, and (Mo) bottom panel during MIT in healthy subjects 
(N = 9), 
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5.3.2. Type 2 diabetes group 
5.3.2.1. Plasma glucose, insulin, and C-peptide 
The repeated measures of pl~ma glucose, insulin and C-peptide concentration during 
MIT are shown in Figure 5-5. 
5.3.2.2. Parameter estimation during MIT 
Parameter estimates were obtained with high precision during MIT. Mo was estimated 
with excellent precision on both occasions (CV ~ 7%). Ml was estimated with good 
precision in both occasions (CV ~ 23%), except in one subject (CV = 27 and 86% on 
occasion 1 and 2, respectively). The individual estimates of the pancreatic 
responsiveness during MTT together with their precision are summarised in Table 5-8. 
Table 5-8. Pancreatic responsiveness indices (Ml and Mo) during MIT on occasions 1 and 2 in 
subjects with T2D. 
Subject MI' CV MI2 CV Mo' CV Mo2 CV 
No. (10·g x 1/min) % (10.9 x 1/min) % (10.9 x 1/min) % (10.9 x 1/min) % 
1 57.61 5- 44.02 5 4.90 6 9.01 5 
2 12.92 23 42.61 6 12.37 3 9.26 4 
3 38.39 10 47.81 7 15.28 4 11.21 5 
4 56.56 8 50.24 6 19.39 5 15.00 5 
5 8.97 27 2.51 86 6.10 5 7.35 5 
6 28.14 7 27.09 7 8.59 5 10.12 4 
7 20.61 7 28.80 8 7.28 5 9.62 5 
8 51.15 12 41.09 10 18.17 4 16.53 4 
9 26.66 5 24.76 6 6.50 5 9.09 4 
11 2.83 9 13.33 6 1.37 5 4.45 5 
12 22.78 5 20.85 6 10.44 5 7.55 7 
13 12.50 8 13.69 7 5.25 5 4.63 5 
Mean 28.26 11 29.73 13 9.64 5 9.49 5 
SE 5.42 2 4.46 7 1.62 0 1.03 0 
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Figure 5-5. Plasma glucose, insulin, and C-peptide profiles during MIT at two separate 
occasions in subjects with T2D (mean ± SE, N=12). 
III 
5.3.2.3. Reproducibility 
Reproducibility of glucose, insulin, C-peptide, and pancreatic responsiveness indices 
(M. and Mo) during MTT are reported in Table 5-9. Within subjects variation (CV) was 
acceptable for all variables (CV ~ 27%). The within subjects variation as a % of total 
variation also was quite low (CV ~ 11 %). No significant difference was found between 
repeated measures. They were significantly and tightly correlated (rs > 0.75, and 
P < 0.05), see Table 5-10. Figure 5-6 shows the relationship between individual 
estimates of repeated measures for pancreatic ~-cell responsiveness indices (M. and 
Mo) during MIT. 
Table 5-9. Reproducibility of pancreatic responsiveness indices (M. and Mo) and glucose, 
insulin, and C-peptide responses during MTT in subjects with T2D (Mean ± SE). 
MTT 
MI Mo AUCG AUCc AUCI 
(10.9 x 1/min) (10.9 x 1/min) (mmoIl1l90min) (nmolll/90min) (mmol/1I90/min) 
Day 1 2B.3±5.42 9.64±1.6 293.1±31.6 75.B:t10.7 21.9:t3.5 
Day 2 29.7±4.4S 9.49±1.0 302.4±28.5 79.3±9.2 23.5±4.7 
Mean 29.0±4.S7 9.6±1.3 297.B±29.0 77.S±9.6 22.7±4.0 
Within subjects CV 27% 21% 13% 17% 21% 
Within subjects variation 11% 9% 7% 7% 3% 
as % of total variation 
95% range for difference 
between duplicate ±6.6 ±1.7 ±32.7 ±10.9 ±O.7 
measurements 
Table 5-10. Speannan correlation and Wilcoxon signed ranks test with Bonferroni corrections 
between repeated measures during MTT in subjects with T2D. 
Spearman correlation Wilcoxon signed ranks test 
Variables Correlation P-value test P-value 
MI O.BO O.OOB 0.000 0.100 
Mo 0.B5 0.002 -0.314 0.754 
AUCG 0.90 0.000 -1.020 0.308 
AUCc 0.75 0.025 -0.510 0.610 
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Figure 5-6. Relationship between individual estimates of repeated measures of pancreatic ~-~ell 
responsiveness indices (M1) top panel, and (Mo) bottom panel during MTT in subjects with T20 
(N = 12). 
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5.4. Discussion 
We investigated the reproducibility of pancreatic p-cell responsiveness indices, M, and 
Mo and the reproducibility of glucose, insulin, and C-peptide to oral challenge tests in 
healthy subjects and subjects with T2D. In the first part we investigated the 
reproducibility of M" Mo, and glucose, insulin, and C-peptide incremental area under 
curve 0-90 min during MTT and OGTT in healthy subjects. In the second part and due 
to the data limitation, we investigated the same parameters during MIT but not OGIT 
in subjects with T2D. The glucose, insulin and C-peptide responses were studied with 
the incremental area under the curve to eliminate the effect of the basal values (165). 
Healthy group 
We observed a lack of reproducibility of glucose and C-peptide profiles during MTT 
and OGIT (within subject CV 2: 30%). Slightly smaller CV values (21 % ~ CV ~ 29%) 
were reported for the repeated 2hr glucose during OGTT in healthy subjects (166). In 
accordance with other studies (167; 168), incremental area under curve 0-90 minutes of 
insulin but not glucose or C-peptide were reproducible during MTT and OGTT. 
McDonald et al (169) reported a lack of reproducibility for the Ih 2h and 3h glucose 
concentration after a IOOmg oral glucose load repeated six times over a period of one 
year in healthy subjects. 
As a result of the lack of reproducibility of glucose and C-peptide, M, and Mo showed 
weak reproducibility during MTT and OGTT. Although they were not significantly 
different, no significant correlation was observed. 
In the present study, glucose, and C-peptide, but not insulin, responses failed to show 
significant correlation between the repeated measures during MIT and OGrr 
(rs 2: 0.78, P ~ 0.07 for insulin). The lack of correlation between glucose AVC during 
OGrr in healthy subjects was reported by Ganda et al (168). The authors reported a 
significant correlation between insulin AUC 0-60 min (rs = 49, P < 0.05). Harding et at 
(167) reported insulin AUC to be more reproducible than glucose AUC in a large group 
of subjects with a high proportion of women of which about 15% exhibited abnormal 
glucose tolerance. 
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Several reports indicated poor reproducibility of the OGIT in healthy subjects and 
subj ects with T2D (37; 166; 170; 171). This was explained in part by considerable 
broad within-subject variation after oral glucose and meal tolerance tests (ISS; 172-
174). The inter-subject variability in healthy young and lean subjects was reported to be 
higher (ISS). The level of reproducibility is also affected by changes in digestion or 
absorption from time to time and uncontrolled environmental factors (175; 176). Other 
studies suggested that day-to-day variations in glucose tolerance could result from 
variation in cortisol secretion in response to stress (167). 
T2Dgrolip 
Pancreatic p-cell responsiveness indices Ml and Mo were reproducible during MIT in 
subjects with T2D, in line with reproducible glucose and C-peptide profiles (within 
subject variation as % of total variation was II and 9% for Ml and Mo, respectively). 
The repeated measures were not significantly different and were strongly correlated 
(rs ~ 0.78, P < 0.05). In subjects with T2D who underwent MTT on two separate 
occasions (73g carbohydrate, 20g lipid, and 31g protein for a total of S96 kcal), Le 
Floch et al (176) reported significant correlations between and sufficient 
reproducibility of glucose and insulin AUC 0-180 min (rs = 0.64 and 0.87 and P < 0.01 
and < 0.001 for glucose and insulin, respectively). 
In the present study the within subject variation as a % of total variation was quite low. 
CV was also good (CV ~ 21%) for glucose, insulin, and C-peptide. Wolever et al (154) 
reported similar CV values for glucose and insulin values over two hours 
(measurement were taken at 0, IS, 30, 45, 60, 90, and 120 min) after repeated mixed 
meal test in subjects with T2D. 
5.5. Summary 
Reproducibility of pancreatic p-cell responsiveness to MIT and OGIT was 
investigated. In healthy subjects the indices of pancreatic ~-cell responsiveness failed 
to show sufficient reproducibility due to lack of reproducibility of glucose and 
C-peptide to MIT and OGTT. Insulin responses to MIT and OGTT were reproducible. 
In subjects with T2D. Ml and Mo were sufficiently reproducible in line with 
reproducible glucose, insulin, and C-peptide responses to MTT. 
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6. Evaluation of two compartment minimal model performance in 
type 2 diabetes during insulin-modified FSIVGTT 
6.1. Introduction 
The one compartment minimal model (ICMM) of glucose kinetics is a powerful 
non-invasive tool to investigate glucose metabolism in physiological studies in different 
pathophysiological states (178-180). It provides two metabolic indices measuring 
glucose effectiveness (So) and insulin sensitivity (SI) in a single individual. So and SI 
are composite parameters, which measure the net effect of glucose and insulin 
respectively to promote glucose disappearance and inhibit endogenous glucose 
production (181). The I CMM method has gained increasing popUlarity and is widely 
used in clinical and epidemiological studies with more than 450 papers up to 2002, 
because it is simple and relatively non-invasive (100). The lCMM is represented in 
Figure 6-1. Recent published reports and studies indicate that So is overestimated (109-
Ill; 113; 182-184) and SI is underestimated (109-111; 184) during ICMM attributing 
the main reason to the under modelling effect of using one compartment to represent the 
glucose pool (113; 180; 185; 186). 
The new two compartment minimal model (2CMM) was first introduced in 1993 to 
measure hepatic glucose production during labelled NGTT by appending a second 
non-accessible compartment to the classic I CMM. The new model was needed because 
at that time the available single compartmental minimal model specifically developed to 
interpret labelled IVGTT data, provided a non-physiological pattern of hepatic glucose 
production (114). In 1997 Vicini et al (107) validated the 2CMM to estimate SI. So, and 
plasma clearance rate during an isotopically labelled FSNGTT. Recently Cobelli et al 
(115) incorporated a priori knowledge on glucose exchange kinetics using Bayesian 
estimation to derive insulin sensitivity and glucose effectiveness with the 2CMM during 
standard IVGTT in healthy SUbjects. However, the study did not test the model 
reliability under other conditions such as insulin-modified FSNGIT and in subjects 
with type 2 diabetes (T2D). 
Based on data published earlier (106), this investigation evaluated 2CMM in type 2 
diabetic subjects during insulin-modified FSIVGTT and compared its performance with 
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1 CMM. The glucose clamp technique is considered the gold standard reference method 
for measuring insulin sensitivity. so it is used here to assess the validity of the 1 CMM 
and the 2CMM measurements. The Bayesian analysis was applied to estimate 
parameters of the 2CMM. However the model failed to give physiologically feasible 
estimate for SG in 7 out of 12 subjects. The iterative two-stage population analysis was 




Male subjects with type 2 diabetes participated in the study (N = 12; age 59 ± 3 year, 
BMI 28.3 ± 0.9 kglm2; mean ± SE). Duration ofT2D was 6.3 ± 0.6 year, see Table 6-1. 
No subject had any medical condition other than diabetes or received drugs except for 
sulfonylureas. All subjects were screened for fitness to participate in the study by a full 
medical history and medical examinations. Participants maintained their normal 
isocaloric diets and sulfonylurea therapy was omitted on the study days. The South 
Glamorgan Local Research Ethics Committee, Cardiff, UK, approved the study 
protocol, and all participants gave written informed consent. 
Table 6-1. Demographic data for the 12 men with T2D participated in the study. 
Age Weight Height 8MI Duration of diabetes 
Sub. No. (year) (kg) (em) (kglm2) (year) 
1 47 92 176 30 4.1 
2 57 94 172 32 9.2 
3 70 72 171 25 4.2 
4 43 99 182 30 7.0 
5 67 62 157 25 6.7 
6 53 95 168 34 6.2 
7 66 85 176 28 9.3 
8 70 71 172 24 6.8 
9 55 75 165 28 8.0 
10 61 96 176 31 7.0 
11 50 77 163 29 1.7 
12 69 65 165 24 5.1 
Mean 59 82 170 28 6.3 
SE 3 4 2 1 0.6 
6.2.2. Experimental design 
Each subject underwent a frequently sampled insulin-modified intravenous glucose 
tolerance test (FSNGTT) and an isoglycaemic hyperinsulinaemic clamp in random 
order with 2-4 weeks between tests while participants maintained their normal 
isocaloric diets. 
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6.2.2.1. Insulin modified FSIVGTT 
Subjects were studied after 12 hours overnight fast. Antecubital veins were cannulated 
in both anns, one for sampling and the other for administration of glucose and insulin. 
The insulin-modified FSIVGTT consisted ofO.3g1kg glucose bolus per body weight at 0 
min over 2 min and O.OSmU/kg insulin bolus at 20 min. Overall, 30 samples were taken 
over 180 minutes to measure plasma glucose and insulin in addition to two pre-test 
samples. The samples were taken at -30, -15, 0, 1,2,3,4,5,6, 7, 8, 10, 12, 14, 16, 19, 
22, 23, 24, 25, 27, 30, 40, 50, 60, 70, 80, 90, 100, 120, 150 and 180 min. 
6.2.2.2. Isoglycaemic hyperinsulinaemic clamp 
This study was conducted after a 12 hours overnight fast. An antecubital vein was 
cannulated and used for glucose and insulin infusions. A second cannula was inserted 
retrogradely into a contralateral hand vein and the hand was wanned in a heated box to 
allow sampling of arterialised blood. After three basal samples for plasma glucose, an 
infusion of human Acrapid (NovoNordisk, Bagsavaerd, Denmark) at a rate of 
160mU/minlm2 commenced for 4 min as a priming dose and then was reduced to 40 
mU/min/m2, which was maintained for the duration of the study. The plasma glucose 
concentration was clamped at the basal (mean of the three basal plasma glucose values) 
by means of variable infusion rate of 20% D-glucose, changed on the biases of plasma 
glucose concentration obtained every 10 min. In addition to samples for plasma glucose, 
blood was sampled for the measurement of insulin at the basal period and at regular 
intervals during the procedure. 
6.2.2.3. Essay methods 
Plasma glucose was essayed using glucose oxidase method on a YSI Y2300 glucose 
analyser (YeIlow Spring, OH; intra-assay CV <2%). Immunoreactive insulin (IRI) was 
assayed by using conventional radioimmunoassay (intra-assay CV <6%) 
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6.2.3. Data analysis 
6.2.3.1. One compartment minimal model 
The ICMM analysis of FSIVGTI data gave insulin sensitivity Sit and glucose 
effectiveness Sal, see Figure 6-1. The non-linear regression analysis was used to 
estimate model parameters during I CMM. The model equations and a full description 
of the model structure are in chapter 2. The equations of the ICMM model are: 
Q(I) = -[PI + X(t)JQ(t) + PIQb Q(O) = Qb + D 
X(t) = -p~(I) + pJ[I(I) - IJ X(O) = 0 




where Q is glucose mass (mg/kg), with Q, denoting its basal (end-test) steady state 
value; 0 is the glucose dose (mglkg), PI= kl + ks, where ~ are rate parameters (min-I); 
X is a variable related to insulin concentration in the insulin remote compartment, and 
X(t) = (l4 +~) l(t); l(t) is plasma insulin concentration (~U/ml); Ib and Gb denote basal 
plasma insulin and glucose concentrations respectively, G is the plasma glucose 
concentration; V is the distribution volume per unit body weight (ml/kg), P2 = k3, and 
P3 = k2(kt+~) are rate parameters expressed in min-l and min-2/)lU I x ml, respectively. 
The lCMM derived parameters SI1 and SQI were calculated as follows: 




sl and Sal at variance with the fractional indices SI and Sa commonly expressed 
elsewhere, and have the same units as the analogous glucose clamp indices allowing 
for direct comparison. 
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figure 6-1. One compartment minimal model (ICMM) (115). 







The 2CMM appends a second non-accessible compartment to the 1 CMM . The 2CMM 
was validated in normal subjects during standard IVGTT by applying Bayesian 
approach to incorporate prior knowledge on k12 and k21 parameters (115). The glucose 
exchange kinetic parameters k12 and k21 were assumed to be normally distributed with 
mean and standard deviation of 0.070 ± 0.018 and 0.050 ± 0.013 min-I, respectively, 
and with a correlation of 0.90. The model equations are as follows: 
Q1ft) = k21Qlt) - k12Qlt) QlO) = Q2b 
X(I) = - p~(I) + pil(l) -IJ X(O) = 0 





where QI and Q2 (mg/kg) denote the glucose masses in the accessible and non-
accessible compartments, respectively, with subscript b denoting their basal (end-test) 
steady-state values; VI is the volume of the accessible compartment (mglkg); kl2 and k21 
are rate parameters describing glucose exchange kinetics (l/min); D, G, I, X, PI. P2, and 
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PJ are variables and parameters already defined for the 1 CMM. TIle 2CMM parameters 
S? and si were calculated as follows: 




The 2CMM differs from I CMM only in allowing an exchange of glucose between the 
accessible and the non-accessible compartment, see Figure 6-2. This added complexity 
brings a priori identifiably problems. Theoretical or a priori identifiably addresses the 
ability of getting unique solutions for the unknown parameters on the basis of the 
experiment generated data. To solve these problems and reach the unique identifiably a 
priori information on the glucose exchange kinetics parameters k12 and k21 was used 
applying Bayesian estimation (115). 
PLASMA 













Figure 6-2. Two compartment minimal model (2CMM) (115). 
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6.2.3.2.1. Bayesian prior on k12 and k21 
Bayesian analysis was applied to estimate 2CMM parameters (insulin sensitivity S? and 
glucose effectiveness SG2) using the available prior knowledge on k12 and k21 from 
healthy subjects because of unavailability of prior knowledge from T2D subjects. The 
prior knowledge was adopted from Cobelli et al (115) who reanalysed published tracer 
bolus injection data obtained in the basal state in healthy subjects with a 2CMM 
corresponding to the one used in the current study and with no irreversible loos from the 
non-accessible pool. The glucose exchange kinetic parameters k12 and k21 were assumed 
to be normally distributed with mean and standard deviation of 0.070 ± 0.018 and 0.050 
± 0.013 min' l , respectively, and with a correlation of 0.90 (l15). 
6.2.3.2.2. Iterative two stage population approach 
The iterative two-stage population analysis was applied to estimate 2CMM parameters. 
This approach is based on calculation of the population mean and the standard deviation 
at each iteration and then uses them as prior information for the individual analysis. The 
use of a prior in the population analysis should improve the precision of the individual 
estimates. All parameters were log transformed before analysis to assure nonnegativity 
of parameter estimates. The model gives insulin sensitivity stPop and glucose 
ffi · S 2·pOP e ectlveness G • 
6.2.3.3. Parameter estimation 
The minimal model analysis of the insulin-modified FSIVGTT data during 1 CMM and 
2CMM was completed using SAAM II © (software applications for kinetics analysis) 
version 1.2 (SMM Institute, University of Washington. Seattle. USA) (187; 188). The 
precision of parameter estimates was obtained from the inverse of the Fisher 
information matrix and calculated as the fractional standard deviation (FSD). 
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6.2.3.2.3. Model evaluation 
The following assessment procedure was applied to the 2CMM with Bayesian analysis 
and the 2CM1\1 with the iterative two-stage population analysis whose parameters have 
been estimated successfully (a priori identifiably). The 1 CMM will not undergo this 
assessment since it has been validated in previous studies (94). 
To assess the adequacy of the 2CMM during insulin-modified FSIVGTT in T2D 
subjects, we evaluated practical (a posteriori) identifiably, and goodness of fit (143). 
The following criteria were used to assess the model validity: 
• Coefficient of variation (CV) measured as the fractional standard deviation 
(FSD) for the assessment of precision of parameter estimates 
• Distribution of normalised residual for the assessment of model's ability to fit 
data (goodness of fit) considering the measurement errors, and to detect any 
systematic deviation between the data and the model prediction 
• Runs test to assess the distribution of the residuals and check for presence of 
model misfit. 
6.2.3.4. Clamp 
Isoglycaemic glucose clamp was used as the gold standard reference when comparing 
the insulin sensitivity indices derived by 1 CMM and 2CMM. SICLA.\1P was derived from 
the steady-state glucose infusion rate [M value (minlmglkg)] during the 3rd hour of the 
clamp corrected for the ambient insulin and glucose concentrations 
S Clam = M (mVmin/kg per ~U/ml) 
I P AlxG 
(6-12) 
where 61 (pmolll) is the increment in insulin concentration from basal, and G (mmolll) 
is the clamped glucose concentration. 
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6.2.3.5. Statistical analysis 
Pearson's correlation coefficient was used to assess relationships between variables. 
Significant differences between insulin sensitivity indices among different models were 
determined by two-way analysis of variance. and pairwise significance was further 
tested by the Games-Howell multiple comparison method. Paired sample t-test was 




6.3.1. Plasma glucose and insulin 
Table 6-2 shows the basal insulin (FPI) and glucose (FPG) values during FSIVGTT. 
Table 6-3 shows data from isoglycaemic hyperinsulinaemic clamp and includes basal 
and clamped values for glucose and insulin, and the M value. FPG and FPI 
concentrations were not different between the two study days (P = 0.13 and P = 0.65, 
paired t-test, respectively). Figure 6-3 shows the profile of glucose and insulin 
concentrations during the FSIVGTT. 
Table 6-2. Basal plasma insulin and glucose values during FsrvGrr in subjects with type 2 
diabetes (N = 12). 
Basal insulin Basal glucose 
Subject No. (pmolll) (mmolll) 
1 64 9.3 
2 132 7.9 
3 48 6.0 
4 80 11.5 
5 132 8.8 
6 152 11.0 
7 60 7.6 
8 78 12.6 
9 132 8.0 
10 42 8.1 
11 116 7.2 
12 182 9.3 
Mean 102 8.9 
SE 13 0.6 
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Table 6-3. Isoglycaemic clamp data in subjects with type 2 diabetes (N = 12). 
Subject No. Basal insulin Clamped insulin Basal glucose Clamped glucose M (pmolll) (pmol/l) (mmol/l) (mmol/l) (min/mglkg) 
1 72 384 8.5 8.4 3.26 
2 141 564 9.0 9.0 3.87 
3 48 438 5.1 5.1 4.11 
4 87 630 9.3 9.2 2.66 
5 90 756 7.7 7.6 3.84 
6 156 528 12.7 12.6 1.71 
7 72 462 6.3 6.2 4.10 
8 75 654 11.6 11.3 6.26 
9 138 492 7.6 7.5 3.09 
10 60 480 7.1 7.0 6.29 
11 162 846 5.7 5.7 3.09 
12 153 630 10.1 10.0 1.92 
Mean 105 572 8.4 8.3 3.68 
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Figure 6-3. Plasma glucose and insulin profiles during FSIVGTT in subjects with T2D (N= 12, 
mean ± SE). 
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6.3.2. One compartment minimal model 
The lCMM estimated S,' and SOl with good precision (mean CV = 13% and 21%, 
respectively) except for SOl in one subject (CV = 246%). Table 6-3 shows lCMM 
parameter estimates. while Figure 6-4 shows distribution of normalised residuals. The 
Runs test was insignificant in 7 out of 12 subjects. 
Table 6-4. Parameter estimates of the one compartment minimal model in subjects with type 2 
diabetes (N = 12). 
PI P2 P3 V S,' 
Subject No. (10-2 x (10-2 X (10-5 x (10-2 x 
1/min) 1/min) ml/min-1/kg per IJUlml) (1/kg) ml/minlkg per IJUlml) 
1 0.001(246)* 0.166(11 ) 0.016 (13) 0.183(4) 1.75(11) 
2 0.011(18) 0.090(36) 0.003(31 ) 0.187(4) 0.57(30) 
3 0.003(83) 0.069(10) 0.008(11) 0.233(5) 2.79(13) 
4 0.010(22) 0.069(11) 0.008(16) 0.146(4) 1.62(11) 
5 0.009(29) 0.100(16) 0.009(18) 0.201(5) 1.86(17) 
6 0.012(15) 0.100(40) 0.002(33) 0.154(3) 0.14(2) 
7 0.014(14) 0.045(14) 0.003(19) 0.140(4) 1.02(21) 
8 0.020(13) 0.050(18) 0.011(13) 0.148(4) 3.35(3) 
9 0.016(15) 0.056(12) 0.010(13) 0.139(4) 2.39(8) 
10 0.009(25) 0.037(14) 0.003(22) 0.134(5) 1.03(17) 
11 0.017(17) 0.058(15) 0.005(18) 0.124(5) 1.05(8) 
12 0.005(33) 0.054(10) 0.007(9) 0.141(3) 1.82(12) 
Mean 0.012 0.074 0.007 0.161 1.62 
SE 0.002 0.010 0.001 0.009 0.27 
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Figure 6-4. Weighted residuals during lCMM for the full test (top panel) and the first 30 min 
(bottom panel), (mean ± SE). 
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6.3.3. Two compartment minimal model 
6.3.3.1. Bayesian prior on k12 and k21 
With Bayesian analysis the 2CMM failed to give a physiologically feasible estimate for 
PI in 7 out of 12 subjects (PI hits the lower limit). Table 6-5 shows model parameter 
estimates. Figure 6-5 shows distribution of normalised residuals. The Runs test was 
insignificant in 6 out of 12 subjects. 
Table 6-5. 2CMM parameter estimates with Bayesian analysis in subjects with type 2 diabetes 
(N = 12). 
Sub. k,2 k2, 
p, P2 P3 V, SI
2 
(10.2 X (10.2 x (10.5 xmllmin' (10.2 x 
No. (1/min) (1/min) 1/min) 1/min) '/kg per ~U/ml) (lIkg) mllminlkg per ~U/ml) 
1 0.05(31*) 0.02(36) O.OOO(NA+) 0.07(20) 0.009(19) 0.15(7) 2.00(3) 
2 0.04(40) 0.03(34) O.OOO(NA) 0.02(22) 0.002(22) 0.17(6) 2.06(S) 
3 0.09(22) 0.06(26) O.OOO{NA) 0.04(17) 0.009(18) 0.17(6) 3.S1(3) 
4 0.O7(29) 0.05(31) O.OOO(NA) 0.05{21 ) 0.012(23) 0.11(7) 2.70(4) 
5 0.06(32) 0.04(35) O.OOO(NA) 0.04(17) 0.008(20) 0.16(7) 3.78(3) 
6 0.08(24) 0.06(24) 0.017(33) 0.03(39) 0.002(35) 0.09(9) 0.57(46) 
7 0.09(23) 0.06(23) 0.013(39) 0.03(17) 0.006(18) 0.09(8) 1.89(25) 
8 0.09(23) 0.06(25) 0.025(77) O.OS(77) 0.017{S7) 0.10(23) 3.59(14) 
9 0.08(23) 0.06(25) O.011(48) 0.05(20) 0.016(23) 0.10(8) 3.32(12) 
10 0.07(21) 0.OS(26) O.OOO(NA) 0.03(13) 0.00S(14) 0.10(6) 1.93(3) 
11 0.O9(22) 0.06(23) 0.01S(46) 0.05(26) 0.008(30) 0.08(8) 1.38(14) 
12 0.08(23) 0.05(2S) O.OOO(NA) 0.03(1S) 0.009(16) 0.10(S) 2.7S(3) 
Mean 0.07 0.05 0.016 0.04 0.009 0.12 2.46 
SE 0.00 0.00 0.002 0.00 0.001 0.01 0.28 
*Precision of parameter estimates expressed as fractional of standard deviation 
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Figure 6-5. Weighted residuals during 2CMM with Bayesian analysis for the fu ll test (top panel) 
and the first 30 minutes (bottom panel), (mean ± SE). 
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6.3.3.2. Iterative two-stage population approach 
Table 6-6 gives parameter estimates with the population analysis. stPOP and SG2.POP 
were estimated with exceIIent precision (mean CV of 16 and 15% respectively), see 
Tables 6-7 and 6-8. Normalised residuals were randomly distributed around the zero 
line, see Figure 6-6. The Runs test was not significant in 8 out of 12 subjects. 
Table 6-6. 2CMM parameter estimation results with the population analysis in subjects with 
type 2 diabetes (N = 12). 
P, P2 
P3 x 10.3 stPOP 
Sub. k12 k21 (10.2 X (10.2 x (10.
5 xml/min" VI (10.2 x 
No. (1/min) (1/min) I/kg per (1/kg) 1/min) 1/min) ~U/ml} mllminlkg per ~U/ml) 
1 0.197(1") 0.0652(0) 0.0138(26) 0.0599(1 ) 0.0059(14) 0.123(6) 1.22(17) 
2 0.200(1) 0.0652(0) 0.0118(16) 0.0591(1) 0.0032(15) 0.147(3) 0.80(16) 
3 0.198(1) 0.0652(0) 0.0087(27) 0.0594{1 ) 0.0080(10) 0.169(4) 2.28(12) 
4 0.198(1) 0.0652(0) 0.0148(20) 0.0596(1) 0.0089(9) 0.105(4) 1.58(12) 
5 0.197(1) 0.0652(0) 0.O122(19) 0.0600(1) 0.0080(10) 0.151(3) 2.01(13) 
6 0.197(1) 0.0652(0) 0.O171(17) 0.0595{1 ) 0.0023(30) 0.108(4) 0.41(32) 
7 0.197(1) 0.0652(0) 0.0213(13) 0.0590(1) 0.0049(21) 0.097(4) 0.80(24) 
8 0.199(1) 0.0652(0) 0.0200(17) 0.0597(1) 0.0169(7) 0.119(8) 3.39(8) 
9 0.197(1) 0.0652(0) 0.0199(15) 0.0591(1) 0.0141(7) 0.102(4) 2.43(9) 
10 0.197(1) 0.0652(0) 0.O133(16) 0.0589(1) 0.0049(15) 0.093(3) 0.77(17) 
11 0.196(1) 0.0652(0) 0.0208(16) 0.0591(1) 0.0071(8) 0.089(5) 1.08(11) 
12 0.198(1) 0.0652(0) 0.0110(20) 0.0585(1) 0.0083(13) 0.098(3) 1.39(14) 
Mean 0.198 0.0652 0.0154 0.0593 0.0077 0.117 1.51 
SE 0.000 0.00 0.0012 0.0001 0.0012 0.007 0.25 
*Precision of parameter estimates expressed as fractional standard deviation 
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Figure 6-6. Weighted residuals during 2CMM with population analysis for the full test (top 
panel) and the first 30 minutes (bottom panel), (mean ± SE). 
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6.3.4. Insulin sensitivity and glucose effectiveness 
The lCMM failed to estimate SG with acceptable precision in one subject (CV > 100%). 
However the 2CMM with Bayesian analysis failed to estimate SG in 7 subjects (PI hits 
lower limit). The 2CMM with population analysis did not fail in any subject. Tables 6-7 
and 6-8 show insulin sensitivity and glucose effectiveness with lCMM (SII and Sol), 
2CMM with the Bayesian analysis (S? and Si), and the 2CMM with the population 
analysis (stPOP and SG2-POP). The insulin sensitivity SICLAMP derived from the clamp 
study is also shown. 
Table 6-7. Insulin sensitivity with the minimal model and during the isoglycaemic clamp in 
subjects with type 2 diabetes (N = 12). 
S,1 S? stPOP S'CLAMP 
Sub. No (10.2 x mllmin/kg per ~U/ml) 
1 1.75(11 )* 2.00(3) 1.22(17) 2.12 
2 0.57(30) 2.06(5) 0.80(16) 5.64 
3 2.79(13) 3.51(3) 2.28(12) 9.58 
4 1.62(11) 2.70(4) 1.58(12) 6.67 
5 1.86(17) 3.78(3) 2.01(13) 8.12 
6 0.14(2) 0.57(46) 0.41(32) 2.00 
7 1.02(21) 1.89(25) 0.80(24) 5.00 
8 3.35(3) 3.59(14) 3.39(8) 12.46 
9 2.39(8) 3.32(12) 2.43(9) 8.99 
10 1.03(17) 1.93(3) 0.77(17) 3.73 
11 1.05(8) 1.38(14) 1.08(11) 4.42 
12 1.82(12) 2.75(3) 1.39(14) 3.80 
Mean 1.62 2.46 1.51 6.04 
SE 0.27 0.28 0.25 0.93 
.Precision of parameter estimates expressed as fractional standard deviation 
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Table 6-8. Glucose effectiveness with the ICMM and the 2CMM in subjects with type 2 
diabetes (N = I2). 
SG' SG2 SG2•POP 
Sub. 10. 
(ml/min/kg) 
1 0.18(246)* O.OO(NA+) 1.70(22) 
2 2.15(14) O.OO(NA) 1.74(14) 
3 0.67(79) O.OO(NA) 1.47(25) 
4 1.48(19) O.OO(NA) 1.56(16) 
5 1.74(24) O.OO(NA) 1.83(16) 
6 2.64(3) 1.53(26) 1.84(14) 
7 1.97(10) 1.17(33) 2.06(10) 
8 3.00(10) 2.37(58) 2.39(13) 
9 2.25(11) 1.12(43) 2.03(11) 
10 1.24(21) O.OO(NA) 1.23(14) 
11 2.06(12) 1.21(40) 1.85(12) 
12 0.69(30) O.OO(NA) 1.07(18) 
Mean 1.81 1.48*"' 1.73 
SE 0.21 0.23 0.10 
• Value not included in the calculation of the mean 
•• Mean reflects 5 subjects and does not include zero estimates 
.. Indicates estimation failure 
6.3.5. Comparability of Insulin sensitivity and glucose effectiveness 
The 2CMM with population analysis and 1 CMM were measuring the same SI and So (P 
= 0.99 and 0.47 respectively), with a strong correlation between Srpop and SICLA.\1P (rs 
= 0.91, P<O.OOl). The 2CMM with Bayesian approach estimated S135% higher than the 
1 CMM but with no significant difference (P = NS). and strongly correlated with SICLAMP 
(rs = 0.83, P<O.Ol). However it failed to estimate So in 7 out of 12 of cases (So = 0). 
Figure 6-7 summarises insulin sensitivity and glucose effectiveness results. Correlation 
results are shown in Table 6-9. Two way analysis of variance was significant for the 
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between parameters variability (p = 0.000). Table 6-10 shows the Games-Howell 
multi-comparison results. Figures 6-8 to 6-10 show the graphical representation of 
relationships between SICl.AMP, Sll, S? and stPOP. Figure 6-11 shows the relationship 
between SOl and S02-POP (rs = 0.76, P<O.OI). Due to the high failure rate in the estimate 
of So during 2CMM with Bayesian analysis it was difficult to relate si to SOl and 
S 2-POP a . 
Table 6-9. Pearson correlation (with the Bonferroni correction) between insulin sensitivity 
indices during 1 CMM, 2CMM, and the clamp method. 
Sl1 S? S?-POP SICLAMP 
SI' 1 0.85* 0.96** 0.81* 
S? 1 0.86* 0.83* 




Table 6-10. The results of Games-Howell multiple comparison between insulin sensitivity 
indices during 1CMM, 2CMM, and the clamp method. 
51' 5? S?:POP SICLAMP 
SI' 1 N5 N5 0.003* 
5? 1 N5 0.012* 
S?-POP 1 0.002* 
51cLAMP 1 
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Figure 6-7. Insulin sensitivity (top panel) and glucose effectiveness (bottom panel). Results are 
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Figure 6-8. Relationship between individual estimates of Sll and Sl2 (top panel), and between SI1 
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Figure 6-9. Relationship between individual estimates of SI1 and SICLAMP (top panel). and 
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During modified FSIVGTT in subjects with T20, the insulin sensitivity index derived 
with the 2CMM applying population analysis was comparable to that measured with the 
lCMM and was strongly correlated with the clamp insulin sensitivity index. Validation 
of the 2CMM in T20 subjects using population analysis was successful. SI and So were 
estimated with excellent precision (mean CV for stPOP and si-POP was ~ 13%). 
Normalised residuals had satisfactory behaviour in terms of both pattern and amplitude 
and were randomly distributed around the zero line indicating a good model fit. 
In the current study, SI2-POP was correlated with S11, sl, and SICLAMP (rs > 0.81), with no 
significant difference from Sil (1.51 ± 0.25 vs. 1.62 ± 0.27 x 10-2 x ml/min/kg per 
llU/ml, P=NS). In healthy subjects during insulin-modified IVGIT, Omenetto et al 
(189) also found no significant difference between insulin sensitivity measured by 
lCMM and 2CMM (12.90 ±1.31 and 13.24 ± 1.40 x 10-2 x rnVrnin/kg per ~U/rnl, SI! vs 
S? respectively). 
In a previous study by Saad et al (16), S!Cl.AMP was correlated with SI! (rs = 0.41, 
P<O.OI) during insulin modified FSIVGTT in T20 subjects. However it was four fold 
higher (0.040 ± 0.006 vs. 0.011 ± 0.003 dVmin per ~U/ml). In healthy subjects, Vicini et 
al (107) reported a strong correlation between st t denotes an index derived from the 
labeled FSIVGTT) and st (rs = 0.95, P<O.OOI) with no significant difference between 
the two indices (12.98 ± 2.21 vs. 13.83 ± 2.54 x 10-2 ml/min/kg per ~U/ml) and 
suggested using 1 CMM instead of 2CMM for its remarkable precision and near-perfect 
correlation with 2CMM (it should be noted that st and S? are derived from two 
models with two and one outfluxes, respectively, and the two indices my present 
different properties). N agasaka et al (190) also found strong correlations between S 11 , 
st and st in healthy and TID subjects. During labelled WGIT in healthy subjects, 
Hoffinan et al (182) reported more reliable estimates with lCMM than 2CMM with no 
difference between insulin sensitivity. In addition the insulin sensitivity indices were 
positively correlated (182). 
In the present study, So2-POP was correlated with SOl (rs = 0.76, P<O.OI) and the indices 
were not significantly different (1.73 ± 0.10 vs. 1.81 ± 0.21 mVmin, P=NS). Nagasaka 
et al (190) found in healthy and T20 subjects a strong correlation between So 1* and si* 
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with no significant difference. Vicini et al (107) also observed a weak correlation 
between Sal- and S02- in healthy subjects. 
Our results during modified FSIVGIT are in accordance with previous studies during 
both labelled and unlabelled FSIVGIT and demonstrate insignificant difference 
between the 1 CMM and 2CMM indices of insulin sensitivity. This insignificant 
difference applies also on the glucose effectiveness indices during 1 CMM and 2CMM. 
The values for the glucose exchange kinetic parameters k12 and k21 during population 
analysis of the 2CMM bad a negligible intersubject variability [0.198 ± 0.000 and 0.065 
± 0.000 min-l, respectively (k21 was identical for all subjects)] suggesting that the 
individual data set is not rich enough to obtain individual estimate of these parameters. 
Parameter estimates of k12 values were three fold higher than k21 (P < 0.001). These 
results suggest that the 2CMM with population analysis tends to treat the two glucose 
pools as one, which could explain the comparability of 1 CMM and 2CMM parameter 
estimates. 
The 2CMM with Bayesian approach estimated insulin sensitivity with good precision, 
35% higher than 1 CMM with no significant difference, and a strong correlation with 
SICLAMP (rs = 0.79, P<O.Ol). However it failed to estimate So in 7 out of 12 T2D 
subjects (more than 50% of the cases). Although Bonadonna et al (191) demonstrated 
no significant difference in the fractional outward transport of 3-0-methyl-o-glucose in 
skeletal muscle between healthy and T2D subjects during insulin clamp. the use of 
informative prior information on k21 and k12 obtained in healthy but not T2D subjects 
may have had a negative impact on the estimation results. 
Applying Bayesian analysis, Cobelli et al (lIS) also experienced difficulties when 
resolving 2CMM exchange kinetics parameters especially k12 with acceptable precision 
in healthy subjects. sl and/or Sa2 precision was unsatisfactory (CV > 100%) in 10 out 
of 22 subjects. Vicini et al (107) reported unsatisfactory precision for Sl estimates 
during labelled IVGIT with 2CMM (st and/or S02- precision was unsatisfactory in 5 
out of 14 healthy subjects). HotTman et al (182) reported difficulties in estimating S?* 
and S02. during labelled IVGTT with reliable precision and suggested using 1 CMM as 
a robust approach in population-based studies which provides more reliable estimates 
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than 2CMM. Due to the high failure rate in the estimate of So during 2CMM with 
Bayesian analysis it was difficult to carry out any comparison of si with SOl and 
S 2-POP o . 
The difficulty of estimating 2CMM parameters with satisfactory precision in previous 
studies indicates that the model is too complex for the experimental data. In addition the 
failure of the model to estimate glucose effectiveness in the current study with the 
Bayesian analysis indicates the unsuitability of the 2CMM model to fit the modified 
FSIVGTI data in T2D subjects. The higher estimate of insulin sensitivity during 
2CMM with Bayesian analysis could be explained as an over estimation attempt to 
compensate for zero valued glucose effectiveness. 
The insulin modification appears to reduce the insulin sensitivity with the 2CMM 
making it similar to the I CMM estimate. This was demonstrated by Omenetto et al 
(189), who studied healthy subjects with insulin-modified IVGTT and observed 
identical estimates of insulin sensitivity with the 1 CMM and the 2CMM, while glucose 
effectiveness was 35% higher with I CMM than with the 2CMM. On the other hand, 
result on standard (unmodified) IVGIT in healthy subjects demonstrated that the 
2CMM glucose effectiveness and insulin sensitivity were respectively 60% lower and 
35% higher than the corresponding lCMM indices (115). 
The main objective of the 2CMM was to solve the under-modelling effect on glucose 
effectiveness and insulin sensitivity. Although the model was successfully validated in 
T2D subjects during insulin-modified FSIVGTT, it is still measuring the same glucose 
effectiveness and insulin sensitivity as the ICMM. For its simplicity and popularity and 
to benefit from the data available in the literature it is recommended to use the 1 CMM. 
6.5. Summary 
The 2CMM was validated successfully using population analysis in T2D subjects 
during insulin-modified FSIVGTT, giving precise estimates of SI and So with strong 
correlation with lCMM estimates and SICLAMP. Insulin sensitivity and glucose 
effectiveness estimated by 2CMM with population analysis are not different from 
1 CMM estimates. 
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7. Application of ISM and 1 CMM to assess glucose metabolism In 
newly presenting type 2 diabetes 
7.1. Introduction 
The pathogenesis of Type 2 diabetes is complex and has yet to be fully understood (65; 
192), however, it has been established that both insulin resistance and deficient insulin 
secretion play decisive roles in the development of Type 2 diabetes (8; 47; 193). 
The minimal model analysis (78) using the standard or insulin-modified intravenous 
glucose tolerance test (IVGTT) measures insulin sensitivity (St) and glucose 
effectiveness (Sa). It also provides a measure of the first phase insulin secretion (AIRa). 
The minimal model has been widely used to assess insulin resistance in various 
pathophysiological states (78; 194) and has become invaluable especially in popUlation 
studies due to its simpler experimental design compared to the glucose clamp 
technique (77). 
In the previous chapter the one compartment minimal model (I CMM) correlated 
significantly with the clamp index of insulin sensitivity and was superior to the two 
compartment minimal model with respect to simplicity and popularity and applicability 
to use in subjects with T20. The ICMM was shown to be able to provide reproducible 
estimates of glucose effectiveness and insulin sensitivity (32; 195). 
The insulin secretion model (ISM) is a recently developed approach to measure fasting 
(Mo) and postprandial (Ml ) pancreatic p-cell responsiveness during a meal tolerance test 
(MTn (32). The MTT is a standardised physiological test and has the benefit of a 
typical postprandial exposure of the pancreas to glucose, other nutrients (fat, protein), 
gut and vagal hormones. The insulin secretion model has been shown to discriminate 
across a wide spectrum of pancreatic p-celJ responsiveness (32) and to provide 
reproducible measurements in subjects with T20 as demonstrated in Chapter 5. 
The generally accepted but as yet not confirmed hypothesis is that the IVGTT and/or 
MIT facilitate the estimation of essential indices of the whole-body carbohydrate 
metabolism. The aim of this study was to investigate whether these indices are able to 
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explain inter-individual variability of clinical measures of glucose control such as 
fasting plasma glucose and insulin, glycated haemoglobin, and the glucose and insulin 
responses to a meal. In this study subjects with newly diagnosed Type 2 diabetes were 
studied as they present the end-point of the natural development of the disease prior to 
therapeutic intervention. 
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7.2. Research Design and Methods 
7.2.1. Subjects 
Subjects with newly presenting type 2 diabetes participated in the study (N = 65; 53 
males, 12 females; age 54 ± 1 year; BMI 30.5 ± 0.7kg/m2; mean ± SE), see Table 7·1. 
The study was approved by Bro Tar Local Research Ethics Committee, Cardiff, UK. 




















The subjects were admitted on two consecutive study days to the Diabetes Research 
Unit, Llandough Hospital (Penarth, UK) following an overnight 12 hour fast. Each 
subject underwent two procedures in random order to assess the parameters of 
carbohydrates metabolism. 
7.2.2.1. Intravenous glucose tolerance test 
The insulin·modified intravenous glucose tolenmce test (NGIT) consisted of a 0.3g1kg 
glucose bolus per body weight given at 0 minute over two minutes, followed by 
0.05mUlkg insulin (Actrapid, Novo Nordisk, Denmark) at 20 minutes (49). Blood 
samples were taken at .30, ·15, 0, 1,2,3,4,5,6, 7, 8,10, 12, 14, 16, 19,22,23,24,25, 
27, 30, 40, 50, 60, 70, 80, 90, 100, 120, 150, and 180 minutes for measurement of 
plasma glucose, insulin, and C-peptide. 
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7.2.2.2. Meal tolerance test 
A standard 500 kcal meal was consumed at 0 minute (75g carbohydrates; calorie 
contribution: 58% carbohydrate, 23% fat and 19% protein) (49). The meal consisted of 
digestion of 15g Weetabix, 109 skimmed milk, 250mL pineapple juice, 50g white meat 
chicken, 60g wholemeal bread, and 109 polyunsaturated margarine. Subjects were 
required to consume the whole meal within 10 minutes. Blood samples were taken at 
-30, 0, 10,20,30,40, 50, 60, 75, 90, 120, 150, 180, 210 and 240 minutes to measure 
plasma glucose, insulin, and C-peptide. 
In both tests blood was taken via an indwelling intravenous cannula which was 
inserted into the antecubital fossa vein and connected via a three-way tap to a slow 
running saline infusion to maintain the patency of the vein. At each sample time 
the infusion is stopped and the first 2-ml blood withdrawn and discarded, prior to 
obtaining the sample for assay. 
7.2.2.3. Assay method 
Glucose was assayed using the glucose oxidase method (Yellow Springs Analyser, YSJ 
23000, USA; intra-assay CV < 2%). Insulin and C-peptide were assayed using 
immunoassays utilising monoclonal antibodies (Dako Dioagnostics, Ely, Cambs, UK; 
intra-assay CV < 5% and < 6% respectively). 
7.3. Data Analysis 
7.3.1. Glucose and Insulin levels 
Fasting plasma glucose (FPG) and fasting plasma insulin (FPI) were obtained as mean 
values of pre-test IVGTf and MIT measurements. Caw,o and Cmu,l were the maximum 
incremental plasma glucose and insulin concentrations during the MTT. AUCo and 
AVCl were the incremental area under the curve of plasma glucose and insulin, 
respectively during MTT from 0 to 180 minutes. 
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7.3.2. Minimal model analysis 
The minimal model analysis of IVGrr data gave insulin sensitivity (Sit ability of 
insulin to enhance the net glucose disappearance from plasma) and glucose 
effectiveness (So, ability of glucose to promote its own disposal) (19). Both S, and So 
are measures of insulin sensitivity; the former measures insulin sensitivity at an 
incremental insulin concentration. the latter at the basal insulin concentration (100). 
The fIrst phase insulin response (AIRo; measure of pancreatic p-cell responsiveness) 
was calculated as the incremental area under the curve from 2 to 8 minutes during the 
IVGIT (122). The disposition index (D,; composite measure of insulin sensitivity and 
pancreatic p-cell responsiveness) was calculated as D, = S, x A1Ro (1 22). 
The package used for the calculation of the minimal model parameters was IS_Ciba 
(Insulin Sensitivity from Ciba, © Ciba-Geigy Ltd .• CH-4002 Basle, Switzerland 1995 
Author: Dr. G.H. Mehring / Medical Department / Biometrics Date of version: 
September 22nd. 1998) (102). 
1.3.3. Insulin secretion model 
The insulin secretion model was used to quantify pancreatic p-cell responsiveness from 
MTT data, providing fasting p-cell responsiveness (Mo; ability of fasting glucose to 
stimulate C-peptide secretion) and postprandial p-cell responsiveness (M,; ability of 
postprandial glucose to stimulate C-peptide secretion) (32). 
Mo represents fasting prehepatic insulin secretion divided by the fasting plasma glucose. 
M, represents the increase in prehepatic insulin secretion given an increment in 
postprandial glucose (32). 
The package used to calculate Mo and Ml was version 1.0 of CPR (Calculating 
Pancreatic Responsiveness; written by R. Hovorka and H.C. Subasinghe. MIM Centre. 
City University, UK, 1997). The model is comprehensively described in Chapter 2. 
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FPG Fasting plasma glucose (mmoVL) 
FPI Fasting plasma insulin (pmolll) 
HbAtc Glycated haemoglobin (%) 
Cmax.G Maximum (above fasting) plasma glucose during MTT (mmoVl) 
Cmu.1 Maximum (above fasting) plasma insulin during MTT (pmoIlL) 
AUCG Integrated (above fasting) plasma glucose during MTT (mmollL per 180 min) 
AUC1 Integrated (above fasting) plasma insulin during MTT (mmollL per 180 min) 
INDEPENDENT VARIABLES 
51 Insulin sensitivity (IVGTT -derived) (1/min per pmollL) 
5G Glucose effectiveness (IVGTT -derived) (1/min) 
MI Post-prandial p-cell sensitivity (MTT -derived) (1 min) 
Mo Fasting p-cell sensitivity (MTT-derived) (1/min) 
AIRG First phase insulin response during IVGTT (pmollL per 6 min) 
0
1 
Disposition index (01 =51 • AI~) (IVGTT -derived) (1/min per 6 min) 
7.4. Statistical analysis 
A Spearman correlation analysis with a Boniferroni correction was carried out to assess 
relationships between indices classified as independent variables for the purposes of the 
study (measures of insulin sensitivity and pancreatic p-cell responsiveness: Sit SG, 
AIRo, Dh Mo, and M,), and dependent variables (clinical measures of glucose control: 
HbAle, FPG, FPI, AUCG, Cmax,G, AUC1 and Cmax,l). The step-wise multi-linear 
regression analysis was used to relate the measures of insulin sensitivity and pancreatic 
p-cell responsiveness to the clinical measures of glucose control. The amount of 
explained inter-individual variability was calculated by the analysis of variance 
(ANOVA). The dependent and independent variables were tested for normal 
distribution and where as appropriate logarithmically transformed. The results are 
expressed as mean ± SE unless stated otherwise. SPSS for Windows V9.0 (SPSS Inc., 
Chicago, IL, USA) was used to carry out statistical calculations. 
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7.5. Results 
7.5.1. Plasma glucose, Insulin and C-peptide 
Elevated fasting plasma glucose and HbA 1C shown in Table 7-3 document the lack of 
control in the newly diagnosed subjects who also presented elevated BMI (see 
Subjects). However, fasting plasma insulin was comparable to that measured in healthy 
subjects indicating a gross reduction in insulin secretion when corrected to the glucose 
stimulus. The AIRa mean value was quite low and close to the FPI values because of 
the weak pancreatic response in newly diagnosed Type 2 diabetes. 
The profiles of plasma glucose, insulin, and C-peptide during IVGrr and MTT are 
shown in Figure 7-1 and 7-2. During IVGTT, the efIect of exogenous insulin at 20 
minutes on glucose lowering is clearly visible. At the start of the experiment, the 
glucose bolus failed to stimulate an immediate insulin response as documented by an 
early drop in C-peptide and resulted in a paradoxical temporary suppression of insulin 
secretion. During MIT, the glucose and insulin levels remained elevated for longer than 
in non-diabetic subjects with peak values reached at 60-90 minutes. 
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Table 7-3. Summary statistics of variables representing glucose control: fasting plasma glucose 
(FPG), fasting plasma insulin (FPI), incremental area under the curve of glucose and insulin 
during MIT (AUCQ, AUel ), incremental glucose and insulin concentration during MIT 
(C""",.G, Cmax,r), and glycated haemoglobin (HbA1c); and variables representing characteristics of 
glucose metabolism: insulin sensitivity (SI). glucose etfectiveness (So), tirst phase insulin 
secretion (AIRo), disposition index (~), and fasting (Mo) and postprandial (M,) pancreatic 
p-cell responsiveness. 
Variable Mean SE (Interquartile range) 
FPG (mmollL) 11.0 0.4 
FPI (pmollL) 60 (31-81) 
AUCG (mmollL per 180 min) 607 41 
Cmax.G (mmollL) 5.2 0.2 
AUCI (mmollL per 180 min) 28.7 (13.6-36.6) 
Cmax.1 (pmoI/L) 233 (115-320) 
HbA1c (%) 7.9 (6.1-9.3) 
SI x10·5 (1/min per pmollL) 1.07 (0.40-1.51 ) 
So xi 0.2 (1/min) 1.5 0.1 
AIRo (pmol/L per 6 min) 313 (143-393) 
D. (1/min per 6 min) 488 (202-732) 
M. xi 0.9 (1/min) 20.1 (11.3-27.4) 
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Figure 7-1. Plasma glucose, insulin, and C-peptide profiles during IVOIT (mean ± SE; N=65) 

















































0 60 120 180 240 
Time (min) 
Figure 7-2. Plasma glucose, insulin, and C-peptide profiles during MIT (mean ± SE; N=65) in 
newly presenting subjects with T20. 
ISS 
7.5.2. Minimal model 
Results of the minimal model analysis are given in Table 7-4. All parameters were 
estimated with acceptable accuracy. As expected, insulin sensitivity SI was markedly 
reduced by about 70% and So by about 20% compared to healthy subjects (197). Table 
I in appendix I shows the parameters for all subjects. The model failed to estimate SI 
with acceptable precision (CV more than 150%) in four subjects. No common reason 
was found among the four subjects, which might explain the failure. 
Table 7-4. Minimal model results in subjects with newly presenting T20 (N - 65). 
Pz Cv P3 cv So CV 51 CV (1/min) (%) (1/min2xpmollL) (%) (10·2x1/min) (%) (10.5 x1/mln per pmollL) (%) 
Mean 0.24 23 0.70 27 1.54 20 1.8 18 
5E 0.03 3 0.09 4 0.07 2 1.3 3 
7.5.3. Insulin secretion model 
The individual estimates of the pancreatic responsiveness indices during MTT together 
with their precision of estimates are given in Table 2 in appendix I. Table 7-5 
summarises the results of ISM analysis. Fasting and postprandial pancreatic p-cell 
responsiveness Mo and Ml were low compared to those measured in healthy subjects 
(197) (reduction by about 50 and 80% respectively; N = 16, age: 50 ± 10 years, BMI: 
29.2 ±3.6 kWm2, FPG: 5.1 ± 0.5 mmollL) (197). They were estimated with excellent 
precision (CV ~ 7%). 
Table 7-5. Insulin secretion model (ISM) results in subjects with newly presenting T20 
(N= 65). 
MI CV Mo CV 
(10·9 x 1/min) (%) (10·9 x 1/min) (%) 
Mean 20.15 7 5.72 3 
SE 1.66 1 0.36 0 
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7.5.4. Co"elation analysis 
The results of the Spearman correlation analysis are given in Table 7-6. FPG was 
negatively correlated with all measures of pancreatic p-cell responsiveness (most 
strongly with MJ) and the composite index DI (Figure 7-3). HbAlc followed a similar 
pattern with an even stronger correlation with MI but correlation with DI failing to reach 
significance after the Boniferroni (conservative) correction, see Figure 7-4. The two 
MTT-related glucose variables Cmax,G, and AUCo were also negatively correlated with 
MI. 
All insulin variables (FPI, Cmax,I and AUCI) were positively correlated with measures of 
pancreatic p-cell responsiveness. In addition, FPI was strongly negatively and AUC, 
was weakly negatively correlated with SI (Figure 7-5). These were the only correlations 
demonstrated by the two insulin sensitivity indices SI and So. 
Table 7-6. Spearman correlation with the Bonferroni correction between measures of glucose 
control (FPO, FPI, AUCG, Cmax,G. HbA1C, AUCI and Cmax,l) and indices of insulin sensitivity and 
pancreatic ~-cell responsiveness (Sb SG, A~, Db Mo. and MJ. 
SI SG AIRG 01 MI Mo 
FPG ~.16 0.10 -0.49** -0.58*** -0.73*** -0.61 *** 
FPI ~.70*** 0.23 0.74*** -0.06 0.40* 0.76*** 
HbA1C -0.12 -0.03 -0.37 -0.43 ~.81*** -0.52** 
Cmax,G 0.16 -0.01 -0.26 -0.08 -0.49** -0.36 
Cmax,1 ~.38 0.15 0.64*** 0.21 0.78*** 0.77*** 
AUCG 0.01 -0.01 -0.26 -0.2 -0.65*** -0.42* 
AUC, -0.43* 0.15 0.64*** 0.19 0.75*** 0.76*** 
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Figure 7-5. Relationship between FPI and Mo (top panel), and between FPI and SI (bottom 
panel) in subjects with T2D (mean ± SE). 
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7.5.5. Regression analysis and explained Inter-individual variability 
The results of the step-wise multi-linear regression analysis are shown in Table 7-6. The 
table lists normalised regression coefficients (z-scores; a higher absolute z-score 
indicates a stronger explanatory ability - this is achieved by transforming the 
independent variables to standardised form which makes the coefficients more 
comparable since they are all in the same units of measure), which entered the 
regression formulae. 
The postprandial pancreatic ~-cell responsiveness M, entered all formulae with the 
exception of that associated with FPI and was the strongest predictor in these 
regressions. The disposition index D, was the second strongest predictor. S, was a strong 
predictor of FPI and also entered the formula associated with Cmu,l. AIRQ predicted 
AUC, and Mo predicted FPI. So did not enter any regression. 
The linear regression analysis was powerful in explaining inter-individual variability of 
all variables with the exception of glucose responses to MTT, see Figure 7-6. Linear 
regression explained 70--80% inter-individual variability of FPI, FPG, HbAIC and 
insulin responses to MIT, and only 25--40% interindividual variability of glucose 
responses to MTT. 
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Table 7-7. Results of step-wise linear regression are shown in the form of z-scores (regression 
coefficients when all variables are expressed in standardised fonn). Dash (-) indicates that the 
independent variables (Sb Sa, AIRo, Db Mo, and M,) did not enter the regression fonnula for the 
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Figure 7-6. Explained inter-individual variability of clinical measures of glucose control using 
indices of insulin resistance and pancreatic ~-cell responsiveness. 
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7.6. Discussion 
The present study documents that at time of presentation, pancreatic p-ceU deficiency 
plays the key role in explaining fasting glucose levels at Type 2 diabetes. This finding is 
consistently supported by MTT and IVGTT data. 
Impaired postprandial pancreatic p-cell responsiveness is the most powerful explanatory 
factor of impaired glucose control. This suggests that most effective normalisation of 
glucose levels in Type 2 diabetes is associated with increased postprandial insulin 
appearance. 
During MIT, fasting plasma glucose and HbAIC were strongly inversely related to the 
ability of basaVfasting and, to a greater extent, postprandial pancreatic p-cell 
responsiveness. Fasting plasma glucose was also inversely correlated with the 
IVGTT -derived first phase insulin response and more strongly with the disposition 
index. This confirms that the disposition index is useful in characterising the overall 
state of glucose metabolism (122). However, in newly presenting Type 2 diabetes, 
postprandial insulin secretion is even more useful as it is more closely correlated with 
fasting plasma glucose. 
Glucose meal responses were only correlated with pancreatic p-cell responsiveness and 
not with insulin resistance. Insulin sensitivity SI failed to demonstrate any relationship 
with fasting plasma glucose and glucose meal responses. Reaven et al (198) also failed 
to find a simple relationship between insulin resistance and fasting plasma glucose in 
non-obese individuals (normal, impaired glucose tolerance and Type 2 diabetes 
subjects). However, Van Haeften et al (199) reported the effect of insulin sensitivity as 
assessed by byperglycaemic clamp on fasting glucose in subjects with normal and 
impaired glucose tolerance. Levy et al (200) documented that the ongoing faU in p-cell 
function assessed by HOMA modelling closely followed a rise in fasting plasma 
glucose in a 10-year prospective study of newly presenting Type 2 diabetes but also 
failed to find any effect of insulin sensitivity. 
The insulin dependent glucose disposal (production) is the product of two factors, the 
ambient insulin levels and the ability of insulin to stimulate (suppress) glucose disposal 
(production). The former factor is influenced by pancreatic p-cell responsiveness and 
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the latter corresponds to the insulin sensitivity index. It is a paradox that only one factor, 
the pancreatic deficiency. is related to glucose control (primarily fasting plasma 
glucose) in the studied subjects. It is unclear why there is a lack of relationship between 
glucose control and insulin resistance and whether methodological issues associated 
with measuring insulin resistance or unaccounted physiological mechanism(s) are 
responsible. 
Our interpretation is that when fasting plasma glucose exceeds say 7mmolll, insulin 
sensitivity is greatly reduced with little or no further reduction with increasing fasting 
hyperglycaemia (subjects in the present study had already achieved their maximum 
insulin resistance). In highly insulin resistant state, insulin dependent glucose disposal 
during fasting becomes negligible and fasting plasma glucose is regulated primary via 
the insulin independent pathways such as the mass effect of glucose on its disposal 
(glucose effectiveness). Thus at fasting, insulin resistance is so high that insulin fails to 
exercise any detectable effect on glucose disposal and production, and in tum on 
glucose concentration. 
This interpretation is not, however. fully consistent with another study finding. Insulin 
sensitivity 51 and fasting plasma ~nsulin have been found tightly (negatively) correlated 
in the present study. This correlation is well documented by others and is normally 
interpreted by a causal chain reasoning that includes plasma glucose. The argumentation 
is that insulin resistance results in elevated plasma glucose, which in tum stimulates 
insulin secretion. Thus insulin resistance is the cause of increased fasting plasma 
insulin. However. this argumentation does not hold in the present study due to the lack 
of correlation between 51 and fasting plasma glucose and we must seek alternative 
explanations. Two candidate theories emerge. Either chronic elevation of plasma insulin 
induces insulin resistance possibly due to the down regulation of insulin receptors or 
some other metabolic variable acts as the "control" messenger between insulin 
resistance and insulin secretion. 
Note that tight correlation between 51 and FPI in the diabetes group supports 
methodological validity of 51 estimates and suggests that insulin modification of IVGTT 
enabled insulin sensitivity to be successfully estimated. 
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Subjects with Type 2 diabetes demonstrate both insulin resistance and reduced 
pancreatic p-cell responsiveness (4S; 193). A previous study on newly diagnosed T20 
showed that both insulin sensitivity (S.) and postprandial p-cell responsiveness (M,) are 
reduced by about 80% compared to BMI-matched healthy subjects, whereas glucose 
effectiveness (So) and fasting p-cell responsiveness (Mo) are reduced by approximately 
25% and 50%, respectively (197). 
Subjects were referred directly after diagnosis by their GPs. The subjects had no 
treatment and did not have any dietary advice. It is possible that they may have made 
their own dietary adjustments, for example they may have given up sugar in their tea 
once they knew they were diabetic, but to all extents and purposes they had had 
absolutely no treatment for diabetes (treatment naive) before undergoing MTT and 
IVGTT. 
Subjects presented a wide range of fasting plasma glucose and fasting plasma insulin 
(S.9--18.4mmoIlL and 20-1S0pmo1lL respectively) probably due to the duration of 
undetected diabetes and/or individual differences in diet and life style. The mean value 
of fasting plasma insulin was close to that observed in healthy subjects, while the mean 
value of fasting plasma glucose was considerably elevated. This observation supports 
the hypothesis that overt diabetes does not appear until the pancreas is not able to meet 
the body's demand for insulin in the face of increasing insulin resistance (193; 201; 
202). This process is then accelerated as glucose is then toxic (glucose toxicity) to the 
p-cell and peripheral tissues (202; 203). 
It has been shown that during the natural development of Type 2 diabetes, fasting 
plasma insulin increases and then decreases as insulin resistance develops (Starling's 
curve of the pancreas). The increase in fasting plasma insulin is generally regarded as a 
compensation mechanism aiming to reverse the effect of insulin resistance and the 
subsequent decrease as a decompensation mechanism reflecting ~-cell 'exhaustion'. 
However, such analysis fails to take into account the level of the stimuli, i.e. the fasting 
glucose level. When insulin secretion is normalised to fasting glucose (such as when 
calculating fasting responsiveness Mo), no increase in insulin secretion, i.e. 
compensation, is observed and there is a consistent pattern of continuously deteriorating 
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fasting pancreatic p-cell responsiveness accompanying elevated fasting glucose. This 
suggests that no compensation mechanism per se exists and that the apex on the Starling 
curve represents a point when the stimuli are not high enough to overcome deteriorating 
pancreatic p-cell responsiveness. It is also known that the early insulin release 
(parameter comparable to M0 during an oral load decreases progressively as the 2-h 
plasma glucose increases. There is no Starling curve for this parameter of insulin 
secretion, which is compatible with our data. 
Fasting plasma insulin correlates negatively with insulin sensitivity (-0.70, p < 0.001). 
This correlation can be explained by the effect of insulin resistance on the stimulation of 
insulin secretion (46; 204) and suggests that elevated fasting plasma insulin is a reliable 
index of insulin resistance. Bonora et a1 (159) also found a negative correlation between 
'insulin sensitivity and fasting plasma insulin in mild glucose intolerance and suggested 
that overproduction of insulin is due to insulin resistance. Olefsky et al (46) found a 
similar correlation in normal subjects, subjects with impaired glucose tolerance and 
Type 2 diabetes, and explained fasting plasma insulin elevation as a result of an attempt 
to overcome insulin resistance. 
The explained inter-individual variability of fasting plasma glucose and HbAlc were 
excellent (> 75%) if we consider intra-individual (day-to-day) variability, which could 
account for 10--20% of unexplained variability (153). A similarly excellent explanation 
was found for fasting plasma insulin and insulin responses to meal. 
Glucose responses after a meal were poorly explained « 45%). It appears that other 
variables not included in the study such as gut absorption and endogenous glucose 
production are responsible for the residual amount of unexplained variability. Thus the 
standard indices of insulin sensitivity and pancreatic p-cell responsiveness do not enable 
reliable predictions of postprandial glucose to be made. 
7.7. Summary 
In conclusion, pancreatic p-cell responsiveness indices from IVGTT and MIT are better 
explanatory factors of fasting plasma glucose, HbAIC, and insulin and glucose responses 
to meal than insulin resistance indices in newly presenting Type 2 diabetes. Postprandial 
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insulin deficiency is the most powerful explanatory factor of elevated fasting plasma 
glucose. glycated haemoglobin and glucose responses to meal. Indices of insulin 
sensitivity and pancreatic ~-cel1 responsiveness are able to explain glucose control well 
with the exception of glucose response to a meal. 
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8. Final discussion 
The primary aim of this thesis was to use modelling techniques employing data 
collected during MTT and IVGTT to progress our understanding of the pathology of 
type 2 diabetes. The secondary aim was to evaluate the domain of validity of the insulin 
secretion model (ISM) and, in part, the minimal model. 
Various methods with varying degrees of complexity have been established and 
developed for the measurement of insulin sensitivity and p-cell function. A review of 
these methods was given in Chapter 2. However, for methodological considerations and 
to eliminate or reduce the effect of the measurement error and the inter-subject 
variability in insulin and C-peptide kinetic, model-based approaches are preferred over a 
simple one or two concentration-point assessment. 
The insulin secretion model (ISM) with MTT is a simple relatively non-invasive tool to 
investigate pancreatic responsiveness (32). It measures the prehepatic insulin secretion 
and assesses pancreatic p-cell responsiveness providing postprandial pancreatic p-cell 
responsiveness (Ml) and fasting pancreatic p-cell responsiveness (Mo). 
A reduced sampling scheme consisting of nine samples has been used and was planned 
to be used in the course of studies in this thesis (49) but its performance with the model 
was still unknown. In Chapter 3, ISM indices of pancreatic p-cell responsiveness were 
successfully estimated and evaluated during MTT with nine-sample and five-sample 
schemes. The five-sample scheme will further reduce the time, labour and cost, 
facilitating a wide use of the model. 
The insulin secretion model was successfully validated during OOTT in healthy 
subjects, and subjects with T2D. The OOTI is the most widely used test because of its 
simplicity. The OGTT is the standard diagnostic test of type 2 diabetes and impaired 
glucose tolerance IGT approved by the World Health Organisation (1). 
In the same chapter (Chapter 4), a comparison between model performance and indices 
during MTT and OaTT was performed. In healthy subjects, as a result of higher 
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C-peptide secretion during MIT with respect to the glucose concentration. MIT 
resulted in 1.5 fold higher postprandial pancreatic ~-cell responsiveness than OGIT. 
In subjects with T2D, glucose response during OGIT was higher than during MTT 
(P = 0.001). whereas the insulin response was slightly higher during MIT (P = NS). As 
a result Ml was two fold higher during MIT than OGIT (P = 0.001). The two indices 
were also correlated. The meal tolerance test provides a more physiological challenge to 
the ~-cell than OGIT. Therefore. MIT is expected to facilitate a more comprehensive 
assessment of ~-cell function. 
In Chapter five, the reproducibility of pancreatic ~-cell responsiveness and the 
reproducibility of glucose. insulin. and C-peptide responses to MIT and OGTT were 
investigated. In healthy subjects the indices of pancreatic ~-cell responsiveness failed 
to show sufficient reproducibility due to lack of reproducibility of glucose and 
C-peptide to MTT and OGIT. However insulin responses to MTT and OGTT were 
reproducible. In subjects with T2D, Ml and Mo were sufficiently reproducible in line 
with reproducible glucose, insulin, and C-peptide responses to MIT. Due to the data 
limitation in subjects with T2D, the reproducibility of these parameters was studied 
during MTT but not OGIT. 
The one compartment minimal model (1 CMM) of glucose kinetics is a powerful 
relatively non-invasive tool to investigate glucose metabolism. However it has been 
criticised by several studies reporting that So is overestimated (109-111; 113; 182-184) 
and SI is underestimated (109-113; 184) due to the under modelling effect of using one 
compartment to represent the glucose pool (113; 182; 185; 186). The new two 
compartment minimal model (2CMM) was suggested and used as an alternative to the 
lCMM, but the 2CMM performance in subjects with type 2 diabetes is still unknown. 
In Chapter 6, the one and two compartmental minimal model performance was 
evaluated and compared to the clamp in subjects with type 2 diabetes during the 
modified NGTT. 
The iterative two-stage popUlation approach was the successful one among several other 
approaches applied during the evaluation and validation of2CMM. Although the model 
was successfully validated in subjects with T2D during insulin-modified FSIVGTT, 
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insulin sensitivity and glucose effectiveness estimated by 2CMM with population 
analysis were not different from lCMM estimates. For its simplicity and popularity and 
to benefit from the data available in the literature it is recommended to use the 1 CMM. 
In Chapter seven the one compartment minimal model and the insulin secretion model 
with MTT were then applied to study newly presenting type 2 diabetes in order to gain 
more understanding of the disease pathology and to investigate the ability of the IVGTT 
and MTT derived indices to explain the inter-individual variability of clinical measures 
of glucose control such as fasting plasma glucose and insulin, glycated haemoglobin, 
and the glucose and insulin responses to a meal. 
Two sets of indices were defined and analysed. One set contained model-based indices 
assessing and presenting the level of insulin sensitivity and pancreatic p-cell 
responsiveness. A second set included several indices of clinical measures describing 
the blood glucose and insulin control ranging from fasting to postprandial measures. 
The impaired postprandial pancreatic p-cell responsiveness was the most powerful 
explanatory factor of impaired glucose control. The explained inter-individual 
variability of fasting plasma glucose and HbAlc were excellent (> 75%) if we consider 
intra-individual (day-to-day) variability, which could account for 10--20% of 
unexplained variability (153). A similarly excellent explanation was found for fasting 
plasma insulin and insulin responses to a meal. 
Glucose meal responses were only correlated with pancreatic p-cell responsiveness. In 
addition insulin sensitivity Sl failed to demonstrate any relationship with fasting plasma 
glucose and glucose meal responses. Fasting plasma glucose and HbAlc were strongly 
inversely related to the ability of fasting and, to a greater extent, postprandial pancreatic 
p-cell responsiveness during MIT. 
Fasting plasma insulin correlates strongly and negatively with insulin sensitivity (-0.70, 
p < 0.001). This correlation was explained by the effect of insulin resistance on the 
stimulation of insulin secretion and suggesting that elevated fasting plasma insulin is a 
reliable index of insulin resistance. 
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Subjects with Type 2 diabetes demonstrated both insulin resistance and reduced 
pancreatic p-cell responsiveness. When insulin secretion was normalised to fasting 
glucose (such as when calculating fasting responsiveness Mo), no increase in insulin 
secretion, Le. compensation, was observed and there was a consistent pattern of 
continuously deteriorating fasting pancreatic p-cell responsiveness accompanying 
elevated fasting glucose. 
This observation supports the hypothesis that overt diabetes does not appear until the 
pancreas is not able to meet the body's demand for insulin in the face of increasing 
insulin resistance (193; 201; 202). This process is then accelerated as glucose is then 
toxic (glucose toxicity) to the p-cell and peripheral tissues (202j 203). 
In conclusion, the model-based approaches used in this thesis, provided simple and 
reproducible relatively non-invasive measures to assess the pancreatic p-cell 
responsiveness and insulin sensitivity. These methods enhanced and raised our 
understanding oftype 2 diabetes pathology. 
8.1. Achievement of objectives 
An outline of the achieved objectives is given below. The achievements are divided as 
the objectives into methodological and clinical. The methodological achievements are: 
_ Pancreatic p-cell responsiveness was successfully estimated and evaluated 
during MTT with nine-sample and five-sample schemes 
_ Insulin secretion model was validated during OaTT in healthy subjects, and 
subjects with T2D. The model is able to assess pancreatic p-cell responsiveness 
from MTT as well as oarr data 
_ In healthy subjects the indices of pancreatic p-cell responsiveness failed to show 
sufficient reproducibility due to lack of reproducibility of glucose and C-peptide 
to MTT and OaTT 
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- In subjects with T20, Ml and Mo were sufficiently reproducible in line with 
reproducible glucose, insulin, and C-peptide responses to MIT 
- The 2CMM was validated successfully using population analysis in TlO 
subjects during insulin-modified FSIVGIT, giving precise estimates of SI and 
So with strong correlation with 1 CMM estimates and SICLAMP. 
- Insulin sensitivity and glucose effectiveness estimated by 2CMM with 
population analysis were not different from 1 CMM estimates. For its simplicity 
and popularity and to benefit from the data available in the literature it is 
recommended to use the 1 CMM. 
The clinical achievements are: 
- Pancreatic p-cell responsiveness indices from IVGTT and MTT were better 
explanatory factors of fasting plasma glucose, HbAIC, and insulin and glucose 
responses to meal than insulin resistance indices in newly presenting Type 2 
diabetes 
_ Postprandial insulin deficiency was the most powerful explanatory factor of 
elevated fasting plasma glucose, glycated haemoglobin, and glucose responses 
to meal 
_ Indices of insulin sensitivity and pancreatic p-cell responsiveness were able to 
explain glucose control well with the exception of glucose response to a meal in 
subjects with T20. 
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8.2. Future work 
Several research questions were raised during the course of study. Recommendations 
for future research encompass clinical and methodological aspects: 
- It is recommended to follow up subjects with newly diagnosed T2D to gain 
more understanding of the disease progression and to detect the effects of 
therapeutic interventions 
- Future work is needed to understand the variability of glucose meal responses 
and its main explanatory factors 
- It is recommended to study the reproducibility of the pancreatic p-cell 
responsiveness during OGrr in subjects with T2D 
- It is recommended to compare the perfonnance of the one compartment minimal 
model with both iterative two-stage popUlation analysis and standard two-stage 
analysis in different pathogenesis states including T2D. 
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Appendix I has three tables including data from 65 subjects with newly presenting type 
2 diabetes who participated in the study described in Chapter 7. Table I shows 
individual estimates of minimal model parameters. Table 2 shows individual estimates 
of insulin secretion model. Individual fasting values of glucose, insulin, and C-peptide 
together with HbA1c are given in Table 3. 
Appendix II contains the published papers and a list of publications derived from the 




Table 1. Individual estimates of minimal model analysis in subjects with newly presenting T2D. 
Sub. No. Pz CV P3 CV Sa CV S. CV 
1/min % (1/min2x~molll} % (10'2x1/min} % (1 0.5 x 1/min ~eq~mollL} % 
1 0.01 54 0.06 45 1.40 11 1.01 74 
2 0.05 25 0.22 32 1.18 17 0.71 23 
3 0.13 15 2.39 17 0.93 36 3.12 5 
4 5.59 n/a· nla nla 1.57 17 0.16 127 
5 0.00 nla 0.00 122 1.20 44 nla nla 
6 5.60 0 nla nla 3.28 12 nla nla 
7 0.03 35 0.35 28 3.51 8 2.22 14 
8 0.05 18 0.41 23 1.52 15 1.28 16 
9 0.02 56 0.04 56 2.04 9 0.47 31 
10 0.19 211 0.09 206 1.86 6 0.08 102 
11 0.10 10 1.25 13 0.22 104 2.08 6 
12 0.04 8 0.37 10 0.92 16 1.59 8 
13 0.06 18 0.92 22 1.38 19 2.48 7 
14 0.07 14 0.74 16 1.19 20 1.72 10 
15 0.05 27 0.87 28 1.38 38 2.82 6 
16 0.06 10 0.96 12 0.68 29 2.78 9 
17 0.21 126 0.17 122 1.77 7 0.14 57 
18 0.07 49 4.85 39 2.72 38 10.83 13 
19 0.31 164 0.35 161 1.73 7 0.19 58 
20 0.04 16 0.25 19 1.67 10 0.94 15 
21 0.05 13 0.33 16 1.60 11 1.00 9 
22 0.05 15 0.32 19 1.64 11 1.01 12 
23 0.06 7 0.73 10 1.07 15 2.19 5 
24 0.06 12 1.07 14 1.34 16 2.77 4 
25 0.03 21 0.63 25 1.11 33 3.32 8 
26 0.05 9 0.58 11 1.16 13 1.82 5 
27 0.07 19 0.24 20 1.73 B 0.57 15 
28 0.08 21 1.65 24 1.37 31 3.35 6 
29 0.07 21 0.23 22 1.38 12 0.57 16 
30 0.08 8 0.99 10 0.88 19 2.12 5 
31 0.00 nla nla nla 2.03 13 nla nla 
32 0.04 21 0.46 23 0.96 33 1.98 26 
33 0.02 30 0.07 34 1.90 B 0.55 19 
34 0.03 14 0.21 18 1.31 13 1.03 10 
35 0.02 25 0.10 32 1.17 14 0.86 22 
36 0.05 9 0.69 12 1.01 20 2.53 7 
37 0.04 12 0.23 15 1.18 11 0.96 12 
38 0.04 23 0.60 23 1.49 26 2.65 6 
39 0.06 35 1.76 27 1.92 35 4.62 10 
40 0.02 18 0.06 21 1.58 6 0.53 12 
41 0.09 18 1.17 22 1.15 31 2.22 10 
42 0.08 26 1.73 28 1.42 38 3.78 7 
43 0.04 29 0.14 35 1.62 13 0.55 26 
44 0.00 nla nla nla 1.61 15 nla nla 
45 0.05 30 0.22 28 1.18 19 0.74 28 
46 0.05 13 0.34 15 1.46 10 1.11 13 
47 0.07 20 0.46 21 1.32 15 1.11 16 
48 0.08 15 0.58 18 1.48 18 1.17 9 
49 0.07 9 1.44 12 3.77 59 3.22 5 
50 0.09 30 0.66 36 2.01 21 1.22 15 
51 0.08 18 0.48 22 1.57 17 1.00 12 
52 0.09 27 0.80 29 1.19 43 1.45 6 
53 0.09 17 1.98 19 1.17 28 3.83 5 
54 0.04 17 0.49 19 1.64 18 2.22 6 
55 0.06 18 0.65 23 1.34 26 1.74 9 
56 0.05 12 0.43 15 1.35 12 1.50 12 
57 0.09 16 0.32 18 1.81 8 0.61 11 
58 0.07 35 1.62 35 1.56 44 3.73 7 
59 0.05 35 1.38 27 1.61 38 4.79 9 
60 0.23 38 0.56 40 1.70 7 0.42 17 
61 0.03 19 0.24 21 1.53 11 1.39 18 
62 0.06 33 0.20 33 1.59 11 0.54 29 
63 0.03 12 0.20 18 1.52 8 1.17 12 
64 0.12 78 0.11 73 2.04 5 0.15 47 
65 005 H Q.18 18 1.Z5 a 0.60 14 
Mean 0.24 23 0.70 27 1.54 20 1.79 18 
SE 0.03 3 0.09 4 0.07 2 0.21 3 
• The estimation did not return any value 
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Table 2. Individual estimates ofISM analysis in subjects with newly presenting T2D. 
Sub. No. M, CV Mo CV 
{10-9x 1/minl % {10'9 x 1/min} % 
1 40?? fi 7O? 4 
2 30.23 8 11.72 3 
3 8.10 6 2.44 3 
4 44.21 4 7.78 3 
5 21.17 8 7.65 3 6 8.53 7 3.72 3 
7 8.63 8 2.93 3 
8 25.47 6 6.09 3 
9 17.53 7 8.12 3 
10 19.62 8 6.25 3 
11 19.72 6 7.20 3 
12 11.54 5 5.35 3 
13 26.38 6 7.83 3 
14 1.94 28 3.02 3 
15 18.21 4 3.22 3 
16 11.64 4 5.05 3 
17 16.94 9 7.90 3 
18 28.50 4 3.51 3 
19 57.91 4 13.62 4 
20 22.40 4 5.04 3 
21 15.77 7 4.73 3 
22 14.84 5 3.75 3 
23 32.26 4 5.52 4 
24 2.41 8 .92 3 
25 45.24 5 9.06 3 
26 11.30 7 4.05 3 
27 6.46 21 4.26 3 
28 14.78 6 4.62 3 
29 12.84 7 5.07 3 
30 13.06 5 2.29 4 
31 17.45 6 6.04 3 
32 37.44 5 10.44 3 
33 29.14 4 5.17 4 
34 29.63 4 4.29 3 
35 5.37 20 5.48 3 
36 7.01 4 1.15 3 
37 12.12 7 3.51 3 
38 34.14 3 3.30 4 
39 6.93 5 2.42 4 
40 26.20 6 8.21 3 
41 11.26 6 2.89 3 
42 21.84 6 4.21 3 
43 15.56 8 6.85 3 
44 16.09 6 3.60 3 
45 15.40 9 10.25 3 
46 37.94 6 7.75 3 
47 9.28 11 6.03 3 
48 16.51 7 7.35 3 
49 7.04 5 1.97 3 
50 7.70 5 2.12 3 
51 15.28 11 4.03 3 
52 4.47 6 2.42 3 
53 14.38 8 5.75 3 
54 38.48 6 12.62 4 
55 41.40 6 9.72 3 
56 39.39 4 7.77 4 
57 9.02 7 5.46 3 
58 13.36 5 3.32· 4 
59 15.15 4 3.03 3 
60 18.91 7 7.36 3 
61 12.23 5 4.69 3 
62 19.27 6 8.85 3 
63 67.77 5 11.75 3 
64 7.41 15 3.16 4 
65 21,01 6 9,41 :3 
Mean 20.15 7 5.72 3 
SE 1.66 1 0.36 0 
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Table 3. Fasting plasma glucose (FPG), insulin (FPI), C-peptide (FPC). and gtycated 
haemoglobin (HbA1c) in subjects with newly presenting T2D. 
Sub. No. FPI FPG FPC HBA1C (pmolll} {mmolll} {nmolll} {%} 
1 1\1 RR n.~~ n/R· 
2 117 8.9 1.598 nla 
3 13 15.7 0.560 nla 
4 82 11.2 1.385 nla 
5 90 15.6 1.793 nla 
6 66 15.8 0.941 nla 
7 25 15.4 0.628 nla 
8 55 9.2 0.764 nla 
9 99 12.4 1.701 nla 
10 148 14.4 1.418 nla 
11 97 8.7 0.921 nla 
12 63 10.6 0.907 8.5 
13 80 6.6 0.685 5.8 
14 42 17.2 0.813 12.1 
15 28 9.0 0.491 6.9 
16 46 8.6 0.711 9.1 
17 99 10.9 1.479 7.7 
18 19 7.7 0.435 6.1 
19 87 7.5 1.403 5.7 
20 36 9.1 0.678 7.2 
21 43 11.9 0.793 9.2 
22 58 10.8 0.646 7.0 
23 38 6.6 0.644 5.7 
24 10 15.8 0.255 9.3 
25 66 6.6 1.299 4.7 
26 32 13.1 0.898 8.3 
27 63 15.0 nla 9.6 
28 36 10.4 0.766 7.1 
29 74 11.2 1.206 10.0 
30 31 10.1 0.366 6.4 
31 72 12.1 1.074 9.9 
32 30 5.9 0.922 5.2 
33 53 8.2 0.797 6.3 
34 52 11.7 0.839 7.6 
35 43 15.4 0.910 11.6 
36 17 15.3 0.276 10.0 
37 51 16.0 0.862 11.3 
38 22 6.3 0.306 4.2 
39 32 8.9 0.411 8.4 
40 79 7.6 1.219 5.5 
41 25 12.1 0.512 7.9 
42 37 10.4 0.662 6.9 
43 63 12.2 1.217 7.7 
44 27 14.1 0.691 7.4 
45 101 8.8 1.390 7.1 
46 77 8.9 0.993 5.7 
47 49 12.2 1.046 9.0 
48 104 9.8 1.218 7.4 
49 21 11.3 0.436 9.3 
50 22 17.0 0.531 12.0 
51 54 15.1 0.868 9.4 
52 30 15.7 0.585 10.5 
53 38 8.9 0.923 10.0 
54 54 6.3 1.339 5.5 
55 81 7.2 1.345 6.0 
56 69 8.7 0.848 6.1 
57 152 11.0 nla 9.2 
58 26 12.3 0.573 8.1 
59 23 10.6 0.625 8.5 
60 118 10.1 1.153 7.4 
61 106 10.5 0.744 5.2 
62 105 8.8 1.194 8.5 
63 69 6.3 0.990 4.9 
64 63 18.4 0.973 13.6 
65 128 Z.Z 1.1QZ 6.1 
Mean 60 11.0 0.901 7.9 
SE 4 0.4 0.045 0.3 
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